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Helen Wareham 
Does good practice quality equate to earlier cancer stage at 
diagnosis? 
Abstract 
 
The early diagnosis of cancer is a priority within the UK, with GPs being identified as playing a 
key role.  The aim of this research was to look at the relationship between GP practice quality and 
cancer stage at diagnosis, for breast and colorectal cancer, within the North East of England. 
This was done by utilising existing healthcare databases, with data being obtained from the 
National Health Service (NHS) information centre, public health observatories and Northern and 
Yorkshire Cancer Registry and Information Service.  Patient data was from between 2006-2008 with 
n = 13,610 cases of breast cancer and n = 11,606 cases of colorectal cancer.  The data was combined 
and a range of analyses conducted to investigate the potential relationship between GP practice 
quality and a patient’s cancer stage at diagnosis. 
For breast cancer there was a significant relationship between GP practice quality and cancer 
stage in both multi-level and base outcome regression analyses.  A range of specific variables, many 
of which were related to patient experience, were found to have a significant effect upon breast 
cancer stage.   Patient age and level of income were also found to have a significant effect upon 
breast cancer stage. 
For colorectal cancer no association was found in multi-level analysis but a significant association 
was found between cancer stage and variables related to patient experience, such as a patient’s 
ability to see a doctor within two days.  Patients of working age (18-64) compared to retirement age 
(65+), were found to be more likely to have a more advanced cancer stage at diagnosis, as were 
patients with low income.  
In summary, significant associations were found between measures of GP practice quality and 
patient cancer stage at diagnosis, specifically GP variables related to patient experience.  This 
association suggests that higher quality of practice may increase the likelihood of being diagnosed 
with earlier stage of cancer.  The limitations of this research are highlighted and directions for future 
research projects and healthcare policy are discussed and outlined.  
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1.  Chapter 1 – Introduction 
 
The primary aim of this thesis was to examine the potential relationship between GP 
practice quality and cancer stage at diagnosis.  The rationale for this being that diagnosis of 
cancer at a less advanced stage is shown to improve patients’ outcomes (Brenner et al., 
2012, Coleman et al., 2003, Richards, 2007, Verdecchia et al., 2007b).  Many countries have 
invested in and developed early detection initiatives and programmes, for example, in the 
UK the National Awareness and Early Diagnosis Initiative (NAEDI) (Richards, 2009).  GPs 
have been identified as playing a key role in early detection and diagnosis, the most 
common diagnostic pathway is through patients presenting their symptoms to a GP and the 
GP referring suspected cancer cases to specialists. 
While inequalities in patient demographics and their impact on cancer diagnosis and 
outcomes is well documented (Cuthbertson et al., 2009, Collerton et al., 2009), there is a 
suggestion that GP factors may contribute to delays in diagnosis (Barrett et al., 2010).  
Equally with the change in economic climate, funding and public service cuts and the 
growing issue of global health, there is a greater pressure on GPs to deliver good and 
accurate service. 
It was hypothesised, therefore, that GPs and practices that perform well in assessments 
of their quality standards would refer patients with suspected cancer earlier and that those 
diagnosed with cancer would have earlier stage disease. 
Within the UK GPs can partake in a national quality scheme, the Quality and Outcomes 
Framework (QOF), which measures their quality of service not just in a clinical capacity but 
also on an organisational and customer satisfaction level.  Schemes such as these mean 
that large databases regarding and containing health data are being developed and created 
which provide a unique and desirable source of data for research. 
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Part of the aim of this research was to utilise existing health datasets, as this research 
was funded by the Economic and Social Research Council (ESRC) as part of their e-health 
initiative. The ESRC’s aim was to build capacity for future research using personalised 
electronic health records, with a particular aim to link and combine existing datasets. 
This particular studentship was to have a focus on cancer in primary care and was 
obtained through a successful bid by FUSE, the UKCRC-funded Centre for Translational 
Research in Public Health which was based at Durham University but jointly supervised 
with Newcastle University. 
The aim and objective of this thesis are therefore as follows: 
 The aim of this project was to investigate whether there was a relationship 
between GP practice quality and patient cancer stage at diagnosis. 
 The objective of this project was to use a secondary data analysis method by 
utilising and obtaining data from existing health databases in order to analyse if 
there was a potential link between GP practice quality and patient cancer stage at 
diagnosis in breast and colorectal cancer in the North East region of England. 
The chapters of this thesis are as follows: 
Chapter 2:  Background literature  
 
This chapter provides an overview of literature in the area of this thesis.  An 
explanation of cancer and the scale of the problem, both within the UK and globally, is 
given before exploring the research surrounding diagnosis and the associated delays and 
barriers.  It summarises the current economic climate and the impact of the recent change 
in government on the National Health Service (NHS) in England.  The current process of 
cancer diagnoses in England, how it is identified and the role GPs have to play in diagnosis 
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is outlined along with the quality measures that have and are currently being used to 
assess GP practice quality.  Finally the study’s primary aim and wider secondary aims are 
outlined. 
 
Chapter 3:  Systematic literature review 
 
In this chapter an overview of quality of care within primary care is provided; how 
quality is defined, issues with the definitions, how it has been measured, how it is 
measured now and the problems of those approaches.  The way in which quality has been 
measured and assessed has been widely debated, therefore it seemed pertinent to conduct 
a systematic review of the literature in this area with the aim to clarify and identify gaps 
within the current research.  A search criteria was developed and a systematic search 
conducted with the aid of a second reviewer before a narrative analysis was conducted on 
the final selected papers. 
 
Chapter 4:  Methods 
 
This thesis used existing healthcare databases as the source of information and data.  
This type of secondary data analysis is a more recent method, with little previous research 
utilising and combining the particular resources used in this study.  As a result this chapter 
discusses the choices and reasons for selecting certain databases, the unique and specific 
challenges of ethics and obtaining the data as well as outlining the planned analysis 
approach. 
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Chapter 5:  Results 
 
In this chapter the results of the analysis are reported, with the two cancer types being 
reported separately.  For each, the findings are outlined from the distributions within each 
variable through each stage of analysis. 
 
Chapter 6:  Discussion 
 
The key findings of the research are summarised and discussed within the context of 
current and previous research.  What they add to the current knowledge and 
understanding in this area and where conflicts with previous findings lay.  How this 
research fits into the current and evolving climate of healthcare in England is discussed, 
along with comments on its impact on the current changes along with recommendations 
for changes within healthcare based on this study’s findings.   
 
Chapter 7:  Conclusions 
 
A summary of the study is provided, along with the strengths and weaknesses of this 
research.  Personal reflections on conducting this project and what changes would be made 
given the opportunity to repeat the experience, along with suggestions for the direction of 
future research in this area and/or as a continuation of this project.  
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2.  Chapter 2 – Background Literature 
 
This chapter contains a general literature review and outlines the current climate 
surrounding cancer diagnosis and GPs.  Starting with a brief outline of what cancer is, its 
causes and prevalence, it then goes on to discuss early detection and its importance in 
cancer diagnosis and survival outcomes and the barriers that have been found to delay that 
process.  Models that have been developed to explain the process of delay and associated 
factors are discussed before an explanation of the different diagnostic pathways that 
patients can take within the English health care system, is outlined. 
These pathways are then put into the context of the current climate; the impact of 
recent economic and political events, such as the recession and future NHS reforms are 
discussed and finally a brief overview of quality of care within primary care is included, this 
is however discussed more in-depth in chapter 3 (systematic literature review), before the 
primary research aim and subsidiary aims are outlined. 
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2. 1.  What is cancer? 
 
Cancer is a generic term for a large group of diseases that can affect any part of the 
body and is characterised by the uncontrolled growth and spread of cells.  What causes 
cancer is still not entirely known or understood, but it is clear that the interaction between 
a person's genetic traits and external agents are important.  These external factors include 
a range of known carcinogens, such as ultraviolet and ionizing radiation, asbestos, aflatoxin 
and arsenic.  Other risk factors associated with cancer include; leading an unhealthy life 
style (poor diet and exercise), tobacco and alcohol use and infections from viruses such as 
hepatitis and human papilloma virus. 
Ageing is a known factor in the development of cancer, as age increases the risk and 
also the incidence of cancer.  This is thought to be most likely due to a ‘build-up’ effect, the 
accumulation of external risk factors combined with the decrease in cell repair efficiency as 
a person ages.   
2. 1. 1.  Most common cancers 
 
Worldwide the most common cancers are; lung, stomach, liver, colon and breast.  
However, the incidence differs between men and women, in particular breast 
predominantly affect females with a low percentage of males being affected.  Within the 
UK the most common cancers differ slightly with breast, lung, colorectal and prostate being 
the four most common.  Between males and females both lung and colorectal are common 
in both groups but in males prostate is the most common and in females, breast 
(Rutherford et al., 2013, Cancer Research UK, 2013).  
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2. 1. 2.  Prevalence of cancer 
 
Worldwide cancer is a leading cause of death, accounting for around 7.6 million deaths 
annually and it is projected that by 2030 these will rise to over 13.1 million.  Within the UK 
in 2009 there were 156,090 deaths from cancer and it is the second highest cause of death 
in the UK, second to circulatory diseases (Cancer Research UK, 2013, Office of National 
Statistics, 2012).  There are approximately 309,527 new cases of cancer diagnosed each 
year in the UK (Cancer Research UK, 2013).  
2. 1. 3.  Ageing 
 
The proportion of global populations aged over 60 years is rising rapidly, by 2050 the 
estimate is that one third of the global population will be aged 60 and over (United 
Nations, 2007).  In the UK this is of particular concern, as the current retirement age in the 
UK is 65 and 10 million people within the UK population are 65 and over (this equates to 1 
in 6 people).  In the UK, between 2006-2008, 89% of newly diagnosed cancer cases were in 
people aged 50+.  36% were in people aged 75+, the highest cancer incidence rate in any 
age group per 100,000 (Boreham et al., 2002).  The current life expectancy for a child born 
today is over 85 years old and at present in those aged 85+, almost a quarter (23.9%) have 
been diagnosed with some type of cancer (Collerton et al., 2009).  
2. 1. 4.  Other factors influencing cancer trends 
 
Certain factors have been identified which, while they do not necessarily cause or 
directly contribute to the development of cancer have been found to either contribute to 
an increased likelihood of developing cancer or influence patient diagnosis and treatment.  
In particular age, sex, ethnic origin, geography and socioeconomic status have been 
identified as factors which have an influence (Downing et al., 2007b, Delamothe, 2008, 
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Conway et al., 2007, Cuthbertson et al., 2009).  The All Party Parliamentary Group On 
Cancer in their 2009 report  on cancer inequalities support this and in addition highlight the 
fact that disability, sexual orientation and cancer type can also have an impact. 
2. 2.  Pathways to cancer diagnosis in England 
 
All residents in the UK are meant to be registered with a local GP practice or surgery in 
order to receive access to health services.  GPs are therefore, generally, the first point of 
contact within the health service.  A patient will present their symptoms to a GP to be 
treated or referred on, as a result GPs act as gatekeepers to specialist care and play a vital 
role in the diagnosis and early detection of cancer.  
In the case of cancer there are two basic diagnostic pathways that patients will receive 
a diagnosis through; symptomatic and asymptomatic. 
2. 2. 1.  Symptomatic/Referral 
 
When a GP is presented with symptoms by a patient, which they suspect to be cancer, 
a referral is usually made to a specialist in secondary care for the relevant diagnostic tests 
to be carried out and assessed.  These referrals can take time, depending on the time and 
resource constraints of the relevant hospital or health care facility/department. Research 
such as the EUROCARE studies have shown differences between European countries in 
cancer survival, and these have been attributed to differences in time to diagnosis (Møller 
et al., 2009, Sant et al., 2009, Verdecchia et al., 2007a, Richards, 2007).  In 1997 the two 
week referral (TWR) was introduced to reduce the waiting time for referrals, if a GP 
suspected a cancer then they could make an urgent referral and the target is for the patient 
to be seen by a specialist within two weeks.   
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Presentations and symptom identification is a problem for GPs in tackling cancer.  With 
more than 200 different types of cancer there are a vast range of symptoms and factors 
which affect their presentation.  In particular certain cancers, such as breast can present 
with a clear set of symptoms such as a breast lump and/or pain, and there are clear 
screening and diagnostic tests which can be used to achieve a diagnosis, such as a 
mammogram or biopsy.  Therefore these cancers can potentially be identified, diagnosed 
and treated quickly resulting in good health outcomes and survival.  However, there are 
equally a number of cancers which do not have clear symptoms.  For example, Barrett et al. 
(2010) identified that there is no validated screening test for ovarian cancer and therefore 
these cases present primarily through primary care as symptomatic cases, similarly in 
pancreatic cancer symptoms are vague and can be easily interpreted and attributed to a 
different health problem, such as back pain. 
This can make it difficult to identify which cases are appropriate for the two week 
referral.  However, to aid GPs identification as to whether a patient’s symptoms should be 
urgently referred on the TWR pathway, a series of guidelines based on ‘red flag’ symptoms 
have been developed and are regularly updated.  These red flag symptoms can also identify 
when to use intrusive diagnostic procedures, e.g. in cases such as colorectal cancer where it 
is difficult to identify and diagnose without the use of invasive procedures such as 
endoscopies (Jones et al., 2007, Hamilton et al., 2009, Hamilton et al., 2005, Jones et al., 
2009). 
The TWR scheme has been met with a mixed response and varied success (Jones et al., 
2001, Barwick et al., 2004, Cornford et al., 2004, Haikel et al., 2011, Potter et al., 2007).  
While, as highlighted above, certain cancers such as breast have benefitted from the 
system in comparison to other cancer types, the introduction of TWR/urgent referrals has 
created a strain on health care resources.  Hospital departments, in an effort to meet 
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targets have reported problems with trying to meet the demand, with some reporting 
seeing double the number of referrals each year.  Equally some research has indicated that 
despite increases in the number of referrals, seen there has been no improvement in the 
proportion of earlier stage cancers diagnosed (McKie et al., 2008). 
It should be noted that there are alternatives to a GP referral via this pathway. Patients 
could, for example, be admitted to hospital as an emergency admission because their 
symptoms are so severe, and then receive a diagnosis this way, thereby by-passing their GP 
and any primary care involvement in the diagnosis.  Emergency presentations are not 
uncommon and vary between cancer types, for example, Raine et al. (2010) reported 
finding an average rate of 15% for breast cancer emergency hospital admissions, while lung 
cancer was as high as 50%.  The National Cancer Intelligence Network has reported an 
average 25% rate of emergency hospital admissions for all cancers and Bottle et al. (Bottle 
et al., 2012) recently reported finding a 21.9% rate.  Higher rates of emergency admission 
to hospital for cancer are generally viewed as an indicator of poor quality within the local 
area/Primary Care Trust (PCT) (Downing et al., 2007b, Forrest et al., 2014).  Cancers 
diagnosed through emergency admissions are also more likely to be at a more advanced 
stage (Brewster et al., 2011, Downing et al., 2007b).   
2. 2. 2.  Asymptomatic 
 
In the asymptomatic pathway patients haven’t presented or experienced any 
symptoms to their GP.  Patients are called to, or participate in, a cancer screening 
programme or initiative which has then detected the cancer.  Currently there are three 
cancer screening programmes run by the NHS in England: 
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1. Breast - the NHS Breast Screening Programme invites all women between the ages 
of 50 and 70 for routine mammograms every three years.  Around 1.5 million 
women are screened every year.  It is important to highlight that this screening 
programme is conducted by and at screening units, not by GPs and their practice; 
however GPs do issue reminders if patients have not attended when invited.  
(http://www.cancerscreening.nhs.uk/breastscreen/index.html) 
2. Cervical – the NHS Cervical Screening Programme; while a major part of its aim and 
goal is to identify cancer it is not a specific screening programme for cancer, rather 
it detects abnormalities in the cervix which could lead to cancer.  All women 
between the ages of 25 – 64 are eligible for screening every 3-5 years, with over 3 
million women being screened each year. 
(http://www.cancerscreening.nhs.uk/cervical/index.html) 
3. Bowel – during this research the NHS Bowel Screening Programme was a new 
initiative that has now been rolled out across England.  The programme will screen 
both men and women aged 60 – 69, increasing to 74 in the near future.  
(http://www.cancerscreening.nhs.uk/bowel/index.html) 
 
Screening programmes for other types of cancer have been suggested, such as routine 
chest x-rays for lung cancer; however, such initiatives and programmes are either not cost 
effective or the validity of the test is not sufficient to warrant a national programme 
(Whynes, 2008). 
Patients can also be diagnosed through other asymptomatic routes.  In the UK the 
majority of health care is provided by the NHS but private health care is available at a cost.  
Annual health checks can include a variety of diagnostic procedures which could identify a 
cancer without the patient having presented any symptoms, for example it is not 
uncommon for chest x-rays or MRI scans to be used in health checks.  The discovery of a 
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cancer during health care treatment for another health issue is yet another avenue.  For 
example, the discovery of breast cancers during cosmetic procedures, such as breast 
augmentation. 
There are limitations to both pathways.  The asymptomatic pathway is limited because 
not all types of cancer can be easily identified through a national screening programme or 
even through simple diagnostic tests.  However, asymptomatic cancers are on average 
diagnosed at a less advanced stage (Rowlingson et al., 2013), although there is debate 
about whether this is always in the patient’s best interest.  For example, in breast cancer 
certain forms are slow to develop and therefore it may be that a patient would never be 
affected by the cancer in their lifetime but having it diagnosed through screening may 
result in them going through biopsies, surgery, chemotherapy etc. which cause discomfort 
and distress.  There is also the problem of false positives particularly in breast cancer where 
in a systematic review Hofvind et al. (2012) identified a false positive rate between 8-21%.  
False positives can cause high levels of stress and anxiety for patients and the clarity of 
information given to patients who participate in screening has been questioned (Gøtzsche 
et al., 2009) with regard to the risk of false positive results.  In addition to this there have 
been concerns expressed about the diagnostic tests used and the cost. In the case of breast 
cancer mammograms, research has suggested that they are no more effective than a 
health care professional who has received training conducting a breast examination 
(Barton et al., 1999). 
In the case of the symptomatic pathway there is an issue of time, as nothing can be 
done until a patient presents symptoms; the GP must make a suitable referral and then the 
specialist needs to make a diagnosis.  At any of these points delays can occur such as where 
a patient has delayed and then presents with a more advanced stage cancer which will 
have a negative impact upon their health outcome.  Delay by GPs has a likewise negative 
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impact upon a patient’s outcome.  With over 200 types of cancer, for the majority there is 
no screening programme and these will be diagnosed through a symptomatic pathway thus 
putting a strain on GPs and health care resources.  This makes the speed and accuracy with 
which a diagnosis is made, all the more important. Research has suggested, particularly in 
the case of ovarian cancer, that countries with a tradition of primary care, i.e. having GPs so 
specialist care is only accessible through primary care referral, have the worst mortality 
rates, therefore it has been suggested that the ‘gatekeeper’ process could be a factor in 
delay to diagnosis (Barrett et al., 2010).  
It should be noted that patients can fail to be diagnosed on either pathway and cases of 
cancer are sometimes not discovered until after death, during a post-mortem autopsy. 
2. 3.  EUROCARE  
 
Information and data regarding cancer is recorded and collated in the UK by regional 
cancer registries.  The data comes from multiple sources, such as death records, NHS 
records etc.  Cancer registries work with a range of organisations within their area; Primary 
Care Trusts (PCTs), Strategic Health Authorities (SHAs), cancer networks and national 
organisations, such as the Office of National Statistics (ONS), to produce healthcare figures 
and publications.   
Cancer registries are established across Europe and worldwide in selected countries.  
Information and data from the registries in Europe has been brought in and analysed 
together (with individual countries compared), in EUROCARE (European Cancer Registry); 
an on-going research project which has collected data and researched the survival of 
European cancer patients since 1989.  Since the project began EUROCARE has, in addition, 
used the data to detect substantial changes across regions and countries over time.   
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2. 3. 1.  Cancer survival rates 
 
The findings of EUROCARE research have impacted and influenced UK policy and 
practice, particularly in recent years as the UK has been found to have one of the lowest 
cancer survival rates in Europe, compared with countries of similar status (Coleman et al., 
2008, Verdecchia et al., 2007a, Allemani et al., 2010, Brenner et al., 2012, Møller et al., 
2009, Sant et al., 2009).  Improvements in cancer survival rates are a crucial measure as 
improvements in survival relate to and cause improvements in other aspects, such as 
quality of life.  For example, in breast cancer each subsequent year of survival has been 
found to increase patient quality of life (Cimprich et al., 2002).  However it should be noted 
that since the start of the EUROCARE studies cancer survival for most cancers has increased  
and the differences between countries has decreased (Richards, 2007).    
From the EUROCARE studies it was also found that in the four most common cancers 
(breast, colorectal, lung and prostate) and ovarian cancer, the UK had lower survival rates, 
compared to other European countries which had a similar national expenditure on health 
(Richards, 2007).  
The use of survival rates as an outcome measure for cancer is common within research 
(Rachet et al., 2010, Bonner et al., 2010, Saunders and Abel, 2014, Hwang et al., 2009, 
Abdel-Rahman et al., 2009), and research into cancer survival rates outside of the 
EUROCARE studies have found similar results (Holmberg et al., 2010, Bonner et al., 2010, 
Morris et al., 2011).  Specifically, in both lung (Holmberg et al., 2010) and colorectal (Morris 
et al., 2011) cancer, when compared with countries with a similar healthcare system, such 
as Norway and Sweden, England had lower five-year survival rates. 
There have been criticisms of this particular EUROCARE finding, regarding the study’s 
methodology; in particular they have been criticised for underestimating UK cancer survival 
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rates (Wilkinson, 2009).  In comparison to the majority of cancer registries across Europe 
the UK does not have a system of compulsory registration of cancer cases, meaning that 
there is a high amount of missing or incomplete data.  This has resulted in England having a 
high rate of registry data which is excluded by the EUROCARE studies, compared with the 
remainder of European cancer registries.  In particular England has over double the rate of 
cancers registered solely on the basis of death certificates (6.1% in England compared with 
2.7% for Europe)(Coleman et al., 2008).  These are obviously excluded because the cancer 
has been identified after death and so there is no diagnosis date and resulting ‘survival’ 
period.  While this does identify an issue in the data used by the EUROCARE studies it also 
highlights issues within the UK.  Even though these are small percentages it still means that 
6.1% of cancer cases recorded by UK cancer registries went undiagnosed during  the 
lifetime of a patient. 
Research has also identified other potential problems, some of which may account for 
or be associated with low survival rates.  Cancer registries do not routinely collect data 
regarding comorbidities in patients and therefore the EUROCARE studies do not sufficiently 
account for the impact that other and complex health issues may have upon delay to 
diagnosis and/or the receipt of treatment (Quaglia et al., 2009, Richards, 2009). 
Since EUROCARE began, as previously stated, survival rates have improved but equally 
improvements in treatment, such as new chemotherapy drugs and surgical techniques and 
diagnostic method, such as population screening programmes, have been made.  Thomson 
& Forman (2009) highlight that in oesophageal and pancreatic cancers improvements in 
chemotherapeutic regimens are responsible for improved survival rates rather than the 
identification of earlier stage cancers.  Brenner et al. (2012) suggested that progress in 
treatment therapy is the most important explanation for survival increases in colorectal 
cancer, but supports that awareness and early diagnosis contribute in some way.  However, 
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EUROCARE is and continues to be an important project as its findings have and do prompt 
further investigation and analysis in areas, such as diagnostic delay. 
What contributes to the low survival rates found in EUROCARE has been a major topic 
of debate within the UK.  Further investigation and analysis of the EUROCARE findings has 
attributed these low survival rates to diagnostic delay, specifically patients presenting with 
more advanced stage cancers at diagnosis (Thomson and Forman, 2009, Richards, 2007).  It 
has been found that the UK does have significantly longer delays in patients receiving a 
cancer diagnosis compared to select countries in Europe (Murchie et al., 2012).  Similarly 
more advanced stage cancers are understandably harder to treat whereas in cancers which 
have seen, for example, advances in treatments, improvements in diagnostic criteria and 
early detection/screening initiatives, survival rates have improved significantly (Evans and 
Møller, 2003, Karim-Kos et al., 2008, Coleman et al., 2003, Coleman et al., 2008).  Even just 
increasing one-year survival rates has been found to have a knock on effect, in particular 
survival after one year is associated with increased likelihood of survival at five years (Sant 
et al., 2009).  It has therefore become a focus and priority in the UK to improve early 
diagnosis and reduce diagnostic delay in an attempt to improve survival rates (Fern et al., 
2011).  However, trying to understand what causes diagnostic delay in the first place is an 
issue that is not fully understood (Tate et al., 2009). 
2. 4.  Barriers to early diagnosis 
 
The importance of delay is echoed by Macdonald et al. (2006) in their systematic 
review of upper gastrointestinal cancer, where they found that while many studies 
discussed delay in primary care, few actually studied it.  While a clear explanation for low 
survival rates and diagnostic delays has not been clearly established, research has 
identified a number of factors or barriers that can affect patients and cause delay on their 
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pathway to diagnosis.  Patient inequalities have been a particular focus in research and 
health care and it has been found that while the aim in health provision is equality for all 
and many strategies have been tried and implemented to provide this, socio-economic, 
geographical and access to healthcare inequalities still exists (Walters et al., 2011, 
Holmberg et al., 2010, Rachet et al., 2010). 
In the context of health care, inequality is seen as when an individual’s experience 
differs from what is perceived as the norm.  In particular age, sex, ethnic origin, geography 
and socioeconomic status are present across the health care system (Delamothe, 2008, 
Conway et al., 2007, Cuthbertson et al., 2009, Downing et al., 2007b).  The All Party 
Parliamentary Group On Cancer in their 2009 report  on cancer inequalities support this, 
highlighting in addition; disability, sexual orientation and cancer type as key inequalities 
that need to be tackled within health care. 
Inequalities in primary care have been particularly highlighted and increases in funding 
and government spending in the last 15-20 years reflect the motivation and need to tackle 
this problem (Asthana and Gibson, 2008b).  The focus has been on primary care as previous 
research has identified that once a diagnosis has been made and patients move from 
primary care into secondary care and beyond, the quality of health care becomes equitable 
(Vedavanam et al., 2009, Downing et al., 2007b, Strong et al., 2006).  However, there is 
research that suggests that there are some positive inequalities present in secondary care, 
for example older patients receiving cancer treatment more quickly than under 50 year old 
patients (Robertson et al., 2004).   
Geographical location has been found to present a number of influencing factors and 
barriers.  The socio-economic status of a region varies across the country, for example an 
inner-city area such as Central Manchester has a higher level of deprivation than North 
Dorset, which is more affluent (Asthana and Gibson, 2008a).  Living in a more deprived area 
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is associated with being diagnosed with a later stage of cancer compared to patients who 
live in more affluent areas (Downing et al., 2007b).   
Areas of the UK have higher numbers of hospital admissions and death rates where 
there are fewer GPs per head of population (Jarman et al., 2010).  The suggested 
explanation for this is that due to the greater demand on the GPs that are available, people 
go untreated, due to limited consultation slots etc., and therefore end up entering the 
health care system at a later stage as hospital emergency admissions.  Practices with more 
nurses perform better by QOF standards and this leads to actual improvements in patient 
health, rather than simply more effective administration (Griffiths et al., 2010).  It is 
generally the case that areas where there is a high demand on GPs are often areas of 
deprivation and within these, patients have reported experiencing delays in accessing their 
GPs (Mercer and Watt, 2007).   
This links to what is known as the ‘inverse care law’, which states that those most in 
need of health care are those least likely to receive it.  This has an impact at a population 
level because as demands on GPs increase, the quality of care decreases; for example 
reduced access to health care, shorter consultation times, which ultimately leads to 
increased hospital/emergency admissions.  Campbell et al. (2001) support this finding. In 
their investigation for quality of care they found deprivation of an area to be a predictor of 
quality of care.  They also found, adequate time for consultation, the size of practice and 
the team climate within the practice to be predictors of quality of care.  In a review of oral 
cancer cases from the Scottish cancer registry it was revealed that increases in the number 
of cases diagnosed were almost entirely attributed to patients living in the most deprived 
areas of Scotland (Conway et al., 2007).  However, Ashworth et al. (2007) found while there 
were differences between practices based on location the overall differences between 
primary care indicators in deprived and affluent areas were small.  Interestingly they did 
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observe that practices engaged in training performed better in deprived areas than their 
non-training counterparts. 
The distribution of funding within Primary Care Trusts (PCTs) has been found to differ 
between geographical regions, for example, in Oxfordshire PCT only £5,182 is spent on 
cancer treatment per patient whereas in Nottingham PCT £17,028 is made available for 
treatment per patient (Delamothe, 2008).   
Differences between cancer diagnoses in patients residing in rural versus urban areas 
have been well documented.  Those living in rural areas have greater distances to travel to 
access GPS and health care facilities which contribute to presenting with advanced cancer 
stage at diagnosis and suffering worse outcomes, and this has been observed both in the 
UK (Campbell et al., 2001, Lovett et al., 2002, Jones et al., 2008) and internationally (Liff et 
al., 1991, Launoy et al., 1992).  However, there is research to the contrary.  A Scottish study 
(Robertson et al., 2004) found that in the case of breast cancer women who lived in rural 
areas, and therefore lived further away from health care facilities, were treated more 
quickly than women living closer.   
Delays such as shorter consultation times can have a psychological impact upon 
patients in additional to delayed diagnosis.  Patients who are given longer consultations by 
their GPs have been found to become more enabled and are therefore generally happier 
and more able to cope with problems (Howie et al., 1999). 
The type of health care centre itself could also contribute towards diagnostic and 
treatment delays.  Cancer centres were found to have longer delays than other ‘non-
specialist’ health care centres (Robertson et al., 2004), possibly due to demand.  However, 
patients admitted to a ‘non-cancer’ centre were almost 50% less likely to go on to receive 
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chemotherapy compared with patients admitted to cancer units or centres (Pitchforth et 
al., 2002).  
2. 4. 1.  Andersen’s model of delay 
 
With such a wide ranging number of factors and barriers, attempts to organise and 
group these together into a model have been made.  The most common of which is 
Andersen’s model of delay (Andersen et al., 1995).  With this model there are three key 
stages that are pertinent to this research: 
1. Patient – an individual recognises a symptom(s) but does not act upon it 
and therefore does not immediately present the symptom(s) to their GP.  
Similarly patients may exclude or play down symptoms when they do see a 
GP.  A patient’s ability to communicate symptoms to a GP can also be an 
issue that causes delay. 
2. Practitioner – the GP fails to recognise the severity of the symptom(s) or 
does not recognise them as cancer symptoms; misdiagnosis.  As a result a 
referral is either not made or isn’t made with the necessary urgency. 
3. Hospital/system – once a GP has made the referral an administration error 
or simply overburdened resources cause delay; for example, long waiting 
lists, lost paperwork, miscommunication, issues with equipment and 
diagnostic sensitivity. 
 
Patient Delay 
 
Tromp et al. (2005) referred to patient delay as; ‘the way in which people cope with a 
symptom’ and the way in which an individual responds to this is vital to their decision to 
seek medical advice, or not to as the case may be.  In their research into Dutch patients 
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with head and neck cancer they found that an individual’s coping style (whether they had 
an avoidant or active strategy), defensive functioning, optimism and health hardiness were 
most related to patient delay.  A systematic review of upper gastrointestinal cancer 
(Macdonald et al., 2006) suggested that patient delay was greater than delays attributed to 
GPs, with symptom recognition, patient history and patient characteristics some of the 
main factors associated with delay.   
In the UK previous research has found that females, in particular those who are 
smokers or those who are in employment, delay seeking treatment for longer compared to 
non-smoking or retired females (Hansen et al., 2009).  Andersen et al. (1995) found that 
the main component of patient delay was how they interpreted their symptoms.  This is 
more recently supported by Corner et al. (2006) who in their investigation of patient delay 
in lung cancer found that, regardless of socio-economic status, patients simply did not 
identify their symptoms as anything serious and therefore did not seek treatment early.  
Following on from this, improving education about health and cancer symptoms has been 
found to contribute towards reducing patient delay.  From community intervention studies, 
such as Lyon et al. (2009) initiatives have been launched to raise awareness of cancer 
symptoms and after a year there were significantly more two week referrals and an 
increase in the number of diagnoses being made. 
GP delay 
 
In the same way that patients can have preconceptions that can cause delays so can 
GPs.  Research into GPs’ diagnoses of coronary heart disease found that when GPs were 
presented with the same symptoms by different people, females were asked fewer 
questions and given fewer examinations and diagnostic tests compared with males (Arber 
et al., 2006).  In addition Hansen et al. (2008) found that well-educated males and females 
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and those with a large household income experienced shorter doctor delays compared 
with their counterparts.  Crawford (2009) observed that there was a mind set in general 
practice of conserving resources (which includes diagnostic tools).  This causes delays and 
inequalities as it is then primarily the articulate and more assertive patients who get 
preferential care and make the most of available resources.   
System delay 
 
System delays can be difficult to measure.  The most researched delay is that around 
date of diagnosis within the UK as there is inconsistency in cancer records as to at what 
point a diagnosis is officially made.  For example, is it when the multi-disciplinary team at 
the hospital meet to make the diagnosis; is it the date the GP practice receives the 
diagnosis or the appointment date in which the GP informs the patient (Tate et al., 2009)?  
System delays can also  be hard to quantify as GPs may act quickly with referrals and 
patients be sent an appointment within the two week period. However, if a patient does 
not attend the appointment and is then subsequently diagnosed with cancer, the non-
attendance is not always accounted for in audit and delay statistics.  In Canada delays in 
breast cancer diagnosis were primarily attributed to system delays, specifically the 
scheduling of diagnostic procedures (Bairati et al., 2007).  Similar types of system delays 
have been reported in the US in the move from primary to secondary care, from receiving a 
diagnosis to getting treatment (Katz et al., 1993)., In particular African-American females 
experienced the most delays, compared with other ethnic groups (Gorin et al., 2007).   
The importance of specifically looking at delay and its causes is echoed by Macdonald 
et al. (2006). In a systematic review of delay to diagnosis in upper gastrointestinal cancer it 
was found that the patient phase of delay was greatest and, where practitioner delay 
occurred, misdiagnosis and the presence/confounding effect of an existing health problem 
were the main causes of delay (Macdonald et al., 2006). 
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The healthcare system within the UK is in some ways unique, and can therefore create 
a problem in terms of comparable research from other countries. However, delay and 
particular factors of delay do appear to be universal, with research in other countries and 
health systems having identified similar determinants and factors associated with delayed 
cancer diagnosis (Bairati et al., 2007). 
To tackle the issue of delays, reallocation of funding and the development of schemes 
and initiatives has been the usual response.  Funding schemes such as the Allocation of 
Resources to English Areas (AREA) are delivering more money and resources into deprived 
areas.  Macdonald et al. (2006), in their systematic review of upper gastrointestinal cancer 
found that in the last twenty years delay intervals have not actually decreased but have 
remained static.  This suggests that despite efforts no real improvements in tackling 
inequalities have been made.  Research by Asthana & Gibson (2008b) suggests that in 
terms of cancer such schemes as increasing funding in deprived areas are misguided.  In 
their re-analysis of data from health databases (including QOF) they found that cancer was 
more of a burden for GPs in less deprived areas.  This goes against conventional opinion 
and the inverse care law, suggesting that cancer is an exception compared to other 
diseases, such as diabetes and cardiovascular disease.  The suggestion for this change in 
pattern is that the elderly population is one of the highest risk groups for cancer and this 
particular group are more likely to reside within more affluent areas.  Another suggestion 
could be that patients in more deprived areas delay seeking consultations etc. and as a 
result are more likely to be diagnosed via hospital admissions, therefore by-passing the GP 
and primary care process all together. 
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2. 5.  Initiatives and Schemes 
 
In response to research and findings, such as EUROCARE, a number of schemes and 
initiatives have been developed and implemented. 
As discussed, in the pathways to diagnosis section, initiatives such as the two week 
wait and screening programmes such as those for breast cancer have been implemented in 
an effort to identify or ‘catch’ cancer at an earlier stage, or where cancer is suspected that 
a referral to a specialist is carried out quickly.  Previous research has linked early diagnosis, 
and diagnosis at a less advanced stage of cancer, with survival outcomes (Virnig et al., 
2009, Richards, 2007, Thomson and Forman, 2009) and the negative affect that delays, 
organisational issues, and access to healthcare can have upon early diagnosis (Holmberg et 
al., 2010, Daly and Collins, 2007, Jiwa et al., 2004).  Johnson et al (2011) identified that in 
endometrial cancer up to 1,600 women a year will delay up to six months, in presenting 
symptoms to their GP, and in their review of EUROCARE findings Abdel-Rahman et al (2009) 
identified that between 6,600 – 7,500 of cancer cases in England resulted in premature or 
avoidable deaths, highlighting the importance of continued research and improvements in 
this area. 
In November 2008 the Department of Health (DoH) created and launched, as part of its 
‘Cancer Reform Strategy’, NAEDI (National Awareness and Early Diagnosis Initiative).  The 
aim of NAEDI is to make progress in improving national cancer outcomes by coordinating 
and providing support to initiatives and research into early diagnosis of cancer.  NAEDI 
currently have four ‘work streams’ to achieve this: 
 
33 
 
1. Achieving early presentation by public and patients – specifically increasing public 
awareness of cancer symptoms and also reducing barriers to patient  access of health 
care services. 
2. Optimising clinical practice and systems – the focus of this is around GPs and their 
awareness of ‘red flag’ symptoms along with improving referral and interaction 
between primary and secondary care. 
3. Improving GP access to diagnostics – this has involved a survey of GPs to ascertain 
which resources, services and support they require to deliver a fast and accurate 
diagnosis.  
4. Research, evaluation and monitoring – this final stream is to ensure that work done 
by NAEDI is accurate and to evaluate any initiatives that are developed. 
 
Of particular interest, in the initial work conducted by NAEDI there has been a 
systematic review of the potential link between more advanced stages of cancer at 
diagnosis and poorer health outcomes in the UK.  The review did find that such a link exists, 
supporting the idea that earlier diagnosis at a less advanced stage will give better 
outcomes, such as increased survival (Richards, 2009). 
2. 6.  Current climate 
 
Since the start of this project there have been a number of economic and political 
changes that have or will affect health care and the NHS in the future.  In particular the 
global recession that first hit in 2008, and again in 2011, has had a profound effect on the 
funding and resources available to the NHS. 
However, everyone is feeling the effects of the global recession.  Being out of work, 
losing a job and the threat of job losses has both a negative physical and psychological 
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impact on people (Torjesen, 2010).  As a result, greater demands have been placed on the 
NHS to help and provide support; for example, within mental health in 2009, 39.1m 
prescriptions were issued for anti-depressants, almost double the number ten years 
previously in 1999 (20.1m (Davis, 2010)) and a 3.2m increase on the previous year 2008, 
35.9m (Torjesen, 2010).  Issues such as patients struggling to afford prescriptions for 
chronic conditions have risen as a result of the recession (Asthma UK, 2009). 
Money into cancer research had been consistently increasing and in the last ten years 
has doubled, in 2010 it was £504 million and as part of the government’s 2010 spending 
review, the fund for cancer drugs was to be increased to £200 million per year.  From these 
figures we can see that there has been a huge amount of investment into tackling cancer 
but since 2010 the NHS has been set the target of reducing its spending by up to £20 billion 
by 2014. 
It’s been highlighted that within England certain regions and areas have been affected 
more by the recession, specifically the northern regions of the country (Whitehead and 
Doran, 2011).  Northern regions have seen increased unemployment rates and higher 
government spending cuts, particularly in welfare benefits and public services (Cox and 
Schmuecker, 2010).  Prior to the recession it had been observed that there was an unequal 
distribution of GPs across the country, with fewer GPs per head of population in the 
Northern regions.  This puts Northern region NHS services in a position of having fewer 
resources but with a greater demand and need for those resources compared to other 
regions in the country.   
The NHS and health care within the UK is constantly changing; regular reforms along 
with changes of government mean that many schemes and initiatives are put in place and 
then changed a few years later.  In 1999, as part of a reform to implement national clinical 
governance the CGST (Clinical Governance Support Team) was established.  The CGST was 
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closed in 2008 and power was transferred to a local level with individual SHAs (Strategic 
Health Authorities) responsible for providing clinical governance in their area.  As part of 
the new health and social care bill SHAs will now be disbanded in favour of clinical 
commisioning groups. 
During the time of this research there was also a change in government in 2010, from a 
Labour government to a coalition Conservative/Liberal Democrat government.  Aside from 
large funding cuts in reaction to the continuing recession, the new government has looked 
to carry out a number of health and NHS reforms.  This has resulted in a number of 
initiatives and schemes that are currently being implemented across the country. 
2. 6. 1.  GP commissioning 
 
As part of the current government’s reform of the NHS it has been proposed that from 
2013 GP-led clinical commissioning groups will be established (Mannion, 2011, Charlton, 
2013).  GP commissioning will give GPs greater control and responsibility of their funding, 
which is worth £60 billion across England.  It is the rationale of this reform that because 
patients generally access health services through their GP, GPs are best placed within 
health care and have the greatest knowledge of where funding and resources would be 
best used.  This reform has received a mixed response with concerns expressed about; 
whether GPs will have and receive the necessary support they will require, if 
commissioning will take up too much of GPs’ time rather than time spent with patients 
(which is already in high demand) and questions about how it will be fairly governed (Smith 
and Mays, 2012). 
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2. 6. 2.  New NHS ‘Health and Social Care Bill’ 
 
The ‘Health and Social Care Bill’ is a complex new Bill by the coalition government 
which will constitute one of the biggest NHS reforms in the NHS history.  Some major 
changes will be the abolishment of PCTs and SHAs and the forming of a range of new 
bodies and regulatory groups. 
Key concerns have been expressed around such a radical restructuring, particularly in 
the current economic climate where NHS resources and time are at their most stretched.  
The introduction of a greater level of competition and privatisation is also of concern as it 
goes against the philosophical foundations of the NHS, specifically the provision of 
universal comprehensive health services (Ham, 2012). 
2. 7.  Quality of care 
 
As mentioned, large scale studies such as EUROCARE have sparked further and more in-
depth research.  From this it has been suggested and found that the quality of care a 
patient receives can contribute and impact upon their survival outcomes.  Sant et al. (2009) 
stated that; 
‘ . . . survival differences are greatly influenced by mortality in the first year, which in 
turn depends largely on tumour stage at presentation and presence of comorbidities, and 
these factors are again partly dependent on the quality of health care.’ 
The quality of care patients receive at every point from presentation through 
treatment has been linked and found to contribute towards survival (Sant et al., 2009, 
Gatta et al., 2010).  However, the issue of what constitutes quality of care and how it is 
measured raises questions.  In particular when looking at elderly populations it has been 
found that as age increases patients are treated less often; specifically, they are less likely 
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to undergo surgical interventions and chemotherapy (Gatta et al., 2010).  This could be and 
is interpreted as being a negative outcome, as not receiving these treatments reduces 
survival. However, if a patient has additional health issues/comorbidities which makes 
receiving such interventions risky or potentially give little benefit to the patient then 
withholding such treatments can be a good quality decision. 
It became clear that quality of care is an important component and issue within 
primary care and therefore a more in-depth look at quality of care and how it is measured 
within primary care was conducted in the form of a systematic review, which can be found 
in chapter 3. 
2. 8.  Health database research  
 
The funding for this research is part of an e-health initiative by the ESRC.  The aim is to 
utilise existing health databases and, where possible to combine them for the purposes of 
research. 
As mentioned there are criticisms of health databases regarding accuracy but equally 
these databases are a large scale resource that can be of great benefit to research.  Despite 
criticisms, cancer registry data is used internationally in research to great effect, such as 
EUROCARE, and within England, regional and national data from cancer registries is 
regularly used within research. 
Common problems are that data can be missing or there is inadequate information and 
also where there is confusion over when events have occurred, for example the use of 
cancer diagnosis dates.  Majeed et al. (2007) supports this notion that databases are 
problematic but suggests that by linking databases together information can be cross 
checked, thereby improving the accuracy of the data available.  This is highlighted in a 
study by Pascoe et al. (2008) where cases of cancer reported in GP records were compared 
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with the cancer registry.  Whilst they found that one in five patients with cancer were not 
identified using database codes in GP records, they were able to identify the other cases via 
the cancer registry database.     
For this research the cancer stage at diagnosis is being used as the key patient variable.  
Downing et al. (2007b) when investigating stage of cancer at diagnosis in the UK, found 
that from the electronic databases used, staging information was available in over 90% of 
cases.  This is reflected in the data available from the Northern and Yorkshire Cancer 
Registry who list breast and colorectal as two of the commonest cancers for staging 
information within their dataset. 
2. 9.  Cancer stage as a measure 
 
The use of stage of cancer at diagnosis is a novel approach, previously such information 
has been limited and inconsistent as it had simply not been recorded into health care 
databases or the guidelines for attributing a stage have been too ambiguous.  Recent 
reforms to the guidelines in the staging classification of cancers such as breast and 
colorectal, the cancers being used in this research, have meant that the quality and validity 
of staging information has improved (Perry and Thurston, 2008, Fox and Fletcher, 2007).  In 
recent years there have also been great improvements in the identification of alarm 
symptoms that are associated with increased likelihood of cancer which can be used to 
help GPs provide quicker referrals and ultimately diagnosis (Hamilton et al., 2005, Jones et 
al., 2007). 
The alternative would be to use time to diagnosis but this is problematic as there is 
often confusion and inconsistency in health records as to what is regarded as the actual 
date of diagnosis.  For example, some consider it to be the date the multi-disciplinary team 
39 
 
meet, the date the letter is sent from the GP practice or even the date of the patient’s 
appointment with a specialist. 
Stage of cancer at diagnosis and inequalities have already been linked in previous 
research, for example as patient distance from a cancer centre increases so does the 
likelihood of a high stage of cancer at diagnosis (Campbell et al., 2001).  In both the US and 
UK inequalities based on ethnicity have also been found; Hahn et al. (2007) observed that 
African-American females were more likely to be diagnosed with a later stage of breast 
cancer, compared with white females.  In the UK Jack et al. (2009) had similar findings, with 
white females firstly more likely to actually have a cancer stage recorded at diagnosis and 
when compared with other ethnic groups this was more likely to be a less advanced stage. 
2. 10.  Research aims  
 
The aim of this research is to utilise these new and improved sources of data to 
investigate the association between GP practice quality and cancer stage at diagnosis.  As 
part of this, the effect of previously identified inequalities, such as deprivation and age, will 
be included to examine how they interact and affect this association.   
By exploring this potential link between practice quality and cancer stage, 
recommendations can be made that can inform future policy, specifically informing the 
direction and distribution of resources and funding within primary cancer care.  The 
working hypothesis for this research is that patients of GP practices that report higher 
levels of quality will show less advanced cancer stage at diagnosis compared with those 
from GP practices which report lower levels of practice quality.  This is based upon the 
assumption that practices which report high practice quality are able to more efficiently 
diagnose potential cancer cases at an earlier stage.  Equally it is hypothesised that practices 
which are located in deprived areas will have more advanced stage cancers.  
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This is an important association to investigate as much previous research has suggested 
that an association exists, and highlighted that GPs have an influence upon cancer 
diagnosis, but as yet a direct investigation has not been made.  In essence we have 
assumed that GP quality influences cancer diagnosis without actually researching that link.  
Greater information and data is now held on GPs, patients and quality practices and 
standards and it is also the aim of this research to utilise that available data to attempt to 
provide more specific explanations for any links or associations found. 
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3. Chapter 3: Systematic Literature Review 
 
This chapter consists of a systematic review of the methods which have been used 
to assess GP practice quality in cancer and its impact on patient outcomes.  Quality of care 
is a widely debated issue within healthcare and a summary of the key points are outlined at 
the start of this review.  Measures that have previously or are now currently used to assess 
quality, specifically in primary care in England, are also outlined. 
A search strategy and inclusion/exclusion criteria were developed and the health 
databases MEDLINE and EMBASE were used for the search.  A second reviewer was used to 
reduce bias and to assist in selecting articles which met the criteria.  After the review 
process, 37 studies remained and a narrative analysis of these studies was conducted, with 
the findings reported in this review. 
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Review title:  
Measurements and assessments of GP practice quality in cancer; 
from presentation of symptoms to diagnosis, and its impact on 
cancer outcomes 
 
Cancer is an increasing disease burden, not just within the UK but on an international 
and global scale.  Cancer is a worldwide leading cause of death and it is predicted that the 
number of deaths due to cancer will nearly double by 2030, to over 13.1m (World Health 
Organisation).  In the UK over 300,000 cases of cancer were diagnosed in 2012, a figure 
which has doubled in the last five years (Cancer Research UK).   
Compared with European countries of a similar status the UK has been found to have 
lower survival rates for cancer and diagnostic delay has been found to be a key contributor 
to these low survival rates (Richards, 2007, Verdecchia et al., 2007a).  In particular the UK 
has significantly longer delays in patients receiving a cancer diagnosis (Murchie et al., 2012) 
and a greater number of patients presenting with more advanced stage cancers at 
diagnosis (Thomson and Forman, 2009), compared to other European countries.  Further 
investigation into the area of diagnostic delays has highlighted the importance of quality of 
care in reducing delays and improving survival outcomes (Sant et al., 2009, Gatta et al., 
2010). 
This systematic review was conducted to examine the methods which had been used to 
assess primary care quality, with particular reference to cancer.  This was in part to review 
what primary care quality measures and resources had been used, to inform this study if 
necessary, but also to see what the current knowledge base of this research area was and 
where the gaps lay. 
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Quality of care is an important issue within health care and within the UK there is some 
evidence that once a diagnosis has been made and a patient moves into secondary care for 
treatment of cancer that the quality of their care becomes equitable (Una et al., 2000, 
Vedavanam et al., 2009).  However, there is good evidence that the quality of care results 
in delays to diagnosis for patients, and that this is mediated by factors such as, socio-
economic status, ethnic background and sex (Abel et al., Herold et al., 1997, Johnson et al., 
2008, Baird and Wright, 2006, McLean et al., 2006, Strong et al., 2006, Adams et al., 2004a, 
Adams et al., 2004b) 
What constitutes quality of care is an area of debate and the ideas and definitions in 
this area are continually changing and updating (Blumenthal, 1996a, Blumenthal, 1996b, 
Blumenthal, 2012, Roland et al., 2012).  There are three key issues that contribute to the 
difficulty in defining quality of care: 
• Perspective - The role or position an individual or group has within the health care 
system affects and alters what is expected in terms of quality.  For example, a GP 
may judge good quality to be that which has a good evidence base and best chance 
of success, while a patient may view good quality of care as the option that causes 
the least disruption to their normal life.  It could also be that just between 
individuals within a group there is a difference in opinion as to what constitutes 
good quality of care. 
• Sustainability – Particularly within the UK, the health care system experiences 
regular reforms, these changes can cause disruption and there is often an 
adjustment period following changes which can affect the provision of quality of 
care.  Additionally, in this recession the health care system in the UK has been 
subject to heavy funding cuts and financial restrictions, which has led to more 
changes and reforms, or the cancelling of services. 
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• Generalisability – While the focus of this systematic review and project is on 
cancer, there are many other diseases, health problems and issues, which the 
health care system must address and treat.  While it could be argued that the main 
points of quality of care are the same regardless of the health issue there are 
individual points that are specific to certain diseases and groups of health issues.  In 
essence, what constitutes quality of care for one disease won’t necessarily be the 
case for another disease. 
Howie et al. (1994, 1997, 2004, 1989, 1991, 1999), investigated and conducted a 
number of studies and reviews during the 1990s into quality of care, particularly at a 
primary care level.  When defining quality of care, in 1994, they stated that;  
‘Effective primary care entails listing the needs of a patient at a consultation, deciding 
on the priority for dealing with these needs, and giving care that meets the need or needs 
selected for attention.’   
This is a particularly patient centred definition of quality of care, in later work they 
added that a patient’s health should be improved or at least deterioration of a disease 
halted, unless deterioration is inevitable and then appropriate support and care should be 
offered.  Additionally, upon leaving a consultation patients should be satisfied and their 
understanding and ability to cope should have increased. 
Campbell et al. (2000, 2002a, 2003), during their research into quality of care in the 
early 2000s, suggested that there are two key dimensions to quality of care; access and 
effectiveness.  Their approach could be considered more from an organisational and 
system’s perspective, focusing on the provision of health care and its effectiveness in 
treating or slowing the deterioration of a disease. 
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The NHS in its definition of quality of care reflects and tries to incorporate these 
different definitions and perspectives.  As the principal provider of health care within the 
UK it has worked to a shared definition of quality which comprises of three key elements 
(Darzi, 2008, National Quality Board, 2011): 
 The effectiveness of the treatment and care provided to patients. 
 The safety of treatment and care provided to patients. 
 The experience patients have of the treatment and care they receive. 
Quality standards within the UK are overseen by national and government agencies, 
the primary one of these is NICE (National Institute for Health and Care Excellence), which 
was a government agency but is now a public body.  Their role is to improve health 
outcomes for the UK public by providing evidence-based guidance and advice and 
developing quality standards for health and social care.  In their definition and guidance for 
what describes and constitutes high quality care for a patient there are fourteen points, 
ranging from effective communication between the patient and health professionals to 
respecting patient wishes and preferences and regular checks throughout their treatment 
(National Institute for Health and Clinical Excellence, 2012). 
3. 1.  How is quality of care measured? 
 
‘The effectiveness of clinical care depends on the effective application of knowledge 
based care’(Campbell et al., 2002b) 
Measures of knowledge are a long established method for assuring and measuring 
quality and internationally, GP reaccreditation and training is a key and common method 
used (Davis and Ringsted, 2006, Lal et al., 2004, Regnier et al., 2005).  In the US specific 
cancer quality assessment tools have also been developed, such as the Quality Oncology 
Practice Initiative (QOPI) (Neuss et al., 2005). 
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In the UK, traditionally responsibility for quality of care has been in the hands of the 
individual GP and professional bodies, such as the Royal College of General Practitioners 
(RCGP).  Continued professional development (CPD), training schemes and the associated 
reaccreditation checks have played a part in quality assurance but have been criticised for 
being imprecise measures (Scrivens, 1995). 
In the later part of the 1990s, despite disagreements about definitions, quality 
improvement in the provision of health care became a high priority on the agenda in the 
UK and internationally (Campbell et al., 2000).  What followed was a large amount of 
investigation and research into quality of health care, how it could be measured and the 
development of a national performance network within the NHS.  As a result incentive 
schemes were introduced, where meeting certain aims or targets results in a financial 
reward.  Importantly for GPs this equated to additional funding for their practice for 
resources, such as equipment, prescriptions and staff. 
These incentive schemes were incorporated into the General Medical Services contract 
and have developed into a scheme known as the Quality and Outcomes Framework (QOF).  
Since its introduction in 2004, QOF has been reviewed annually and is continually changing, 
in 2001/12 QOF was made up of 142 indicators across four domains.  These were: 
 clinical care: the domain consists of clinical areas, i.e. coronary heart disease, heart 
failure, hypertension. 
 organisational: the domain is across six organisational areas – records and 
information; patient communication; education and training; quality and 
productivity; practice management and medicines management. 
 patient experience: the domain relates to length of consultations. 
 additional services: the domain is across four service areas – cervical screening, 
child health surveillance, maternity service and contraceptive services. 
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QOF has received a lot of criticism since it was first introduced.  Initially there were 
questions regarding whether it was measuring the correct indicators and whether it was in-
line with the guidance of other quality agencies, such as NICE (Vedavanam et al., 2009, 
Downing et al., 2007b, Short, 2007).  Particularly for the question asked in this review, 
where the focus is on quality of care in cancer, QOF indicators related to cancer are limited, 
mainly relating to prevalence and follow up care rather than diagnosis. 
There have also been a number of questions raised about the option for GPs to 
exception report within QOF.  This is where GPs can exclude patients from the numerator 
for an indicator on specified grounds.  A trend of high exception reporting was observed 
within deprived areas, with the suggestion that this trend was an attempt to maximise 
funding rather than legitimately excluding exceptional cases (Sigfrid et al., 2006, McLean et 
al., 2006). 
Brook et al.(1996) stated;  
‘It will never be possible to produce an error-free measure of the quality of care’. 
This is an important consideration, as while an error-free measure is impossible, it is 
therefore all the more important to ensure that the measure(s) that are being used are as 
appropriate and accurate as possible.  Concerns have been voiced and research has found 
that inappropriate methodologies and inaccurate data have been used to measure quality 
of care and this ultimately has a negative impact upon quality but also wastes resources 
and can mean real issues are side-lined (Blumenthal, 1997, Blumenthal, 2012, Brook and 
McGlynn, 1996, Campbell et al., 2002b).   
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3. 2.  Review objectives 
 
The aim of this review is to identify and assess recent and current assessments of GP 
practice quality and the potential link, influence and impact this has upon cancer diagnosis. 
3. 3.  Search strategy 
 
For this review a search string of relevant key words was developed to find articles 
which related to cancer and the quality of primary care.  The searches were conducted in 
EMBASE and MEDLINE.  Keywords were identified through MeSH terms relating to cancer 
and practice quality from already identified literature and subgroups available in EMBASE 
and MEDLINE.   
For this review the key aspects were; cancer and GP quality.  While certain terms were 
kept general and open, such as the keywords for cancer (cancer or neoplasm), there were 
problems with identifying suitable keywords for practice quality.  In particular when quality 
was used as a keyword the majority of articles that were returned related to quality of life.  
More specific and direct keywords were developed from the MeSH terms (i.e., health care 
quality or quality control in EMBASE) and primary care as a keyword was added to help 
reduce the number of palliative/secondary care articles.   
Measuring GP practice quality is a reasonably new concept with systems such as QOF 
only being introduced within the last ten years.  Equally healthcare practices and structures 
are constantly changing and therefore studies, for example, from the 1950s would not be 
relevant.  As a result a cut off was placed, by the lead reviewer, to only include studies from 
1980 to 2011.  While the UK health care system is unique and articles from other countries 
may not be directly relevant these were still included, for comparative narrative analysis, 
provided they assessed practice quality and cancer. 
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Slightly different strategies were required for the two databases due to differing MeSH 
terms, for example, family physician instead of general practitioner.   
It is worth noting that the need to vary MeSH terms could be down to the different 
make-up of the two databases.  In particular the results from EMBASE were much more 
likely to be UK and European articles, where the term GP or general practitioner is used.  In 
comparison when searching MEDLINE the use of GP or general practitioner was not 
recognised but physician or family physician was.   
While both EMBASE and MEDLINE are well-known and used biomedical databases 
there are differences between the two.  MEDLINE (Lancet Oncology, 2001) is part of the US 
National Library of Medicine and currently consists of over 19 million references from 
5,600 different worldwide journals in the area of life science, with a concentration on 
biomedicine.  EMBASE (Hansen et al., 2008) in comparison is a biomedical database by the 
European based, global publishing company Elsevier, and has over 25 million references 
from over 7,600 different worldwide journals. 
While there is a large amount of overlap between the two databases in their aims and 
the references they contain, there would also appear to be differences in their approach.  
In particular, the fact that MEDLINE is led by a US based organisation might contribute to 
and explain why the majority of studies in the MEDLINE search output were US based 
studies.  This may also explain why using the term physician in the search strategy, which is 
more commonly used in the US, worked more efficiently in the MEDLINE search. 
Between the two databases some differences in the joining of terms had to be made.  
Specifically the combining of terms such as GP and primary care by using ‘and’ or ‘or’.  
Initially terms related to GP (GP, general practice and general practitioner) were combined 
together and terms related to primary care (primary health care and primary medical care) 
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were combined together separately.  This worked well in EMBASE but in MEDLINE a large 
number of palliative care articles were returned.  This could be due to the involvement of 
GPs in post diagnostic care as co-ordinators for continuous and palliative care and it is a 
QOF indicator that GPs are required to do a three to six month review of cases.  The 
decision was made in MEDLINE to combine the ‘GP’ and ‘primary care’ terms to reduce the 
number of continuous and palliative care studies. 
3. 4.  What to include/exclude? 
 
Cancer is a wide ranging disease, affecting different areas of the body, and each cancer 
type presents in different ways.  As a result patients arrive at a diagnosis through a range of 
pathways and scenarios.  While GPs are often thought of as the gatekeepers to secondary 
care there are cancer pathways which can by-pass GPs.  Diagnostic pathways can be 
categorised as follows; 
1. Symptomatic – this could be considered the more traditional pathway whereby a 
patient makes an appointment to see their GP, presents symptoms which could be 
cancer and is subsequently referred for diagnostic/specialist test(s). 
2. Asymptomatic – in this case the patient has not presented any symptoms to a GP 
and may in fact not demonstrate any outward health problems but has been 
through a screening examination that has picked up potential signs of cancer and a 
resulting referral for diagnostic/specialist test(s) has been made.  For example, in 
England there is a national breast screening program which targets women 
between the ages of 50-70 (the high risk age group for breast cancer) to have a 
mammogram every three years during this age range.  This screening is co-
ordinated via regional centres rather than through their GP; in contrast the cervical 
screening programme is delivered through general practice. 
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The decision to include international studies means it is important to bear in mind the 
differences in health service provision between countries.  In the UK screening for selected 
cancers, such as breast and the use of mammograms, has also become part of private 
practice.  Patients, at a cost, can request such screening as part of a health check or 
examination.  The use of private health services is increasing within the UK but in other 
parts of the world, such as the USA, it is well established. 
The distinction between symptomatic and asymptomatic patients is important because 
it impacts upon the level of interaction and therefore the quality of care the patient 
receives from their GP.  While the quality of screening techniques and programmes may 
influence cancer outcomes GPs do not always conduct or are involved with cancer 
screening.  Therefore, for this review measurements and assessments of screening and 
asymptomatic cancer pathways were not included as the involvement of a GP is not 
consistent. 
Within England there has been an effort to measure and reward GP practice quality 
with the introduction of the Quality and Outcomes Framework (QOF).  QOF has only been 
introduced in the last ten years and has already undergone a number of reforms.  Similar 
systems are not yet established in other countries.  For this review systems such as QOF are 
useful as they provide a clear measure of quality with clear outcomes.  In the absence of 
such a system, GP practice quality can be measured by a wide variety of alternative 
methods.  When trying to determine whether a method is appropriate for this review it is 
important to remember and focus on whether firstly GP quality is actually part of the 
outcome and secondly whether there is some form of quantifiable measure. 
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3. 5.  Inclusion/exclusion criteria 
 
To meet the objective of this review, inclusion and exclusion criteria were required to 
identify which studies should be included in the narrative synthesis.  The criteria were as 
follows: 
1. Cancer related – All cancers were included.  Other diseases may be mentioned or 
be the focus but cancer must be included in the analysis in some way.   
2. Measures or assesses GP quality – A form of measurement or assessment needs to 
be used.  On a specific note, articles which look at guideline adherence would also 
be a measure of quality.  Decisions to refer for screening can be included and used 
as a measure of quality.   
3. Diagnosis – Studies of patient after care and management were excluded, since the 
focus of this review is on the period leading to diagnosis.  Studies which look at 
delay to presentation or care after diagnosis were not included. 
4. Genetic testing – Studies of genetic risk assessment were excluded. 
5. Skin surgery – Studies in this area needed careful consideration.  Skin lesion 
removal is a common procedure by GPs.  GPs’ performance can be measured 
against guidelines, e.g. for excision margins, and these studies were included.  
However, studies which compare GPs’ performance against that of specialists, but 
not against objective standards or guidelines were excluded. 
6. Screening - It is important to highlight that cancer screening programmes operate 
in different ways.  For example, breast cancer screening is not done by GPs.  
Therefore any articles which solely addressed breast cancer screening were 
excluded.  However, other cancer screening, such as cervical, is done in practice 
and is a measure of practice quality.  As a result articles which related to screening 
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were carefully considered and only included if they were directly related to GPs 
and/or practice and the quality/provision of services. 
7. Additional –  
a. Reports had to be of primary studies, therefore reviews, editorials etc. 
were excluded.  Articles should be in English, articles in other languages 
were excluded and articles had to have been published in or after 1980. 
b. Influences on GPs - measures such as GP preferences and patient influence 
on GP, i.e. sex of GP, patient demands or GP behaviours like smoking are 
not direct measures of quality.  However these articles were included as 
they look at influential factors which ultimately impact upon quality and 
generally these articles to discuss the impact upon a quality measure, e.g. a 
study into why GPs overuse PSA testing. 
3. 6.  Review process 
 
Once the search strategy and review criteria had been developed, the principal 
investigator (HW) then conducted the review.  First, by carrying out the search strategy in 
both EMBASE and MEDLINE and then reviewing the two sets of search results, excluding 
any studies which did not fulfil the review criteria.  A number of studies could be excluded 
by reviewing the titles; for example, if there was mention of continuous or palliative care 
within the title, but the majority required a review of the studies abstracts to make the 
decision as to whether it met the review criteria.  Once both search results had been 
reviewed the process was then repeated by a second reviewer. 
To help reduce any investigator bias a second reviewer (Lynne Forrest) reviewed the 
search outputs.  Once the search strategies have been developed and carried out, a copy of 
the outputs and the above inclusion/exclusion criteria was given to LF.  LF then 
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independently reviewed the search results, excluding articles which did not fulfil the review 
criteria.  The next step was to review the abstracts that remained and further exclude any 
articles which did not meet the criteria on further scrutiny.  The principal investigator (HW) 
and LF then met and discussed which studies they had identified as being eligible.  Any 
study where there was not a consensus was then discussed as to decide its eligibility and 
whether it would be included in the final number; if an agreement could not be reached 
the study was given to a third reviewer (Greg Rubin) for a decision. 
Once an agreed list had been compiled, then the full article was reviewed by the 
principal and second reviewer and any final discussions or exclusions were made.  The final 
studies were then selected and for these, the reference sections were hand searched, by 
HW, for additional articles which may have been of interest/relevant to the review. 
3. 7.  EMBASE 
 
The keywords and number of articles, number shown in the brackets, which were 
found in the EMBASE search were as follows: 
1.     cancer.mp. or neoplasm/ (1559275) 
2.     GENERAL PRACTICE/ or GENERAL PRACTITIONER/ (94851) 
3.     exp HEALTH CARE QUALITY/ or QUALITY CONTROL/ (1504228) 
4.     PRIMARY HEALTH CARE/ or PRIMARY MEDICAL CARE/ (79202) 
5.     1 and 2 and 3 and 4 and 5 (309) 
One article was unavailable in English and this was excluded.   
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3. 8.  MEDLINE 
 
The search was also conducted in MEDLINE, with slight changes to the keywords as the 
two databases have differing MeSH terms, i.e. family physician instead of general 
practitioner.  Initial searches in MEDLINE brought back large numbers of articles and also a 
large number of palliative care and quality of life articles so the search had to be further 
refined and made more specific and detailed (compared to the EMBASE search) to reduce 
the number of these articles. 
1.     Cancer.mp. or Neoplasms/ (876977) 
2.     Health Care Surveys/ or "Delivery of Health Care"/ or "Outcome and Process 
Assessment (Health Care)"/ or "Quality of Health Care"/ or Quality Assurance, 
Health Care/ or Family Health/ or "Outcome Assessment (Health Care)"/ or Quality 
Indicators, Health Care/ (224644) 
3.     Family Practice/ or Physicians, Family/ (68792) 
4.     Family Practice/ or General Practice/ or Primary Health Care/ (97226) 
5.     3 or 4 (106970) 
6.     Delayed Diagnosis/ or Early Diagnosis/ (7751) 
7.     "Referral and Consultation"/ (44673) 
8.     Healthcare Disparities/ or Health Status Disparities/ (6173) 
9.     6 or 7 or 8 (58205) 
10.   2 or 9 (277090) 
11.   1 and 5 and 10 (845) 
12.   Remove duplicates from 11 (837) 
13.   Limit 12 to (english language and yr="1980 -Current") (759) 
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3. 9.  Final articles 
 
After review the final number of studies was 37.  Due to the nature of the topic area 
and the wide variety of methods within the studies it was deemed appropriate to group 
together studies which had common themes, for narrative synthesis.  As a result four 
primary categories were produced, with two of these being further sub-divided: 
1. Self-reported guideline adherence – referral to screening [18] 
a. Guidelines only [11] 
b. Other influencing factors [7] 
2. Organisational [4] 
3. Clinical guideline adherence [12] 
a. Screening [3] 
b. Referrals [5] 
c. Excisions [4] 
4. GP influences [3] 
A Table (1) outlining and summarising each article follows: 
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Table 1.  Outline summary of the papers included in the systematic review. 
Self-reported guideline adherence 
Guidelines only 
Author/Date Title Location Topic Sample 
(N) 
Measures and 
method of 
assessment 
Summary of study 
Ka’ano’i et al., 2004 
(Ka'ano'i et al., 2004) 
Primary care 
physicians’ 
knowledge, 
attitudes and 
practices related to 
cancer screening 
and cancer 
prevention clinical 
trials 
US - Hawaii Cancer 
screening 
and clinical 
trials 
N = 254 GPs surveyed GPs responded that that they were familiar with screening 
guidelines, ranging between 55-90% for different types of 
screening.  Awareness and interest in clinical trials was 
around two thirds. 
McGregor et al., 
2004 (McGregor et 
al., 2004) 
Colorectal cancer 
screening: 
practices and 
opinions of primary 
care physicians 
Canada Colorectal 
cancer 
screening 
N = 965 GPs surveyed 41.9% of the GPs were not familiar with the current 
guidelines but most (72%) thought screening was 
beneficial but had concerns about cost-effectiveness and 
access to resources.   
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Stokes-Lampard 
et al., 2005 
(Stokes-Lampard 
et al., 2005) 
Vaginal vault smears 
– ‘know more – do 
less’: a 
questionnaire 
survey of primary 
health care 
practitioners 
UK - England Papanicolao
u smears 
N = 424 GPs, nurses 
etc. postal 
survey 
Nurses took significantly more smears than GPs.  No difference in 
knowledge scores between nurses and GPs, however those with 
higher knowledge scores took less smears.  To the vignette 
question only 11% of respondents gave the correct answer. 
Yabroff et al., 
2009 (Yabroff et 
al., 2009) 
Specialty 
differences in 
primary care 
physician reports of 
Papanicolaou test 
screening practices: 
a national survey, 
2006 to 2007 
US Papanicolao
u test 
N = 
1,212 
GP survey - 
questionnair
e with 
vignettes 
Surveyed using vignettes found that many primary care physicians 
were over testing against guidelines recommendations, for 
example, continuing to pap test when there is no cervix in older 
women. 
Xilomenos et al., 
2006 (Xilomenos 
et al., 2006) 
Colorectal cancer 
screening 
awareness among 
physicians in Greece 
Greece - 
national 
Colorectal 
cancer 
screening 
N = 211 Survey 50% of physicians recommended screening as part of a usual check-
up.  Cost of tests was found to potentially influence the 
recommendation to screen, with 77% of physicians recommending 
screening to people over 50 and this dropped to 53% when cost 
was taken into account.  Younger physicians (aged 30 or less) were 
found to significantly recommend CRC screening less than older 
physicians. 
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Youl et al., 2006 
(Youl et al., 
2006) 
Attitudes, knowledge 
and practice of CRC 
screening among GPs 
in Queensland. 
Australia - 
Queensland 
Colorectal 
cancer 
screening 
N = 769 Survey 66.4% recommended screening for patients over 50 and 97.4% recommended 
colonoscopy for patients with a significant family history of CRC.  71.2% reported 
receiving at least one type of guideline for CRC screening, only 5% reported not 
finding the guidelines useful.  Between 1999 (date of previous survey) and 2002 
(date of current survey) there has been a significant increase in knowledge and 
recommended screening.  
Smith & Herbert, 
1993 (Smith and 
Herbert, 1993) 
Preventive practice 
among primary care 
physicians in British 
Columbia: relation to 
recommendations of 
the Canadian Task 
Force on the Periodic 
Health Examination. 
Canada – 
British 
Columbia 
Cervical, 
breast, lung 
and 
colorectal 
cancer 
N = 186 Survey 90% of physicians reported compiling with task force recommendations and 
guidelines.  Lack of patient compliance was cited as a frequent reason for patients 
not being screened.  Physician and practice characteristics were also examined but 
not found to have any significant impact upon physicians’ decisions to screen or 
order tests. 
Federici et al., 
2005 (Federici et 
al., 2005) 
Survey on colorectal 
cancer screening 
knowledge, attitudes, 
and practices of 
general practice 
physicians in Lazio, 
Italy. 
Italy - Lazio Colorectal 
cancer 
screening 
N = 699 Survey 95% of respondents understood that CRC is a preventable disease but 22% do not 
recommend screening.  A high screening knowledge score, agreement with 
international guidelines, and the use of scientific literature as a source of 
information, increased the probability that screening was correctly recommended.  
GP characteristics were not found to have any affect upon correct recommendation 
for screening.  32% recommend inappropriate follow-up tests. 
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Pendleton et 
al., 2008 
(Pendleton et 
al., 2008) 
Knowledge and 
attitudes of 
primary care 
physicians 
regarding prostate 
cancer screening. 
US - Florida Prostate 
cancer 
screening 
N = 104 
physicians  
Survey and 
questionnaire 
Mean knowledge score was 66%, with correct responses to 
questions ranging from 14 – 98%.  Only 53% of physicians offered 
screening to minorities, compared to 70% to patients with a 
family history of prostate cancer.  Attitude responses to prostate 
cancer screening guidelines ranged from 45 – 93% agreeing with 
the correct recommendations. 
Roetzheim et 
al., 1991 
(Roetzheim et 
al., 1991) 
Compliance with 
screening 
mammography.  
Survey of primary 
care physicians.   
US – Tampa 
Bay 
Breast cancer 
screening 
N = 565 Survey 92% of respondents reported that they were familiar with ACS 
guidelines, but only 62% reported being in full compliance, 
younger (under 50) physicians and female physicians were 
significantly more likely to be in full compliance with guidelines. 
Klabunde et al., 
2003 (Klabunde 
et al., 2003) 
A national survey 
of primary care 
physicians’ 
colorectal cancer 
screening 
recommendation 
and practices. 
US - national Colorectal 
cancer 
screening 
N = 1,235 Survey Despite high awareness of CRC screening guidelines, several of 
the CRC screening recommendations and practice which 
physicians reported following were inconsistent with current 
guidelines, for example, 50% of primary care physicians 
recommended screening in younger patients.  Despite 98% of 
physicians reporting that they would recommend CRC screening 
to average risk patients, national figures for the ordering of tests 
is low. 
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Other influencing factors 
Author/Date Title Location Topic Sample 
(N) 
Measures and 
method of 
assessment 
Summary of study 
Gormley et al., 
2006 (Gormley 
et al., 2006) 
Prostate-specific 
antigen testing: 
uncovering 
primary care 
influences. 
UK – 
Northern 
Ireland 
Prostate 
testing PSA 
N = 704 Postal survey of 
GPs 
Prostate cancer screening is not recommended by guidelines 
however PSA testing is common.  Awareness of guidelines 
among GPs was low, 49%, with more male GPs carrying out PSA 
tests compared with female.  Patient’s requests, working full-
time, influence of services (urology dept.) and training meetings 
etc. had an influence upon GPs’ behaviour. 
Haas et al., 2007 
(Haas et al., 
2007) 
Association of 
regional variation 
in primary care 
physicians’ 
colorectal cancer 
screening 
recommendations 
with individual use 
of colorectal 
cancer screening. 
US - 
national 
Colorectal 
cancer 
screening, 
regional 
variation 
N = 12,727 Two national 
health and cancer 
screening surveys 
(NHIS, NCI-SCCP) 
On average 53.3% of physicians recommended initial screening 
within the guidelines, and 64.8% advised follow-up screening at 
the recommended frequency.  Regional differences were found 
and if a physician was located in a ‘low-screening’ region then 
this percentage reduced.  Hispanics were significantly less likely 
to have been screened and those with a lower level of 
education. 
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Santora et al., 
2003 
(Santora et 
al., 2003b) 
Breast cancer 
screening beliefs 
by practice 
location. 
US – New 
York 
Breast cancer, 
practice 
location 
N = 469 clinicians, 199 
nurse practitioners, 
202 primary care 
physicians, 68 
physician assistants 
Survey Urban practitioners were more likely to be board-certified 
and involved in training.  Younger physicians were more 
likely to answer three or more items correctly regarding 
screening, and female physicians were also significantly 
more likely to correctly answer three or more items.  65% 
of respondents reported using some form of written 
screening guideline, with urban and suburban physicians 
less likely to use written guidelines compared with rural 
area physicians. 
Haggerty et 
al., 2005 
(Haggerty et 
al., 2005) 
Patients’ anxiety 
and expectations: 
How they 
influence family 
physicians’ 
decisions to order 
cancer screening 
tests. 
Canada Prostate, 
breast, 
colorectal 
cancer 
screening 
N = 351 Survey with 
vignettes 
88% of physicians reported that patients’ anxiety or 
expressed expectations of being tested influenced their 
decision to order a test.  Most physicians were aware and 
followed guidelines but whether they agreed with them 
was most influential on their decision to order test, 
followed by patient factors such as anxiety or expectation 
to be tested. 
Gorin et al., 
2007 (Gorin 
et al., 2007) 
Intraurban 
influences on 
physicians’ 
colorectal cancer 
screening 
US – New 
York 
Colorectal 
cancer 
screening, 
location 
variation 
N = 1,685 Self-report 
questionnaire 
Differences in the methods of screening where found, with 
physicians based in low-SES urban practices more likely to 
screen using fecal occult blood test, while physicians in 
upper-SES practices were significantly more likely to 
recommend and screen using colonoscopy.  Physicians in 
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practices. upper-SES practice were significantly more likely to be a US 
medical school graduate, non-Hispanic white, been 
practising for longer, see fewer patients per week and the 
majority of patients are non-Hispanic white.  However, 
there was no significance difference in the knowledge of 
CRC risk factors etc. between physicians. 
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Shieh et al., 
2005 (Shieh 
et al., 2005) 
The impact of 
physicians’ health 
beliefs on 
colorectal cancer 
screening 
practices. 
US – St. 
Louis 
Colorectal 
cancer 
screening 
N = 115 Self-report 
questionnaire 
Self-reported compliance with guidelines was reported as 91.3%, with 
79% of physicians agreeing with the published guidelines.  For 
physicians who were eligible for CRC screening 82.6% personally 
participated, with a significant difference between those who 
personally participated in screening and their recommendation for 
screening to patients. 
Sorum et 
al., 2003 
(Sorum et 
al., 2003) 
Why do primary 
care physicians in 
the United States 
and France order 
prostate-specific 
antigen tests for 
asymptomatic 
patients. 
US – New 
York, 
France 
PSA testing N = 32 US 
physicians, 32 
French 
physicians 
Self-report 
questionnaire 
A significant predictor of ordering PSA tests was if a physician had 
previously not tested a patient who had later been found to have 
advanced stage cancer.  US physicians also ordered significantly more 
tests than French physicians, and the US physicians also reported 
higher scores for concerns about malpractice and feeling pressure 
from patients. 
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Organisational 
Author/Date Title Location Topic Sample (N) Measures and 
method of 
assessment 
Summary of study 
Downing et al., 
2007 (Downing 
et al., 2007b) 
Do the UK 
governments new 
quality and 
outcomes 
framework (QOF) 
scores adequately 
measure primary 
care performance? 
A cross-sectional 
survey of routine 
healthcare data 
UK - 
England 
QOF N = 2PCTs 
(516,620) 
QOF and hospitals 
admissions 
QOF data was linked to hospital admissions.  Higher 
scores in the clinical domain were associated with lower 
hospital admission rates, specifically with cancer.  No 
clear association between the organisational domain 
and admissions.  High levels of deprivation were 
associated with increased likelihood of admission and 
females overall had significantly fewer admissions for 
cancer than males. 
Any associations observed were generally not 
consistent but were significant in cancer.  Admissions 
were most strongly associated with deprivation rather 
than QOF. 
Wang et al., 
2006 (Wang et 
al., 2006) 
Practice size and 
quality attainment 
under the new 
GMS contract: a 
cross-sectional 
UK - 
Scotland 
QOF practice size N = 638 QOF and practice 
information 
Single-handed and small practices accounted for 45% of 
all urban practices, had greater list sizes compared with 
larger practices and were less likely to participate in 
voluntary quality schemes and training.  Patients who 
attended these smaller and single-handed practices 
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analysis. lived in more socioeconomic deprived areas, had poorer 
health and premature mortality.  Patients were also 
more likely to be of an ethnic minority.  Single-handed 
and smaller practices scored lower overall but the only 
significant difference was in the organisational domain.  
Smaller practices also reported higher levels of cancer 
prevalence and conditions such as COPD and mental 
health. 
Gavagan et al., 
2010 (Gavagan 
et al., 2010) 
Effect of financial 
incentives on 
improvement in 
medical quality 
indicators for 
primary care. 
US – 
Harris 
County 
Financial incentive 
scheme, 
Papanicolaou 
smears, 
mammography 
N = 11 
clinics 
Retrospective 
review of 
administrative 
data, survey of 
clinicians 
Outcomes of primary care clinics which had a financial 
incentive scheme and clinics which did not were 
compared and no significant difference was found.  The 
survey of clinicians found that many reported they did 
not feel that incentives were effective in improving 
quality of care. 
Hippisley-Cox et 
al., 2001 
(Hippisley-Cox et 
al., 2001) 
Do single handed 
practices offer 
poorer care?  
Cross sectional 
survey of 
processes and 
outcomes. 
UK – 
Trent 
region 
Breast and 
colorectal cancer 
referral rates 
N = 300 
colorectal 
cancer 
cases 
N = 131 
breast 
cancer 
cases 
Cancer stage A borderline association was found in late presentation 
of colorectal cancer and a high number of referral rates, 
but overall no clear or substantial outcomes were found 
between the number of referrals made by a practice 
and the patient’s cancer stage. 
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Clinical guideline adherence 
Screening 
Author/Date Title Location Topic Sample 
(N) 
Measures and 
method of 
assessment 
Summary of study 
Parkerton et al., 
2003 (Parkerton 
et al., 2003) 
Effect of part-time 
practice on patient 
outcomes 
US  GP hours N = 194 Patient data and 
physician 
characteristics 
GP practice information was reviewed and it was found that 
GPs who worked part-time had significantly higher cancer 
screening and patient satisfaction levels.  A number of 
reasons why this may be are proposed including that part-
time GPs are less stressed, compensate in their performance 
because they’re only part-time, have more time outside of 
working hours to keep up-to-date with skills training, 
guidelines etc. 
Hoffman et al., 
1998 (Hoffman 
et al., 1998) 
Prostate-specific 
antigen testing 
practices and 
outcomes. 
US – New 
Mexico 
 
Prostate-
specific 
antigen test 
N = 1,448 Retrospective cohort 
study from New 
Mexico SEER tumour 
registry 
Testing practices varied considerably from guidelines, 
specifically annual testing was not conducted and a 
substantial proportion of testing occurred outside of the 
recommended age range.  For example, 16% of tests were 
conducted on men over 75 which is not recommended by 
the current guidelines. 
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Salinas et al., 
1998 (Salinas et 
al., 1998b) 
Quality differences 
between rural and 
urban primary 
care: the case of a 
cervical screening 
programme. 
Mexico – 
Nuevo 
Leon 
Papanicolaou 
test 
N = 750 Review of cervical 
smear reports 
No technical, physical or administrative failures were found 
and the overall smear processing quality was found to be 
highly satisfactory; however, the quality of sampling was 
found to be unsatisfactory.  33.4% of smear test samples 
were found to be unsatisfactory.  Overall there was no 
difference between rural and urban location but the quality 
of smear sampling differed significantly between rural and 
urban locations. 
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Referrals 
Author/Date Title Location Topic Sample 
(N) 
Measures and 
method of 
assessment 
Summary of study 
John et al., 2007 
(John et al., 
2007) 
Inter general practice 
variability in use of 
referral guidelines for 
colorectal cancer. 
UK Colorectal 
cancer 
referrals 
N = 175 
patients 
 
N = 129 
GPs 
Postal survey for 
GPs and patient 
data 
While many of the GPs surveyed said they were aware of 
guidelines, they were unable to answer questions correctly that 
referred to guidelines.  Only a quarter of GPs had received 
training regarding guidelines.  In practices there was a 
discrepancy between the use of TWR and cancer diagnosis.  In 
53% of practices surveyed no colorectal cases were diagnosed 
through the TWR system and their use of the TWR pathway was 
lower than practices which had diagnoses made through the 
TWR system who used the TWR system more. 
Debnath et al., 
2002 (Debnath 
et al., 2002) 
Guidelines, compliance, 
and effectiveness: a 12 
months’ audit in an 
acute district general 
healthcare trust on the 
two week rule for 
suspected colorectal 
cancer. 
UK – 
North 
East 
Colorectal 
cancer 
referrals 
N = 239 Information from 
case notes and 
pathology 
departments. 
96.2% of patients received an appointment within two weeks 
once a referral was made, higher than national average figures 
for England (81.2-81.8%).  There was a significant association 
between diagnosis and guidelines compliance.  However, it was 
found that there was a high rate (97.5%) on incompleteness in 
referrals, for example, that information and details such as 
family history were missing. 
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Webb & Khanna, 
2006 (Webb and 
Khanna, 2006) 
Can we rely on a 
general 
practitioner’s 
referral letter to a 
skin lesion clinic to 
prioritize 
appointments and 
does it make a 
difference to the 
patient’s 
prognosis?  
UK – West 
Midlands 
Skin lesion 
referrals 
N = 202 Review of GP referral 
letters. 
22% of letters did not comply with guidelines.  42% 
of referral letters gave no indication of priority (i.e. 
urgent etc.).  Of the 35 cases which were later 
found to be cancerous, only 5 complied with two 
week wait guidelines. 
Khawaja & Allan, 
2001(Khawaja and 
Allan, 2001) 
Audit of referral 
practice to a fast-
access breast clinic 
before the 
guaranteed two 
week wait. 
UK - 
Eastbourne 
Breast 
cancer 
referrals 
N = 100 Fast-access/two week wait 
referral information for 100 
consecutive patients was 
reviewed. 
Only 80% of referrals adhered to the guidelines.  
20% upon review by a specialist were deemed to be 
inappropriate and 30% were deemed ‘non-urgent’. 
Melia et al., 2008 
(Melia et al., 2008) 
Urological referral 
of asymptomatic 
men in general 
practice in 
England. 
UK – 
Chichester, 
Sutton & 
Merton, Truro 
and York 
Urological 
referrals 
N = 5,348 Referral requests and 
pathology reports before 
and after new guidelines 
were launched. 
No significant difference in referrals was observed 
after the introduction of new guidelines.  No 
significant differences were found or observed 
between the different practice and hospital 
locations. 
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Excisions 
Author/Date Title Location Topic Sample 
(N) 
Measures and method of 
assessment 
Summary of study 
Neal et al., 2008 
(Neal et al., 
2008a) 
Excision of malignant 
melanomas in North 
Wales: effect of 
location and surgeon 
on time to diagnosis 
and quality of excision 
UK - Wales Melanoma 
excision 
N = 578 Patient data 16% of lesions were removed in general practice, 
after 1997 guidelines there was a decline.  However, 
there were differences between the quality of 
excision, with excisions being done in general practice 
having the lowest quality margins and least 
adherence to guidelines on margins compared to 
excisions done in hospitals. 
Bakhai et al., 
2010 (Bakhai et 
al., 2010) 
A retrospective study 
comparing the 
accuracy of 
prehistology diagnosis 
and surgical excision 
of malignant 
melanomas by general 
practitioners and 
hospital specialists. 
UK – London Melanoma 
excision 
N = 213 
reports 
GP and specialist data 
between 1989 – 2006 - 
Histopathology reports 
and recorded excision 
margins. 
GPs carrying out excisions on suspected melanomas 
do not perform as well against guidelines as hospital 
specialists (GP = 29.8% compliance versus 70.5%).  
Although since the introduction of new guidelines 
they have improved but are still significantly 
outperformed by specialists (GP = 41% compliance 
versus 80%). 
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Pockney et 
al., 2009 
(Pockney et 
al., 2009) 
Recognition of skin 
malignancy by 
general 
practitioners: 
observational 
study using data 
from a population-
based randomised 
control trial. 
UK - 
Southampton 
Skin 
malignancy 
N = 491 Quality of minor surgery 
performed by GPs and hospital 
doctors from records and reports 
collected during a randomised-
control trial. 
Agreement between the diagnosis by a GP and the 
histology was agreed to be moderate at best, with 
GPs failing to recognise one-third of the skin 
malignancies.  However, it is highlighted that 
hospitals do not have the capacity or resources to 
take on these minor surgeries. 
Goulding et 
al., 2009 
(Goulding et 
al., 2009) 
Dermatological 
surgery: a 
comparison of 
activity and 
outcomes in 
primary and 
secondary care. 
UK - London Skin 
malignancy 
N = 1,111 Retrospective review of 
histopathology reports and 
specimens. 
GPs were found to be less accurate in their eventual 
diagnosis and had higher excision margins compared 
with dermatologists.  Plastic surgeons were most 
likely to perform inappropriate procedures.  13.8% of 
tumours which GPs operated on should have been 
referred to secondary care. 
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GP influences 
Author/Date Title Location Topic Sample 
(N) 
Measures and method 
of assessment 
Summary of study 
Carney et al., 
1993 (Carney et 
al., 1993) 
The periodic 
health 
examination 
provided to 
asymptomatic 
older women: an 
assessment using 
standardized 
patients. 
US – New 
England 
Cancer 
prevention 
services 
N = 57 Standardized patient 
(actress) presenting 
identical symptoms to 
different GPs 
The development of a standardised patient as a measure of GP 
quality and consistency.  The response to identical requests for a 
‘check-up’ (which included cancer screening) varied widely in 
cost, service and time spent with GP.  Cancer guidelines were 
not met to varying degrees and prevention advice, such as 
cessation of smoking, while recommended, little assistance was 
given. 
Daly & Collins, 
2007 (Daly and 
Collins, 2007) 
Barriers to early 
diagnosis of 
cancer in primary 
care: a needs 
assessment of GPs 
Ireland Cancer 
diagnosis 
N = 929 GPs - Focus groups and 
postal questionnaires 
GPs reported a lack of communication between themselves and 
hospital services, difficulties in accessing hospital services, and 
unclear cancer guidelines.  GPs did observe a difference between 
the access and waiting times for private and public patients, 
private patients being referred quicker and receiving better 
access to services. 
Jiwa et al., 2008 
(Jiwa et al., 
Referring patients 
to specialists: A 
Australia - 
Western 
Colorectal 
cancer 
N = 260 GP survey which 
included vignettes 
Referral decisions between the two countries were similar, but it 
was found that location and clinical variables influenced GPs’ 
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2008) structured 
vignette survey of 
Australian and 
British GPs 
UK - 
England 
referrals decisions (however this was not further investigated).  Australian 
GPs had better outcomes for colorectal cancer, despite this 
study’s finding that referrals are similar; therefore it is proposed 
that problems in diagnosis and secondary care could be to 
‘blame’ for poorer outcomes. 
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3. 9. 1.  Self-reported guideline adherence – referral to screening 
 
This group of studies all have the primary outcome measure of GPs’ adherence to 
guidelines in relation to screening, specifically whether they are following guidelines when 
recommending screening to patients or demonstrate accurate knowledge of current 
guidelines.  The methodology used in all the studies is self-report surveys of GPs.  A variety 
of questionnaires have been developed and used, some with questions about the GPs’ 
recommendations, direct questions about guidelines and patient vignettes to assess 
knowledge and behaviour.   
The immediate problem with the quality of these studies is that they are self-reporting, 
specifically GPs may respond more positively about their attitude and adherence to 
screening guidelines.    
3. 9. 1. 1.  Guidelines only 
 
This sub-group of 11 studies all have the primary aim and objective to measure 
screening behaviour.  Only one study is from the UK with the others coming from the US 
[5], Canada [2], Europe [2] and Australia [1].  The majority focus upon colorectal cancer 
screening but cervical smear, vaginal vault smears, breast and prostate screening are also 
covered. 
Yabroff et al. (2009) found that 84.3% of GPs responding to their questionnaire 
believed that screening guidelines were influential on their behaviour.  When presented 
with patient vignettes however, on average less than 25% of responses were consistent 
with current guidelines.  This finding is repeated in nearly all the studies with a high 
proportion of GPs reporting being familiar or having good knowledge of the guidelines but 
then in practice, compliance or correct responses to vignettes is low (Roetzheim et al., 
1991, Ka'ano'i et al., 2004, Klabunde et al., 2003, Smith and Herbert, 1993, Stokes-Lampard 
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et al., 2005, Xilomenos et al., 2006).  One study compared their results against (Youl et al., 
2006) a previous survey and found that knowledge and compliance, while still not 100%, 
had improved significantly in a five year period. 
Federici et al. (2005) found a strong association between GPs who demonstrated good 
knowledge of guidelines and compliance with guidelines, however Pendleton et al. (2008) 
failed to confirm this.  In a survey of Greek GPs (Xilomenos et al., 2006), where there are no 
national guidelines and overall knowledge of colorectal screening is poor, half the GPs 
recommended colorectal cancer screening as part of a routine check-up for high risk 
groups.  European guidelines were cited as the ones most commonly followed (Xilomenos 
et al., 2006). 
Seven studies recorded GP demographic information and investigated its relationship 
to GPs’ beliefs and attitudes to screening.  Significant differences were found between GPs’ 
compliance with guidelines and age, with GPs over 50 being less compliant (Roetzheim et 
al., 1991, McGregor et al., 2004).  Pendleton et al. (2008) found older and urban based GPs 
had higher attitude scores towards screening, i.e. were more likely to offer screening 
annually, to minorities and over 50s.  Differences in the GPs’ specialisms were also 
observed to affect behaviour, specifically GPs who specialised in obstetrics and 
gynaecology were significantly more likely to order pap screening (Yabroff et al., 2009).  
However, a similar number of studies found no association between GP demographics and 
specialism with screening attitudes and beliefs (Smith and Herbert, 1993, Stokes-Lampard 
et al., 2005, Xilomenos et al., 2006). 
The quality of these studies is generally poor.  Knowing whether or not GPs are 
adhering to guidelines can be considered a valid measure of quality but when the 
information is self-reported, its veracity is questionable.  The number of respondents in 
each study varied widely (n = 104(Pendleton et al., 2008) – 1235(Klabunde et al., 2003)) as 
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did the response rates (range = 39.39 (Pendleton et al., 2008) – 80% (Stokes-Lampard et al., 
2005)).  Studies reporting associations between GP demographics and behaviour do add an 
extra dimension, demonstrating that GP factors such as age and sex may have an influence 
upon behaviour and practice.   
3. 9. 1. 2. Other influencing factors 
 
Seven studies examined screening guidelines adherence through the use of self-
reported surveys but the primary focus of the paper included additional factors; physicians’ 
health beliefs, patient, geographical, international and primary care influences.  The 
majority [4] of the studies were from the US, with one comparing US and French GPs, one 
paper from Canada and two from the UK (Northern Ireland and England). 
Haas et al. (2007) draws data from both GP and patient surveys.  64.8% of GPs 
reported being compliant with recommended screening interval but with the addition of 
patient survey data it turned out that only 37.4% had in fact been compliants. 
Studies of geographical influences found that more GPs in rural areas reporting using 
some form of guideline compared with urban GPs (Santora et al., 2003a), though one 
Canadian study (Haggerty et al., 2005) found there no difference between rural and urban 
practices.  Socio-economic factors were found to play a significant part in access to 
screening in Haas et al. (2007) with patients of non-white ethnicity, specifically Hispanic, 
and of a lower level of education less likely to be screened for colorectal cancer.  Once 
screened, however, these inequalities disappeared and no demographic factors had a 
significant impact upon their access to continual routine screening.  Patients in areas of 
high socio-economic status had better access and more diagnostic options available to 
them and GPs in these areas are significantly more experienced than GPs in low SES areas 
(Gorin et al., 2007).   
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The personal beliefs and demographic characteristics of the GP were found to have an 
influence.  Younger and female GPs are significantly more likely to recommend breast 
cancer screening (Santora et al., 2003a) while PSA testing is more commonly recommended 
by male GPs (Gormley et al., 2006).  A study by Shieh et al. (2005) found an association 
between GPs’ own participation in colorectal cancer screening and recommendations to 
patients to participate.  Older GPs (those over the recommended colorectal screening age 
of 50) were more likely to have participated in screening, while younger GPs who were 
identified as high risk, were significantly less likely to have participated in screening.  Self-
reported compliance with guidelines was particularly high in this study, with 91.3% of GPs 
saying they followed guideline recommendations.   
Sorum et al. (2003) surveyed and compared responses between US and French GPs 
with regard to prostate cancer screening and found that the two groups differed 
significantly on a number of points.  In particular the US GPs ordered significantly more 
routine PSA (Prostate-Specific Antigen) tests, many for healthy patients with no signs or 
symptoms.  The authors attributed this to the US GPs reporting feeling greater pressure 
from healthy patients requesting tests, fears of malpractice law suits and fear of missing a 
diagnosis.  Pressure from patients was also reported in a second study (Haggerty et al., 
2005) which found almost 90% of GPs reporting that patient anxiety and/or expectation of 
being tested influenced their decision to order a cancer screening test they would not 
usually recommend. 
All studies in this section, while still using self-reporting data, additionally examined 
other factors that could influence screening beliefs and practice.  Again the number of 
respondents in each study vary widely (n = 65(Sorum et al., 2003) – 12,727(Haas et al., 
2007), mean n = 2,088.57) and the response rates ranged from 9 – 80.5(Sorum et al., 
2003)% (mean = 59.14%). 
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3. 9. 2.  Organisational 
 
These studies mainly examined the impact of financial incentive schemes and their 
potential to improve quality/performance.  Gavagan et al. (2010) examined the effect of a 
financial incentive system implemented in two medical schools in the US on cancer 
screening but found no significant differences between incentivised and non-incentivised 
groups in their meeting of quality criteria.  In the case of mammograms both groups 
improved in their meeting of quality criteria but there was a non-significant trend in pap 
tests where the incentivised group improved in meeting quality criteria but the non-
incentivised group remained reasonably constant.  Despite the study failing to show an 
effect, 70% of the GPs involved felt that the scheme was very or extremely effective in 
improving quality. 
Two of the studies used data from QOF, one examining the effect of practice size 
(Wang et al., 2006) and the other looking at population demographics (Downing et al., 
2007b).  The former of these found that practice size in Scotland (n = 636 practices) had a 
significant effect upon the total QOF points attained, with smaller practices attaining fewer 
points than larger practices.  On closer investigation it was found that the significant 
difference was solely attributed to QOF factors in the organisational domain, so the quality 
of clinical care was no different.  Interestingly it was found that smaller practices had high 
prevalence levels of cancer and were more likely to be located in areas of socio-economic 
deprivation and have a higher percentage of ethnic minority patients.  Downing et al. 
(2007b) also found that deprivation had an effect, finding an association between 
increasing deprivation and increased mortality and hospital admission rates.  The key 
finding of this study however was that when two PCTs (n = 516,620 combined patient 
population and n = 94 combined practices) were compared, higher clinical domain scores in 
QOF were significantly associated with fewer emergency admissions for cancer.  This could 
80 
 
be interpreted as a demonstration of good quality care from GPs leading to more cases of 
cancer being identified and at earlier stages. 
In relation to referral rates Hippisley-Cox et al. (1997) aimed to look at the potential 
association between low referring practices and later stage of cancer at diagnosis.  No 
association was found suggesting that low GP referral rates do not result in adverse 
outcomes for the patient, however the number of cancer cases used in this study were not 
particularly high (breast cancer n = 131, colorectal cancer n = 300).   
Overall these studies showed mixed results to the use of financial incentive schemes, 
while Downing et al. (2007b) found improvements in cancer outcomes in the form of 
reduced emergency admissions, Gavagan et al (2010) did not find any improvement to 
cancer screening after the introduction of an incentive scheme.  Equally GP practices’ 
performance in such schemes is significantly affected by the size of the practice and socio-
economic and demographic factors. 
3. 9. 3.  Clinical guideline adherence 
 
Like the earlier group of self-reported guidelines adherence this group of studies all 
have the primary outcome measure of GPs’ adherence to guidelines.  The primary 
difference is in the methodology used in all the studies where instead of self-reporting 
surveys a physical measure is used, such as patient records, screening uptake rates or 
practice audits etc.  This means that potentially the quality of the studies is better because 
the measurement of quality is a physical outcome and therefore more accurate than a 
belief or perception.  The studies have been further divided by the type of guidelines as 
there were studies which focused on guidelines for referral and excision of skin lesions and 
those relating to screening guidelines. 
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3. 9. 3. 1.  Screening 
 
Of the three studies two were from the US (Parkerton et al., 2003, Hoffman et al., 
1998) and one from Mexico (Salinas et al., 1998a) and they cover PSA testing, smear tests 
and colorectal screening. 
Salinas et al. (1998b) examined the number of smear tests conducted and the quality of 
the tests, test results were measured against national and international parameters in an 
area where an early detection programme had been running.  Urban and rural practices 
were compared for smear test sampling quality and these were significantly different, with 
urban practices performing better.  The quality improvements that were anticipated were 
not achieved by either urban or rural practices, for example in urban practice 64.2% 
sampling quality was expected but only 38.5% was attained.  This suggests that guidelines 
relating to the execution of smear tests is not being met. It was also noted that a higher 
than expected number of women over 25 had not previously received a smear test which 
again suggests that guidelines related to early detection testing are not being followed and 
met.  
A study of PSA testing by Hoffman et al. (1998) using patient records and the US cancer 
registry found widely varied screening practices from guidelines.  15.7% were tested 
outside of the recommended age range and 23.7% of patients, once tested were retested 
within six months, contrary to guidance, demonstrating that guidelines for PSA testing 
were not followed by a substantial minority. 
An analysis of GP screening rates in association with whether the GP worked full or 
part-time was conducted by Parketon et al. (2003).  In terms of cancer screening it was 
found that part-time GPs had significantly higher rates of screening.  While this did not 
impact upon patient outcomes, which were measured by patient satisfaction; diabetes 
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management, cancer screening and ambulatory costs and association between working 
part-time and quality of care was.  Patient and GP satisfaction were both higher in part-
time GPs. 
The size of each of these studies varies (n = 194(Parkerton et al., 2003) – 1,500(Salinas 
et al., 1998a), mean n = 1,047.33).  All three studies are older pieces of research, 1998 
(Hoffman et al., Salinas et al.) and 2003 (Parkerton et al.) however, what the former two 
studies show is that guideline adherence is low and varied compared to GPs self-reporting 
of their behaviour and adherence.  Even since 2003 there have been many changes and 
updates to guidelines and practice and the lack of more current research which uses better 
quality data from patient records etc. highlights the gap in this research area. 
3. 9. 3. 2.  Referrals 
 
There are five studies covering colorectal, breast, skin and prostate cancer, all from 
England.  Within the UK there are guidelines for referrals, specifically if a patient presents 
with a number of red flag or alarm symptoms then they would be placed on an urgent 
referral pathway (for select cancers, such as breast, this is known as the two week wait). 
All studies reported that guidelines were not being followed, ranging from 37.66% of 
the sample cases not adhering to guidelines (Debnath et al., 2002), 48% (Webb and 
Khanna, 2006) and 52.5% (Khawaja and Allan, 2001).  Melia et al. (2008) studied the effect 
of a change in prostate cancer referral guidelines for asymptomatic patients.  They found 
that changes in GPs’ referral patterns were low and significantly lower than expected 
suggesting that GPs were not aware of and/or adhering to the new guidelines. 
John et al. (2007) surveyed GPs (57% response rate) about their knowledge of referral 
guidelines and combined responses with the referrals rates for the practice.  Only 58% 
reporting being primarily influenced in their referral decisions by guidelines and while 78% 
83 
 
of surveyed GPs reported being aware of guidelines only 8% could correctly answer one of 
the survey questions about fast-track criteria for colorectal cancer.  A high variability was 
observed between practices with 53% of practices not using the two week wait referral 
pathway for colorectal cancer and a significant association was found between use of the 
two week wait pathway and higher incidence of colorectal cancer.  It is suggested this could 
be because GPs are identifying alarm symptoms and correctly referring patients rather than 
a diagnosis being missed and patients entering through emergency hospital admissions. 
Debnath et al. (2002) observed that in GPs and practices where compliance to 
guidelines is high there are more frequent diagnoses of cancer.  This could suggest that GPs 
who are not following guidelines are missing incidences of cancer. 
In both Khawaja and Allan (2001) and Webb and Khanna (2006) it was reported that a 
high number of GP referrals were not meeting guidelines.  In the latter, a review of patient 
referral letters for skin lesions was carried out and found 41.58% of the referrals written by 
GPs gave no indication of priority, while 22.41% of the urgent/two week wait referrals did 
not meet guidelines.  In the case of Khawaja and Allan (2001) referrals to the fast-access 
breast clinic should only be made if a new breast lump was found, however, in 20% of the 
referrals from GPs in this study no new breast lump had been presented by the patient.  
Where GPs had indicated a breast lump in the referral, only half actually had a lump. 
This group of studies is a mixture of qualities, with study numbers ranging from 100 
patients – 17,000 patient records.  The majority were short studies of a year or less 
(Debnath et al., 2002, Khawaja and Allan, 2001, Webb and Khanna, 2006, John et al., 2007) 
while Melia et al. (2008) was a continuation of a study following the launch of amended 
guidelines in 2002.  Some studies employ and report suitable statistical methods and 
analysis (John et al., 2007, Melia et al., 2008, Debnath et al., 2002) while the remaining 
studies (Khawaja and Allan, 2001, Webb and Khanna, 2006) simply report percentages, 
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standard deviation and means.  In these latter two studies, while guidelines are used as 
part of the framework to assess quality and appropriateness of GP cancer referrals there is 
also an element of a specialist’s interpretation and opinion.  For example, in Khawaja et al. 
(2001) the presence of a breast lump is taken as the measure of whether a referral is 
appropriate and while 80 patients were referred with a lump it was later determined only 
42 had an actual lump.  In this case, what is a lump?  If a patient is presenting to their GP 
and reporting that something is abnormal but which a specialist later says it is not a lump 
but a benign breast change, who is right? 
3. 9. 3. 3.  Excisions/diagnosis 
 
All four studies are from the UK (three from England and one from Wales); three use 
excision margins in melanoma/skin tumours as the measure of quality and one looks at the 
accuracy of a GP’s diagnosis after excision (Pockney et al., 2009).  Two of the studies are 
long-term (one is eight years (Neal et al., 2008a) and the other 17 years (Bakhai et al., 
2010) retrospective analyses of patient reports.  Significant differences in the quality of 
excision were observed in both studies between specialists and GPs, with GPs not 
performing as well; specifically having narrower excision margins (therefore the whole 
affected area may not be removed).  This pattern was supported by Goulding et al. (2009) 
who in their three month retrospective review found that against specialists, GPs did not 
perform as well but also failed to meet guidelines.  In particular 13.8% of the excisions 
performed by GPs should have been referred, according to NICE guidelines.  It would be 
expected that GPs would not perform as well against specialists; however, a demonstration 
that GPs are not meeting guidelines is of interest and a measure of quality.   
Bakhai et al. (2010) additionally highlighted in their study that improvements in 
excision margins across specialists and GPs were observed after the introduction of new 
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guidelines; however, guidelines outlining that primary care excisions by GPs should be 
avoided had little or no significant impact on the number of excisions carried out by GPs.  
This was not supported by Neal et al. (2008a) who observed a decline in excision of lesions 
in primary care. 
Pockney et al. (2009) in a retrospective study examined the accuracy of the GPs’ 
diagnoses and their adherence to guidelines.  It was found that GPs’ diagnostic accuracy 
was poor with less than half the lesions which GPs diagnosed as malignant turning out to 
be.  Equally there was a small number which GPs had identified as benign which were later 
diagnosed as malignant, but these missed lesions accounted for a third of the total 
malignant lesions in the study.  It should be noted that the vast majority, 85% of the sample 
lesions were accurately diagnosed as benign by GPs (91% when accurately diagnosed 
malignant lesions are added).  In Pockney et al. (2009), and in Goulding et al. (2009), 
decisions regarding whether guidelines had been met were in some parts of the analysis 
made by specialists retrospectively reviewing cases.  As previously highlighted, specialists 
are more accurate and therefore including their input in analysis as to whether GPs have 
correctly identified malignant cases or followed guidelines correctly, could exacerbate 
findings.   
3. 9. 4.  GP influences 
 
The remaining three studies are a mixture from Ireland (Daly and Collins, 2007), the US 
(Carney et al., 1993) and a comparison of UK and Australian GPs (Jiwa et al., 2008) 
Jiwa et al. (2008) used questionnaires with structured vignettes, based upon referral 
guidelines, to compare the referral behaviour of English and Australian GPs (response rate 
– 52%, n = 260).  It was observed that there was no significant difference between the two 
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countries and just over half of the vignette cases were placed on the correct pathway, but a 
higher than necessary number were placed on the urgent pathway. 
Daly and Collins’ (2007) focus was upon GPs’ perceived barriers to patient cancer 
diagnosis.  This is important to include within this review as it shows factors that could be 
affecting GP quality.  In particular from the survey (response rate - 46.7%, n = 929), the lack 
of clear screening recommendations was highlighted by GPs as were long waiting times for 
patients sent on urgent referrals. 20% of the GPs surveyed reported that patients had to 
wait longer than two weeks for an urgent appointment.  Lack of access to hospital 
screening services, longer waits for non-private patients and poor communication with 
hospital services were also highlighted.  No attempt was made in this study to see if there 
were any significant differences, all analyses were simply numbers and percentages. 
Finally Carney et al. (1993) is a novel approach to assessing GP quality as they used a 
standardised patient to present cancer risk family history to see if GPs would follow 
guidelines and recommend screening.  It was found that the offering of screening was 
based upon the cancer type, with breast cancer mammograms being offered by almost all 
GPs but checking for oral cancer was only done by a few.  Guideline recommendations 
were not consistently met, or as highlighted above, some services were not provided; 
equally recommendations regarding lifestyle such as smoking cessation were not 
universally given despite guidelines stating such a recommendation.  This is a unique study 
in that the method of assessing GP quality is particularly novel, but is not 20 years old. 
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3. 10.  Discussion 
 
This review demonstrates that GP practice quality for cancer has been assessed in a 
number of ways with varied outcomes and findings.  Adherence to guidelines, through 
whatever method, is the most common outcome measure of quality (30 of 37 studies) and 
these are in general agreement that GPs do not fully comply and adhere to cancer 
guidelines, from screening through to diagnosis with percentage compliance ranging from 
10.6%(Stokes-Lampard et al., 2005) – 91.3%(Shieh et al., 2005).  What has also been found 
is that a range of factors influence GPs’ adherence to guidelines and referral practice.  In 
particular GP demographics such as age (Pendleton et al., 2008, McGregor et al., 2004, 
Roetzheim et al., 1991) and specialism (Yabroff et al., 2009), geographical location (Santora 
et al., 2003a, Pendleton et al., 2008), patient influences (Sorum et al., 2003, Haggerty et al., 
2005) and the type of cancer (Ka'ano'i et al., 2004, Smith and Herbert, 1993) seem to be 
associated with GPs’ decision and practice to screen for cancer, make referrals etc.  
Interestingly in studies with longitudinal data it was observed that after the introduction of 
new/updated guidelines, GPs’ practice and compliance improved (Salinas et al., 1998a, 
Melia et al., 2008, Bakhai et al., 2010, Neal et al., 2008a) suggesting that guidelines do in 
themselves have an impact on GP behaviour but are possibly confounded by the above-
mentioned additional influences. 
Developing a suitable and accurate measure of quality is clearly a complex issue and 
large scale attempts such as the introduction of quality assessment and financial incentive 
schemes have, particularly in England with QOF, been a major health care reform.  While 
they have had an influence upon how GP practices operate and GP behaviour, it was 
surprising that only two studies (Wang et al., 2006, Downing et al., 2007b) were identified 
through the search strategy.   
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It could be suggested that QOF has not been in place and operating for an adequate 
length of time to be used as a research data source; however, at the time of this review 
QOF had been in place for over five years and neither of the papers included in the review 
were recent (within the last five years) studies (2006 and 2007).  Another suggestion could 
be that researchers are simply unaware of what data is available from the NHS information 
centre, this issue was recently highlighted by Curcin et al. (2012), who identified that NHS 
data was not utilised to its best due to it being unclear as to what was available and its 
provenance.  Despite this, QOF data has been and is, regularly used within healthcare 
research (Kiran et al., 2010, Ashworth et al., 2007, McLean et al., 2006, Wright et al., 2006, 
Strong et al., 2006, Sigfrid et al., 2006), and while it has been used in cancer research it is 
often limited to investigations into prescribing behaviours and hospital admissions (Bottle 
et al., 2012, Rowlingson et al., 2013, Ashworth et al., 2007, Downing et al., 2007b, Iyen-
Omofoman et al., 2011).  It has been identified as a limitation for cancer research that QOF 
has a small number of indicators, presently three, which are cancer specific.  Therefore, the 
lack of papers relating to cancer and GP quality that utilise QOF may be indicative of this 
limitation as to the validity and practicality of QOF as a quality measure for cancer.  Equally 
this could simply indicate that there is a lack of research in this area that needs to be 
addressed. 
Almost half (18 out of 37) of the studies used a self-reporting methodology to 
investigate whether GPs were adhering to cancer screening guidelines.  This cannot be 
considered a rigorous methodology and in a number of the studies either no statistical 
analysis was used or was inadequate (Smith and Herbert, 1993, Ka'ano'i et al., 2004).  
Studies which used a physical measure of guideline adherence, generally the use of patient 
and GP practice records (12 of 37 studies), were of better quality with more rigorous 
methodologies; however, there were some biases.  Specifically it had been previously 
identified that there are a number of studies which, in their method to assess whether GPs 
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had made referrals and excisions/diagnosis correctly were simply reviewed by specialists as 
a method of analysis, or in fact the accuracy of excisions etc. by GPs and specialists are 
compared.   
While these types of studies were excluded, there were studies included in the final 
papers where specialists had reviewed GPs’ referrals etc., but GPs’ and specialists’ actions 
were also compared to current guidelines (Bakhai et al., 2010, Goulding et al., 2009, Neal et 
al., 2008a, Pockney et al., 2009, Khawaja and Allan, 2001, Webb and Khanna, 2006).  This 
inclusion of comparing against guidelines does aid in reducing any bias or personal opinion 
that specialists may have, but equally it was not always part of the primary aim or analysis; 
for example, in some papers (Khawaja and Allan, 2001, Webb and Khanna, 2006) the use of 
guidelines in the analysis was secondary or simply a tool which specialists used in their 
review of GP referrals. 
What is most clearly demonstrated by this review is not only the varied way in which 
GP and primary care quality has been assessed but also the wide range of factors that 
influence the quality of care and services provided.  Generally the quality of studies in this 
review was poor, with many using limited methodologies and analysis.  Fewer studies were 
from within the last five years (2007-2011, n = 14) and the majority were from the UK and 
US (UK n = 15, US n = 14). 
3. 10. 1.  Strengths and weakness of the review 
 
This is an area which has not previously been subjected to a systematic review.  More 
than one database was used and while there was an expected level of overlap between the 
two databases, due to their specialism in medical and biomedical research, there were a 
number of papers reviewed which came from just one database.  Equally the search 
strategies, despite not being consistent due to the highlighted problems of different 
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terminologies between the databases, did produce a number of articles which were found 
in both databases from using the respective strategies for each database.   
The inclusion/exclusion criteria developed were also effective in identifying appropriate 
articles, as through the second review process, while some articles needed discussion there 
was a general agreement on the studies meeting the inclusion criteria between the 
reviewers.  The inclusion of a second reviewer process was a strength of this review, as it 
meant that reviewer bias etc. was reduced. 
Once the final papers were agreed upon, the reference sections of each paper were 
hand searched and any potential papers reviewed against the criteria and by the second 
reviewer.  This helped to identify an additional three papers which were included in the 
final review. 
Unfortunately due to the nature of the studies this had to be a narrative review, as it 
was not possible to conduct a meta-analysis due to the varied and mixed outcome 
measures of the studies.  As a result of this varied nature the use of an established quality 
checklist was not deemed to be appropriate to use to more rigorously assess the quality of 
the final studies.  However, these limitations of the review in themselves highlight and 
establish the limitations and mixture in the level of quality and lack of sufficient and 
consistent research in this area. 
3. 10. 2.  Implications and future research 
 
This review has highlighted the lack of clear and consistent measures of GP practice 
quality; this is a problem as current and future health care priorities move towards 
improving the quality of primary care.  GPs’ adherence to guidelines was most commonly 
used as an outcome measure, but the majority of studies which used this as a quality 
measure were using GPs’ self-reported adherence, which could differ from their actual 
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adherence.  In countries such as the UK where quality monitoring schemes are in place, 
such as QOF, there is a distinct lack of studies which utilise this data source for research. 
It is therefore recommended that future research should be focused upon utilising such 
data sources and established frameworks of quality assessment, rather than simply relying 
on GP self-reporting surveys, to improve the quality of future studies and provide a more 
accurate and unbiased measure of primary care quality.   
This review also found that a number of external factors affected GPs’ provision of 
quality care and influenced their decisions in areas such as screening and referrals, these 
ranged from the GPs’ personal beliefs and characteristics (Parkerton et al., 2003, Xilomenos 
et al., 2006, Shieh et al., 2005) to patient pressure and demographics (Sorum et al., 2003, 
Gorin et al., 2007).  Further research into the effect of these factors and how they 
contribute, or hinder, the delivery of quality primary care is also recommended.    
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4. Chapter 4 – methods 
 
This chapter will outline the methodology used for this research.  The aim of this 
research is to test the hypothesis that a patient’s cancer stage at diagnosis is influenced by 
the GP practice they attended, specifically by how that practice performs on certain quality 
measures.  This research was funded as part of an e-health project, therefore part of the 
aim is to obtain and use data from existing health databases and possibly combine health 
databases together.  The consideration about what databases and sources were available 
and could be utilised for this project, are discussed within this chapter. 
There were a number of new and unique issues that arose throughout this part of the 
research.  Once the decision regarding which health sources and databases was made, the 
process of obtaining ethical approval, preparing the data, merging databases together and 
putting together a plan of analysis had to be organised and the challenges of these 
processes is discussed within this chapter. 
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4.1. Theoretical considerations 
 
The systematic review and general exploration of literature and research in this area 
raised some factors that required consideration and impacted upon the approach and 
methods used in this research. 
From the systematic review it became clear that measuring quality of care is a complex 
and varied issue, and it bought into question whether QOF was the best choice as a 
measure of primary care quality.   
In the UK, traditionally responsibility for quality of care has been in the hands of the 
individual GP and professional bodies, such as the Royal College of General Practitioners 
(RCGP) (Birch et al., 2000, Scrivens, 1995, Scrivens, 2002).  In the latter part of the 1990s 
quality improvement in the provision of health care became a high priority on the agenda 
in the UK and internationally (Campbell et al., 2003, Campbell et al., 2000).  What followed 
was a large amount of investigation and research into quality of health care, how it could 
be measured and the development of a national performance network within the NHS.   
Ultimately such research led towards the development of a financial incentive scheme, 
whereby GPs had to hit certain health targets and for doing so received additional 
funding/financial reward for their practice.  The Quality Outcomes Framework (QOF) was 
introduced in 2004 and is the current scheme which measures primary care quality in 
England.  QOF is a voluntary annual programme for all GP surgeries in England but despite 
the scheme being voluntary in 2009/2010 over 8,000 practices in England took part, which 
is 99.7% of registered practices.  QOF measures achievement against 134 indicators, across 
clinical care, organisational, patient experience and additional service domains.  In the case 
of the clinical indicators many of these reflect health conditions and diseases which are of 
priority, such as coronary heart disease, hypertension, COPD and diabetes.  Between 
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2008/2009 the average achievement in England was 95.4%, with 2% of practices within 
England achieving 100%.      
In their review of QOF in the three years since its introduction, Doran et al. (All Party 
Parliamentry Group on Cancer Report, 2009) in their report found that in the first year 
deprivation was associated with low achievement in quality of care and therefore causing 
inequalities.  In the subsequent two years, achievement in these areas has increased, 
suggesting an improvement in tackling inequalities as a result of QOF.  In mental health 
research QOF has been found to be a useful and valid tool for measuring and assessing the 
delivery of health care services (Ivbijaro et al., 2008). 
McLean et al. (2006) have also highlighted the benefits of QOF for tackling inequalities 
as there are systems in place, in particular the exclusion system, which reduce the risk of 
practices being penalised because of the populations they serve.  In contrast Sigfrid et al. 
(2006) in their research on diabetes and QOF found that practices located in more deprived 
areas were more likely to report exceptions.  As a result this could suggest that within 
these populations there are unmet needs being disguised by selective reporting, as 
practices try to gaining additional funding.  Following from this there is a well recognised 
positive bias within QOF, with many practices achieving the maximum score to receive 
maximum funding (Doran et al., 2014).  
Questions about the validity of QOF have arisen.  Downing et al. (2007b) examined 
hospital admissions and their relationship to QOF.  They found that QOF scores were not 
linked to the rate of hospital admissions, which appears to be counter intuitive as the 
pattern we would expect to see is that as quality of care improves,  hospital admissions 
should reduce.  Short (2007) also highlighted that the guidelines QOF outlines, particularly 
in smoking cessation, do not match those of other quality organisations such as NICE.   
95 
 
Prior to the implementation of QOF practice quality there was a lack of standardised 
methods that assessed the quality of health care (Thiru et al., 2003).  If practice quality was 
investigated it would probably have used Membership of the Royal College of General 
Practitioners (MRCGP) as a measure.  By using information about which practices are 
engaged in training and CPD schemes the assumption is that those practices taking part in 
such schemes have a desire to improve quality.  However, within research this has not been 
a widely used measure and it could be easily argued that engagement in training is not 
necessarily a measure of current good quality health care.  
Therefore, databases such as QOF are beneficial resources for research and for this 
specific research project there is a need for a quality measure that is used and consistent 
across a wide number of GP practices which QOF provides.  However, it is important to 
remember that good quality documentation does not equal good quality care (Heath et al., 
2007).  There are a number of arguments which must be acknowledged that highlight and 
express that quality of care can never be adequately measured or that wide-scale 
quantitative measures such as QOF cannot capture important aspects of quality such as 
patient/GP communication (Becher, 1999, Howie et al., 1999), but an attempt to 
incorporate these factors is outside the scope of this research and is not possible at this 
time. 
In addition to more careful reflection of appropriate measures of quality of care, more 
exploration was required of the decision to use cancer stage at diagnosis as the outcome 
measure.  As previously discussed, in chapter 2, this was a novel approach at the start of 
this research, previously cancer records of staging information have been mostly 
incomplete and poor; however, it has become more commonplace to use cancer stage at 
diagnosis as an outcome measure within research (Forrest et al., 2014, Lyratzopoulos et al., 
2012a, Rutherford et al., 2013). 
96 
 
 This more recent work has highlighted the need to consider factors that could 
influence cancer stage at diagnosis as a measure, specifically the variation between cancer 
types in consultation and referral rates (Lyratzopoulos et al., 2013).  Between breast and 
colorectal cancer there are a number of differences regarding their primary care interval, 
with colorectal patients receiving a higher number of consultations prior to diagnosis and 
higher primary care referral and interval times.  Tørring et al. (2013) in their Danish cohort 
study reflects these variances in interval time, with breast cancer having a shorter primary 
care interval compared to colorectal cancer. 
Equally it must be kept in mind that while the focus of this study is on GP quality of 
care and cancer stage at diagnosis there are a number of factors that can contribute to 
cancer stage.  As previously mentioned in chapters 2 and 3, age, sex, ethnic origin, 
socioeconomic status (Downing et al., 2007, Cutherbertson et al., 2009, Delmothe, 2008, 
Conway et al., 2007, Johnson et al., 2008, McLean et al., 2006) increase the likelihood of 
developing cancer but also influence diagnosis and treatment.  Other forms of delay, such 
as patient and system delays as outlined in the model by Andersen et al. (1995) can also 
contribute to delays in diagnosis.  Not all of these factors are measurable, and in some 
cases are beyond the scope of this research, however where it has been possible to request 
data regarding these factors they have been included, for example, patient age and sex, 
and income domain quintile as a measure of socioeconomic status. 
Breast and colorectal cancer differ widely and these differences in consultation and 
interval rates between breast and colorectal cancer support and highlight the decision to 
separate the dataset and analyse the two cancer types separately as they are not 
comparable;  therefore, any comparison that could be made would not be of benefit for 
future research and policy. 
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4. 2.  Databases 
 
This research only used data from pre-existing databases, no new data was collected.  
The databases that have been used in this study are as follows: 
 Cancer related data came from the Northern and Yorkshire Cancer Registry and 
Information Service (NYCRIS).  Specifically the data that was extracted included; 
patient’s cancer type, cancer stage at diagnosis, year of diagnosis, GP practice, sex, 
age and deprivation index. 
 Practice quality data was obtained from the practice profiles, which covers the 
Northern and Yorkshire region.  Practice profiles are available via the Association of 
Public Health Observatories (APHO) website, this data is in the public domain.  The 
specific data that was extracted included; all variables related to cancer, local area 
and practice deprivation index scores, practice demographics and patient 
satisfaction scores.  
 Quality and Outcomes Framework (QOF) data was also included, this is included in 
the practice profiles but where specific indicators or practices were missing the 
most recent QOF data from the NHS Information Centre website was obtained.  
This is publically available data that is freely available to download. 
NYCRIS is one of eleven cancer registries around the UK, which routinely collect cancer 
data from multiple sources.  In addition to collating local cancer information, cancer 
registries work with a range of organisations within their area, i.e. PCTs, SHAs and cancer 
networks and national organisations, such as the ONS, to produce health and care 
publications.  NYCRIS covers a large geographical area of Northern England and Yorkshire 
(excluding a small area of South Cumbria) with a total population of around 6.6million with 
over 50,000 new cancer cases recorded per year.  Further details about NYCRIS are 
available via the NYCRIS website (http://www.nycris.nhs.uk/). 
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Through discussions with NYCRIS it was suggested that two or three specific cancers 
were selected for analysis, the reason for this was primarily two-fold.  Firstly by selecting 
just two or three types this would simplify data management and analysis but also more 
common and priority cancer types can be focused on, which also ensures a sufficient 
number of cases for analysis.  Secondly the recording of cancer stage is not consistent 
across the cancer types, for example it had been hoped that lung cancer could be included 
in this research, because of its prevalence and high mortality rate which therefore has 
made it a priority within cancer targets.  However, the number of cases which had a stage 
recorded was very low (less than 10%).  In comparison breast and colorectal cancer, which 
are both prevalent and priority cancers, had at least 70% of cases with a cancer stage 
recorded, specifically colorectal cancer had 25.9% of cases with an unknown stage and 
breast cancer was 7.3%.   
Currently there are a number of methods by which cancer stage can be recorded; 
specifically for colorectal cancer, Duke’s staging is the common method but for breast TNM 
is the more common staging method.  Cancer registries within the UK are managed by the 
Office of National Statistics (ONS) which collates information from the registries to produce 
national statistics.  When cancer registries submit cancer stage information, regardless of 
the cancer type, they use a standardised system which is as follows; 
 0= In Situ  
1= Local Involvement Only  
2= Extension to Adjacent Tissues  
3= Lymph Node Involvement  
4= Metastases  
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5= Unknown 
The NYCRIS data fields requested included patients; sex, type of cancer (breast or 
colorectal), stage of cancer at diagnosis, age at diagnosis, patient-level income domain 
score (which was provided in quintile, with 1 being the least deprived and 5 the most 
deprivied), year of diagnosis and the patient’s GP practice code for the previous three years 
(2006-2008).  In the event of missing data it was requested that these cases not be 
excluded, just that whatever information in the requested fields was included, this was to 
try and keep numbers for analysis as high as possible but to also record and observe where 
missing data was most commonly occurring.      
After the data had been obtained it was decided that information related to whether 
patients had been diagnosed through a screening pathway would be of benefit.  Diagnosis 
via screening bypasses the GP practice and therefore cases diagnosed in this way would 
only obscure and bias the results.  Screening information for the 2006-2008 period was 
requested and received, but this was only available for breast cancer.  The NHS Bowel 
Cancer Screening Programme in England started in July 2006, this was for men and women 
aged 60-69 to whom an invitation for screening was automatically sent through the post, if 
they were registered with a GP.  However, within the Yorkshire region this programme was 
only partially rolled out in 2006 and as a result screening information regarding bowel 
cancer was not available.   
The APHO is made up of 12 PHOs around the UK that collate and produce information, 
data and intelligence on people's health and health care for practitioners, policy makers 
and the wider community.  A recent initiative has been the production of practice profiles, 
designed to assist GPs, emerging consortia and PCTs to ensure that they are providing and 
commissioning effective and appropriate healthcare services.  Information from a range of 
sources, specifically QOF, GP patient survey data, the Attribution Data Set and Primary care 
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mortality data, was collated to produce these profiles which provide data regarding the 
practice population, deprivation, measures of quality etc.  Where possible the most recent 
data was used, in the case of this research that was data from 2010. At that time it was 
reported that 3% of practices in England were not included in QOF results, this was either 
because the practices had chosen to not participate in the QOF scheme or the practices 
had small list sizes so were excluded on this basis.  The profiles became publicly available in 
late 2010 and were reviewed in mid-2011.  The practice profiles are available through the 
APHO website (http://www.apho.org.uk/pracprof/).  
QOF data is a primary component of the APHO practice profiles.  QOF is a voluntary 
annual reward and incentive programme for all GP surgeries in England.  It was introduced 
as part of the GP contract in 2004 and despite the scheme being voluntary, in 2009/2010 
over 8,000 practices in England took part, which is around 99.7% of registered practices.  
QOF during this time period measured achievement against 134 indicators, across clinical 
care, organisational, patient experience and additional service domains.  The more points 
and therefore higher score that GP practices achieve the more money they receive but 
adjustments are made based on the practice’s workload and the proportion of chronic 
conditions within the local area.  Results from QOF are available through the NHS 
information centre website (http://www.qof.ic.nhs.uk/index.asp).  In addition to the data 
which was obtained from the practice profiles the individual domain scores and overall 
total QOF score for each practice was obtained from the QOF website for 2010. 
It should be acknowledged that there is a distinct difference between the two primary 
sources of data.  While data from NYCRIS is at an individual patient level, the data from the 
APHO etc. is an aggregation of a group of patients within a practice.  Therefore, the data 
being used to measure practice quality may not accurately reflect an individual patient’s 
experience of quality of care.  Equally there is the risk of generalising results which have 
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limited power when using organisational level data, such as practice measures of quality.  
Saunders & Abel (2014) highlight this issue using the example of hospitals within England; 
with only 160 hospital in England even the inclusion of all of these within an analysis would 
give good but limited power to a study.  Walker et al. (2013) support this identifying that 
surgeons may not conduct a sufficient number of specialists procedures within a year for 
the quality of patient outcomes to be adequately measured and therefore could lead to 
and result in false reporting. 
There is a much greater number of GP practices within England however, and this 
research project has looked at a large geographical area, capturing 792 GP practices in the 
colorectal cancer dataset and 840 in the breast cancer dataset.  Had these numbers been 
smaller a greater exploration of power and the use of organisational group measures would 
have been necessary and adjustments or alternative designs would have been explored; 
further discussion on this can be found in Chapter 6. 
4. 3.  Ethical approval 
 
The practice profile data and QOF data which came from the APHO and NHS websites 
are both publicly accessible and the data is freely available to download. 
In contrast data from NYCRIS is not publically available and therefore a formal data 
request was made.  While no patients were being directly recruited or contacted for this 
research project, data from NYCRIS is classed as potentially identifiable data, specifically as 
a geographical identifier (GP practice) and details regarding the type and stage of cancer at 
diagnosis were requested.  This level of detail means that individual cases could be 
potentially identifiable particularly where there are a small number of cases within a 
practice.   
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Due to the use of patient data, NHS REC (Research and Ethics Committee) approval was 
required. However, because of concern regarding the issue of potentially identifiable data 
the NIGB (National Information Governance Board) was contacted prior to ethical 
submission.  With their help, adaptations were made to the design of the study to ensure 
that patient information was sufficiently anonymised and could not be identified.   
In particular the NIGB were concerned with small numbers, where within a GP practice 
there were less than five cases of a specific type of cancer, e.g. three cases of breast cancer 
or four cases of colorectal cancer.  In these cases the NIGBs required changes were to 
amalgamate some patient information and data, specifically patient’s age and the year of 
diagnosis, to reduce the identifiability.  How these changes and ethical stipulations altered 
and affected the data are discussed later in this chapter.  
Once these changes were made to the design of this study an ethics application was 
made to the NHS REC and approval was granted, see appendix 1. 
4. 4.  Working with the data 
 
Once all data was obtained it became evident that a process of data preparation and 
cleaning was required before all the data could be merged together into a cohesive 
dataset, before analysis could take place. 
The decision was made to combine all three years of data, rather than keep each year 
of diagnosis separate for analysis; this was in line with the NIGB changes to anonymise the 
data.  By amalgamating all years together it avoided a large number of practices from being 
excluded from the analysis because of small numbers, based on the guidance and 
stipulations set by the NIGB, that had to be met to gain ethical approval.  It was also 
observed that a small number of patients were diagnosed at a young age, which could have 
again caused an issue of small numbers. To resolve this, existing age ranges were combined 
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into broader age categories.  Specifically two age categories were used; working age (18-
64) and retirement age (65+), this ensured that NIGB stipulations were followed and  
prevented a number of patient cases and practices from being excluded.   
Previous research has combined and grouped cancers together (Howlader et al., 2010, 
Jemal et al., 2011) and this was considered as an option for this research; however, it was 
eventually decided that the two cancers should be analysed separately.  This meant 
creating two datasets for analysis, one for breast cancer and the other for colorectal 
cancer.  In light of this it was decided that in addition to the ethics committee requirement 
that a minimum of five cases must be present, it was appropriate to additionally remove 
any small numbers within cancer type.  For example if a practice had a total of 13 cases but 
11 of these were breast and only two were colorectal then the colorectal cases were 
removed.  However, the breast cancer cases for that practice could remain in the breast 
cancer dataset, as there were more than five cases.   
After obtaining the data it was decided that the inclusion of information related to 
screening would be of benefit.  NYCRIS does hold information related to screening but this 
is not 100% complete.  Also for the time period of 2006-2008 the national breast screening 
programme was running but routine screening for colorectal cancer had not yet been 
introduced.  Therefore screening information was only available for breast cancer during 
this time period. 
The NYCRIS screening data comes from the NHS Breast Screening Programme which is 
a population screening programme inviting all women between the ages of 50 and 70; an 
invitation is first sent between the ages of 50 – 53, for routine mammograms every three 
years.  Around 1.5 million women are screened every year at screening units across the 
country.  The programme is aimed at asymptomatic women. Due to limitations in the 
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mammography technology it is not suitable/as accurate for younger women, therefore this 
group would most likely be presenting and be entering diagnostic pathways via their GPs. 
The screening programme is monitored and checked for quality and this is overseen by 
regional Quality Assurance Reference Centres (QARCs).  These centres collect and collate 
data about the performance and outcomes of the breast screening programme, organise 
quality assurance visits and provide support for the regional director of quality assurance 
and the professional coordinators. 
Knowledge of screening status is important because detection through screening is not 
done via a GP. Therefore it can be argued that the quality of practice of a patient with 
screen-detected cancer has not influenced the stage at diagnosis.  Therefore by knowing 
which cases have been detected via screening, they could be isolated or excluded from the 
analysis. 
The screening categories that were provided by NYCRIS are wide ranging and detailed.  
Definitions of the categories were gained from NYCRIS and from the QARC and a 
breakdown of the ten categories is as follows: 
1. Screening detected cancer – the diagnosis has been made from the screening 
process not via the GP or other routes. 
2. Interval cancer – the diagnosis has been made between screening episodes, so the 
patient is attending screening and their last result was negative but has presented 
with symptoms prior to next scheduled screening. 
3. Cancer in non-attender – patient has never attended any screening despite being 
invited, so has presented via another route. 
4. Overage – patient is over the age range for screening at the time of diagnosis, 
according to QARC they would also have attended their last screening (so should 
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not be any non-attenders in this group).  NYCRIS say that in fact these are screen 
detected cancers where the patients has requested to continue screening after the 
age of 70. 
5. Cancer in lapsed attender – attended at least one round of screening but did not 
attend their last scheduled screening prior to diagnosis. 
6. Cancer in uninvited – patient has not been invited for screening, but not underage.  
QARC say this is most likely because they are close to screening age (50-52) but 
recently moved so the invite is lost and NYCRIS said something similar and added 
that input errors on the records system can also result in eligible individuals not 
being invited. 
7. Underage QARC – Patient is under the age range for screening at time of diagnosis, 
QARC says it is women aged 49, NYCRIS adds that it is women who are called to the 
screening process early and who have in fact been detected through screening.  
They may have been called to the screening process early due to family history etc. 
8. Uncategorised at QARC – this is due to insufficient information being available to 
categorise a case. 
9. Unmatched at QARC – NYCRIS say the patient cannot be matched at QARC so may 
not have an NHS number etc. QARC say it is because of an absence of screening 
record within the region. 
10. Unknown – no screening data. 
It was decided that these categories would be best simplified for analysis and instead 
divided into just three categories: 
1. Screen detected – this includes the screen detected, underage and overage 
categories. 
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2. Not screen detected – this includes, interval, non-attender, lapsed, uninvited, 
uncategorised at QARC and unmatched at QARC. 
3. No information – this is cases from the unknown category where there is no 
screening related information. 
Within the breast cancer cases there was a small number of stage 0 cases (n = 100).  
Stage 0, or carcinoma in situ, in breast cancer is often referred to as a pre-cancerous stage 
and in conjunction with the small sample number it was decided that these cases should be 
excluded from the dataset and analysis.   
Prior to linking the datasets they were reviewed for problems and errors, specifically if 
there was any important missing information, or information that was incorrect.  This was 
important as it ensured that the data received had all the relevant and required 
information, particularly in the case of the NYCRIS dataset which provided GP information 
for each case.  Each GP practice that participates in the QOF scheme is given a code which 
is unique to that practice. It was through this code that the patient’s information regarding 
cancer stage etc. was linked with the GP practice information regarding practice quality.  
Therefore, it was of great importance that any issues or unknown GP codes were identified 
in an attempt to reduce the number of practices that would be excluded from analysis.   
Data from the practice profiles has already undergone a review by the PHO which 
meant that problems like missing data and clerical errors have already been addressed.  
Practice profile data is publically available and accessible to download from the practice 
profiles website as needed; however, this data is only available to download in large Excel 
spreadsheets which contain all the practice profile data.  This became a problem as a large 
amount of time was spent excluding any unnecessary data, specifically fields which are not 
related to this research, such as, QOF indicators about asthma or mental health.  The 
practice profiles are grouped by PCT, with each Excel file containing data for each practice 
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within that PCT.  In total there were 23 PCTs and resulting Excel files, which were combined 
and converted from Excel to Stata.   
While this data is freely available to access and download, the format in which it is 
downloaded was not workable for this research and does not lend itself to data 
manipulation.  Also as identified above, the practice profiles contain a large amount of 
information and variables which were not required for this research and as a result the 
Eastern Region Public Health Observatory (ERPHO), who are the lead on the practice 
profiles, were contacted.  Upon request for data from specific PCTs and practice profile 
indicators ERPHO were able to provide the requested data in a raw data file.  This meant 
only the data required was included and the data was in a more workable format, 
specifically it was able to be manipulated and moved between software packages more 
easily. 
In contrast the NYCRIS data presented a very different set of problems.  The data had 
not been cleaned and prepared to the same extent as the practice profiles and required 
data cleaning to resolve the problems of missing data and errors within the dataset.  
Problems with the use of cancer registry data have been highlighted in previous research 
(Parkin and Bray, 2009, Pascoe et al., 2008), specifically with regard to the issue of missing 
data. 
The first problem was whether the data could be located from another source.  For 
example, in the case of cancer stage if this was unknown then little could be done to find 
out this information but in comparison if a GP practice code was unknown but the GP 
address was within the data then the practice code could potentially be found. 
In the case of missing data that could not be retrieved, for a variable such as cancer 
stage this data was kept within the dataset and the cancer stage labelled as unknown.  
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While the preference would be to know the cancer stage, equally having a record that the 
cancer stage has not been recorded or obtained provides information for comparison and 
analysis.  It could be argued and interpreted that a lack of cancer stage is an example of 
poor practice quality, because perhaps certain diagnostic tests have not been conducted or 
delays in reports or test results has meant that a diagnosis has been delayed or simply that 
organisation issues have prevented a cancer stage from being properly recorded.   
The GP practice code is of critical importance within the NYCRIS dataset, as this is the 
variable which was used to link the NYCRIS data to the data from the practice profiles and 
QOF.  Therefore, where GP practice was unknown, that particular patient case could not be 
linked to the practice data and would therefore have to be excluded from analysis.  There 
were 1,874 cases with no practice details and these were excluded from any analysis. 
However, there were an additional 1,437 cases which did not have a practice code but had 
other practice details, such as practice name, address and postcode. 
In these latter cases, attempts were made to find out the GP practice code.  In 427 of 
these cases the code had simply not been inputted and by visually checking the practice 
name and address that was listed against another case with the same practice name and 
address a code could be identified and inputted.  This then left 1,010 cases without a GP 
practice code. 
In hindsight the identification of these practice codes was a time consuming process, 
particularly as they only account for 2% of the dataset.  The key reason for trying to find the 
GP practice codes is to retain as many practices as possible to maintain the sample size for 
analysis.  Also identifying where problems and errors occur and how to deal with and 
overcome these can be used to inform future practice and research using these databases.   
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Even with excluded data, knowing the GP practice code means that a note can be made 
on the number of practices that had to be excluded from analysis and for what reasons and 
also whether there are any common characteristics, i.e. whether they are perhaps single-
handed practices or located in very rural areas. 
4. 5.  Weaknesses and errors in the dataset 
 
The most common errors were as follows: 
Clerical errors – these were most commonly misspellings of practice names, address 
and/or postcodes.  For example, a postcode may have been recorded as DL7 8DO, when in 
fact it is DL7 8DP.  These could be difficult to identify, as ordering/sorting the data by 
practice postcode etc. did not always highlight these errors, therefore hand searching 
through missing or anomalous data was required, which takes time.   
Other clerical problems – the use of generic names when either details are unknown or 
perhaps records are illegible.  For example, where the real practice name is unknown at a 
stage of recording this information it may have been completed simply with ‘the surgery’, 
or various similar combinations, such as if the practice is on a road called ‘front street’ or 
‘front street practice’.  This causes a particular problem when practices are within health 
centres and it becomes harder to differentiate and accurately identify the practice. 
Health centres - health and medical centres are commonly occupied by more than one 
practice, each with their own practice code but sharing the same address.  This caused two 
problems, firstly which practice name was recorded; and if the individual practices have 
their own names, which are those used for the APHO practice profiles or QOF tables, but 
secondly the health centre also having an overall name.  In the NYCRIS database the health 
centre name may have been recorded instead of the GP practice name, for example, Trinity 
Riverside Practice and Dr S Chander are both located at the Flagg Court Medical Centre but 
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both of the former may be recorded as the latter.  In cases where the address was identical 
for multiple practices it was not possible to assign a practice code and the cases had to be 
excluded.   
Branch practices – select practices have more than one practice or site.  In these cases 
there is only one GP practice code and only the address of the primary/main practice is 
used in the practice profiles and QOF.  In the NYCRIS dataset however, the address of a 
secondary branch practice may have been recorded instead of the primary site address.  
This causes a problem if just the address has been recorded and the GP code is missing, as 
it is not initially evident that the practice is part of a branch/group.  In these circumstances 
it is of particular importance to identify the GP code and unify the cancer cases together, as 
only one or two cases of cancer maybe recorded at each practice site but as a whole the 
practice has seen a higher number of cancer cases and can be retained in the dataset 
rather than excluded.   
4. 6.  Process used for identifying GP practice codes 
 
In the process of preparing the data and trying to identify GP practice codes the 
following process for identifying missing GP practice codes was developed. 
Stage 1 
 The NHS has a practice code ‘look-up’ table (http://www.ic.nhs.uk/statistics-and-
data-collections/supporting-information/audits-and-performance/the-quality-and-
outcomes-framework/qof-2007/08/data-tables).  This Excel database lists the 
details, practice code, address, postcode etc., of all practices registered to QOF 
during 2007/2008 (no updated version is available).  In addition there is an older 
file from 2004/2005 which if no results are found in the 07/08 file then the same 
information can be checked in this older file to see if perhaps the practice did exist 
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and has moved (http://www.ic.nhs.uk/statistics-and-data-collections/supporting-
information/audits-and-performance/the-quality-and-outcomes-framework/qof-
2004/05/qof-2004-05-detailed-spreadsheets).  
o Within the Excel file the find function can be used to search for the 
postcode. 
 What seems to work best when searching within this database is to 
search for the first half of the postcode and then go through the 
resulting options.  This is because sometimes the search does not 
always recognise the postcode, despite it being in the database, 
and sometimes by viewing the other postcodes in that area errors 
are picked up earlier.  For example, when searching for a postcode 
such as TS17 1AY, there may be a postcode which is TS17 3AY and 
on closer inspection the latter is actually the correct postcode. 
Stage 2 
 If using the postcode in a search is not successful then the next step is to check the 
postcode is correct. 
o Searching for other address details in the look up files, such as street or 
village names, as the postcode boundaries may have changed. 
o There are also alternative websites and search options available if the NHS 
practice look up table does not prove successful. 
 Try an online map website – using such a website enables you to 
see if a postcode matches up with other address details.   
 Try Royal Mail address finder 
112 
 
 Can input postcode to the finder and it will display the 
address for that postcode, which can be compared against 
the address that has been provided. 
 Can input first line of address and see if any of the 
postcode options match up. 
o Once a postcode error has been found, then it is advisable to return to the 
practice code look up table and search again using the correct postcode or 
other address details to see if the practice can be identified. 
Stage 3 
 If practice code can still not be found the next step is to search for the practice in 
the NHS search tool 
(http://www.nhs.uk/servicedirectories/Pages/ServiceSearch.aspx?ServiceType=GP)
.  
 Details of the practice, such as the postcode, can be used to search 
for GPs near a location. 
 In particular GPs which are a branch practice or part of a larger 
practice/medical group, can easily be identified using this tool.  
Once the practice has been found details about other premises are 
listed on the practice page. 
Stage 4 
 If no results are found from the NHS search then the next step is to use a generic 
internet search engine, such as Google. 
o Often this type of search will bring back directory websites (i.e. yell.com) 
and these can be used to confirm the existence of the practice and possibly 
113 
 
provide correct (i.e. if something has been spelt incorrectly) or additional 
details (i.e. phone number, GP’s name). 
o This type of search may bring up the practice’s own website and this is 
worth checking if no errors have been found in case the practice is part of a 
wider group or has relocated more recently (i.e. post 2008).   
Other options 
 Still no results then can try searching alternative details, for example, if postcode 
has been used try the practice name or street name.  Equally searching for any 
additional details that have been found, such as telephone number, may yield a 
result. 
 If you have a practice name or GP name you can try looking at the listed practices 
in a PCT on the APHO practice profile website (http://www.apho.org.uk/pracprof/).  
However, only the practice names and the GP codes are listed on this website and 
therefore a clear practice name is needed (i.e. something like ‘the surgery’ or ‘the 
health centre’ will not work).   
 If after these steps a GP practice code can still not be found then it is likely that the 
GP is not registered with QOF and therefore does not have a practice code.  These 
are then coded as ‘NULL’ 
 
During data preparation it was discovered that the NYCRIS data is not laid out with 
each case (or line of data)as an individual, but rather each line of data is an individual case 
of a cancer tumour, therefore in individuals who experience multiple tumours or the 
development of other cancer tumours there are multiple cases/lines of data for these 
individuals.  For example, there may be an ID number of ‘12345’ and this may appear twice 
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within the dataset but one case can be for a stage 2 breast tumour from 2007 while the 
other is a stage 1 breast tumour from 2008.    
1,454 multiple cases were found and within these there were 715 individuals/patients; 
this equates to just over 5% of the dataset consisting of multiple cases. 
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Figure 1. Incidences of multiple cancer cases in a patient. 
 
In the majority of multiple cases there were just two cases, but there were instances 
within the dataset of patients having three or even four tumours recorded per patient 
within the time period (2006-2008).  In 654 individuals the multiple cases are the same 
cancer, i.e. two cases of breast, but in 61 individuals the cases are for different cancers.  As 
only breast and colorectal cancer are being focused upon in this research it is only known if 
an individual had both of these cancers.  There is no indication in the NYCRIS dataset 
whether an individual developed another type of cancer within the time period (2006-
2008) or whether they had already had a case of cancer or a resulting case after the time 
period. 
The realisation of these multiple cases caused a problem as to whether they should be 
left in or whether their presence caused some kind of bias.  There is a chance that some of 
the multiple cases are in fact errors and a tumour case has been recorded twice.  The 
decision was made to keep the first recorded tumour and remove any subsequent cases 
26,684 cancer cases 
1,454 cancer cases 
where an individual has 
more than one case 
within the time period 
715 individuals with 
more than one case of 
cancer within the time 
period 
25,230 individuals with 
only one case of cancer 
in the time period 
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with a later date.  Where there were multiple cases within the same year for an individual, 
the tumour with the most advanced stage was retained and the others removed and in 
cases where an individual had both cases of breast and colorectal cancer in the time period 
the first cases of both of these were retained and any secondary tumour cases removed.   
Once these secondary cases were removed this presented a new problem for the 
dataset, as it reduced the number of cancer cases to below five for some practices, and as a 
result both datasets has to be searched again for small numbers and any practices with less 
than five cases were removed. 
4. 7.  Data combination 
 
The data started in two separate datasets, data from NYCRIS in one dataset and in the 
other the data from the practice profiles and QOF.  The two datasets were imported into 
Microsoft Access and combined using the GP code as the common data item. 
Some alterations had to be made to the datasets to enable the combining of the data.  
Primarily there was a problem with the layout of data in the practice profile dataset where 
the data had to be rotated. 
Once the data was combined then checks at random intervals were made to ensure 
that the data was still accurate and the merger of data had been successful.  The data was 
moved back into Stata and divided into two working datasets based on cancer type (1; just 
breast cancer data and 2; just colorectal cancer data). 
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4. 8.  Software 
 
The decision was made to undertake analyses using the Stata (Version 11, StataCorp 
LP) statistical software package.  There were two primary reasons for this choice.  The first 
was the quantity of data that was being used and the level of manipulation that was 
required; other packages such as SPSS would have been inadequate for this task.  Secondly, 
Stata was capable of the planned types of analysis, including a three level multi-level 
analysis.  Alternative packages such as MLWin were an option but Stata is widely used 
within health statistics, support for this program was available within the University and it 
is also viewed as more user-friendly. 
4. 9.  Analysis 
 
With all the data combined together and then separated into the two cancer specific 
datasets the analysis could begin.  Outlined in this section is the plan of how the analysis 
was planned to be conducted and the resulting issues and changes which were made. 
4. 9. 1.  Variables 
 
For the analysis there were a number of variables which related to different levels, 
these were patient variables, GP practice variables and PCT variables.  A breakdown of the 
specific variables at each level is below:  
  
118 
 
Patient variables: 
1. Age (2 groups; 18-64 or 65+) 
2. Sex (2 groups; male or female) 
3. Cancer type (2 groups; colorectal or breast) 
4. Cancer stage (5 groups; 1, 2, 3, 4 or unknown) 
5. GP code (nominal data, lots of groups) 
6. Screen detected (3 groups; yes, no, no info.  Only for breast) 
7. Income domain quintile (ordinal 1, 2, 3, 4 or 5) 
GP variables: 
1. QOF scores 
a. Clinical domain (ordinal data, scores are in both percentage and actual 
score) 
b. Organisational domain (as above) 
c. Patient experience domain (as above) 
d. Additional services domain (as above) 
e. Total score (as above, combined from the previous 4 domains) 
2. Specific points from the practice profiles.  
a. Indicator 275 – Cancer: review within 6 months of diagnosis 
b. 276 – Cancer: QOF prevalence (all ages) 
c. 277 – Exception rate for cancer indicators 
d. 336 – Percentage of patients age 65+ years 
e. 338 – Deprivation score (IMD 2007) 
f. 340 – IDAOPI (income deprivation affecting older people) 
g. 342 – Percentage satisfied with phone access 
h. 343 – Percentage able to see doctor within 2 days 
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i. 344 – Percentage able to book appointment >= 2 days ahead 
j. 345 – Percentage satisfied with opening hours 
k. 346 – Percentage able to see preferred GP 
l. 641 – Percentage aged 75+ years 
m. 642 – Percentage aged 85+ years 
PCT variables: 
Same as GP but grouped by Primary Care Trust (PCTs). 
4. 9. 2.  Preliminary analysis 
 
There was a need at first to see how the data was distributed before more detailed 
analysis was conducted, this way it is easier to determine which analysis would be most 
appropriate, particularly as this is a large data set with a large number of variables. 
 The first stage was to look at the distribution of the key variables.  The primary aim is 
to look at whether there is an association between cancer stage and GP practice quality, 
therefore cancer stage was plotted against primary quality measures, such as QOF total 
score and the individual QOF domains (organisational, clinical, patient experience and 
additional services).  The secondary aim of this project is to look at other variables that may 
influence cancer stage or the practice quality (if cancer stage and practice quality are 
associated) therefore looking at variables such as cancer stage and age etc. is also 
beneficial to see if there is an association and whether it is statistically significant. 
In addition to producing graphs as a visual representation of the distribution of the 
data, correlation matrixes were also conducted to see if there is any relationship between 
the variables. 
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4. 9. 3.  Regression analysis 
 
Once the distributions and correlations of the data were examined a regression analysis 
was carried out.  Regression analysis was chosen due to the large number of potential 
explanatory variables; this form of analysis offers the best way to see how each of these 
interacts and influences the outcome.  Again this was done separately for the two cancer 
types and initially all variables were included. 
The primary aim of this research is to investigate the association between cancer stage 
at diagnosis and GP practice quality, therefore the outcome measure is the cancer stage.  
Within the dataset, cancer stage is a categorical variable and has five categories (stage 1, 2, 
3, 4 and unknown).  Regression analysis requires the outcome variable to only have two 
categories for comparative analysis, i.e. stage 1 v 2, stage 1 v 3 etc.  A results base outcome 
regression was chosen as this form of analysis allows the selection of a base category for 
the remaining categories to be compared against.  Due to the stage system used to classify 
the development and progression of cancer cases a number of previous studies have 
adopted the use of base outcome, or multinomial in Stata, regression for their analysis 
(Keating et al., 2010, Tarlov et al., 2009). 
This worked well for this research as it separated and compared the various 
combinations of stages enabling a more in-depth look at how any potential associations 
may work.  
It should be noted that the standard output in Stata for multinomial regression 
includes; coefficient, standard error, z, P>[z], and the 95% confidence interval range.  The 
presentation of coefficients is not always preferable for interpretation and a change to 
Odds Ratios (OR) would be standard practice.  However, Stata does not produce ORs for 
multinomial regression (mlogit) but produces Relative Risk Ratios (rrr) which have been 
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used in the outputs and results that follow.  There has been debate about whether RRR are 
an equivelant of (or even the same as) Odds Ratios (Gutierrez, 2005), Rabe-Hesketh & 
Skrondal (2012) in their book (pg. 637) on categorical modeling in Stata demostrate that 
RRR in Stata and OR are comparable.   
4. 9. 4.  Multi-level model  
 
Using base outcome regression, analysis is however unable to separate and specify the 
potential influence that GP practice and even living within a particular PCT can have.  It was 
decided that using multi-level modelling would help to identify specifically how much of the 
variance between cancer stages could be attributed to the GP practice and PCT.   
Within the dataset there are 3 levels of data: 
1. Patient/individual cases 
2. Practice – combination of patient data within a practice (identified by 
practice code) 
3. PCT – combination of practices within a PCT (identified by PCT code) 
The primary question is to see if there is a potential link between practice quality and 
stage of cancer at diagnosis, which requires the two levels of patient and practice level to 
be analysed.  PCT is important to put in as a third level because of the influence PCTs have 
upon a practice regarding commissioning and finance.  How a PCT divides out funding etc. 
and also what schemes and interventions they get involved with influences the practice 
and therefore should be included.   
Multi-level modelling is regularly used as a method of analysis where it is thought that 
higher, level processes are influencing processes at a lower level.  In the case of this 
research higher level processes are the GP practice and PCT level which are providing the 
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health care to diagnose and treat patients, which are the lower level.  While the base 
outcome regression is able to identify variables which contribute towards cancer stage at 
diagnosis, conducting a multi-level analysis provides a more specific and clear look at how 
much GP practice or PCT variables are contributing to cancer stage (Luke, 2004). 
Again a base outcome approach was used, while this was in part due to the same 
analysis limitations as before the regression analysis also showed that not all cancer stage 
comparisons provided a significant result.  A similar method has been used in previous 
research which examined factors which affected the stage of prostate cancer at diagnosis 
(Zhou et al., 2008). 
 To begin with all variables were included in the analyses but this was refined and the 
variables reduced based on the findings from the first regression analyses and the 
outcomes of the initial multi-level models.  This was done to get a clearer indication of the 
impact of significant variables on the outcome.  For example, many initial models were 
non-significant due to the majority of variables being non-significant and therefore 
influencing the overall significance of the model. 
Figure 2. Outline of multi-level model 
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4. 10.  Additional analysis 
 
4. 10. 1.  Deciles 
 
Looking at the distribution of QOF data it was found to be positively skewed, see 
figures 3 & 4.  This was to be expected, since it is a common criticism of QOF and reflects 
the fact that practices are financially incentivised to achieve high scores.  However, looking 
at the graphs, there are a number of outlier practices which do not achieve the maximum 
number of points and in fact achieve less than the average total score.  
Figure 3.  QOF total score and patient colorectal cancer stage.  
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Figure 4.  QOF total score and patient breast cancer stage. 
 
It was discussed that this positive skew could impact upon the analysis and the 
observation of the outliers led to the decision to split the data into deciles.  This way a 
comparison could be made in analysis of the top performing 10% of practices and the 
bottom 10% of practices, basically comparing what has been assessed as the best and 
worst practices in QOF.  The aim of doing this is to try and account for the positive skew 
and reduce the effect of having many of the practices clustered together.  Previous 
research has used this approach of comparing top and bottom percentage groups in a 
range of cancer research from comparing top and bottom socio-economic status quintiles 
(Smith et al., 2012, Linseisen et al., 2011, Møller et al., 2012) to specific outcome measure 
variables such as the top and bottom quintiles of dietary fibre scores (Cui et al., 2011, Fung 
et al., 2010, Tworoger et al., 2011, Wilson et al., 2010).    
This division into deciles was initially done based upon the QOF total score.  However, 
the QOF total score is made up of four domains, clinical, organisational, patient experience, 
and organisational.  Following some of the results from initial analyses the decision was 
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made to repeat this process of separating the data into deciles with each of the four QOF 
domains, as for example, a GP practice may perform well and score highly in three of the 
domains but score poorly in one domain and bring the practice’s total score down into the 
bottom decile.  Equally a practice may perform poorly across the majority of the domains 
but achieve the maximum score in the other domain(s) and that may bring the practice into 
the top decile. 
The decile ranking based on each individual QOF domain was therefore calculated for 
both the breast and colorectal datasets and the regression analysis was repeated using the 
decile ranking of each of the four QOF domains and the top and bottom deciles were 
compared. 
4. 10. 2.  Screening effects 
 
In the case of the breast cancer dataset there was concern after the analysis that there 
could be a screening effect within practices.  GP and practice factors were found to 
influence breast cancer stage at diagnosis, and while screen detected cases were removed, 
there is an argument that there could be a wider reaching effect.   
Of primary concern is the potential for wide variation between GP practices in breast 
cancer screening uptake, which could affect the analysis.  For example, in a GP practice 
where the screening uptake is 20% and another where the uptake is 80% this variation in 
screening uptake would result in the practice with 80% potentially having a higher 
proportion of less advanced staged cancer cases.  Previous research has shown that screen 
detected cases have a less advabnced stage at diagnosis comapred to sympotmatic cases.   
This concept is similar to the Hawthorne Effect, which was first observed in industrial 
research but has since been observed and applied to a number of clinical research and 
126 
 
practice settings (Fernald et al., 2012, Efraimsson et al., 2008, Pascoe, 1983, McCarney et 
al., 2007).  The Hawthorne Effect suggests that an intervention, regardless of what it is, will 
have a positive effect.  In this case a GP and/or practice that demonstrates good screening 
behaviour could potentially have a positive effect across the practice, specifically less 
advanced stage of breast cancer at diagnosis.  However, it has been shown that there is 
variation between practices in breast screening uptake and screening referral behaviours.   
Chapter 3 highlights the influence that a GP can have on cancer referrals and 
reccomendations, such as precieved barriers to diagnoistic tests (Daly and Colins, 2007) and 
interpretation of symptoms (Carney et al., 1993).  Previous research has also shown that 
variations in deprivation and ethnicity within the patient population can also affect 
screening uptake numbers.  Bell et al., (2010) and Jack et al., (2014) both found that ethnic 
minority groups had a lower uptake of breast screening compared to white British females, 
therefore in certain geographic regions where practices have high numbers of ethnic 
minority patients this will affect the breast screening uptake rate of the practice in general.  
In addition, Gatrell et al., (1998) found low breast screening uptake in practices located in 
deprivied areas, while Carney et al., (2013) found that patient income did not affect 
screening uptake, but past screening behaviour was found to have a signficant effect. 
With these concerns in mind another version of the breast cancer dataset was 
prepared with all cases of patients aged between 50-70 (the age range for the national 
screening programme at this time) removed.  From the data that remained this has to be 
checked for small numbers of cases within a practice, to ensure that the ethical guidelines 
and stipulations are met. 
The regression analyses and multi-level analysis were then repeated on this dataset to 
account for any confounding due to practice variation in screening uptake and potential 
screening effect, but also served to see if repeated analysis influenced the results. 
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4. 11.  Dichotomised and unknown stage 
 
In the colorectal dataset there were a high percentage of cases with unknown stage, 
25.9%.  How to treat this stage status needed consideration as it could simply be that 
patients have died etc. which has resulted in a stage not being recorded but equally it could 
be due to organisational and clinical issues of quality.  Previous research has identified that 
patients with an unknown cancer stage generally have poorer outcomes, greater risk of 
mortality and reduced access to treatment (Merrill et al., 2011, Ciccolallo et al., 2005, 
Comber et al., 2005).  As a result unknown stage cases have been treated as and grouped 
with more advanced stage cancers (Virnig et al., 2009).  
Analysis was repeated with and without unknown stage cancer cases to determine how 
this modified the results.   
Additional analysis was also conducted with the cancer stages dichotomised, into less 
advanced (stage 1 & 2) and more advanced (3, 4 & unknown) cancer stage at diagnosis.  
The decision for this was to try and account for the uneven distribution across the cancer 
stages, specifically in breast cancer where the majority of cases are diagnosed at stage 1 
and 2; by grouping the later stages together it increased the sample size for that group.  
Dichotomising cancer stage is a common practice within cancer research (Lindstrom et al., 
2009, Haikel et al., 2011) and specifically within breast (Van den Eynden et al., 2005) and 
colorectal (Lee et al., 2000). 
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5. Chapter 5:  Results 
 
This chapter will outline the findings of the analysis conducted for this study. 
The primary aim of this study was to see if there was any evidence of GP quality 
influencing a patient’s cancer stage at diagnosis in breast and colorectal cancer cases. 
Data relating to GP quality came from the GP practice profiles that are constructed by 
the Eastern region public health observatory and additional GP data had come from the 
NHS information service regarding QOF scores.  Cancer and patient data came from 
NYCRIS, further details of the data acquired for this project are outlined in the methods 
chapter. 
As breast and colorectal cancer differ significantly in the way they present and their 
symptomology, screening programmes, how they are identified, diagnostic methods etc., it 
was decided that they should be analysed separately.  So the dataset was divided into 
breast and colorectal cancer and the range of analyses was carried out on both cancer 
datasets separately. 
A range of analyses were used.  Initially descriptive and correlation matrixes were used 
to understand how the data was distributed.  From this the decision was made to also 
separate the data into deciles, in an attempt to account for the positive bias and skew of 
the QOF data. 
A base outcome regression analysis was used, this was most appropriate due to the 
categorical nature of the data and dependent variable (cancer stage at diagnosis) and then 
a multi-level regression analysis was then conducted.  Once these had been carried out the 
findings led to the addition of further regression analyses and a trend analysis to 
investigate certain results more closely. 
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With regards to the primary research aim, the multi-level analysis showed that the GP 
practice a patient attends does have an influence upon breast cancer stage at diagnosis, in 
some cases accounting for over 25% of the variance.  The regression analyses of the breast 
cancer data did show a relationship between QOF and cancer stage at diagnosis and some 
specific practice variables appear to have an impact upon cancer stage at diagnosis, 
particularly whether a patient is able to see their preferred GP.  Patient variables, 
specifically age and level of income (a measure of deprivation), were found to produce a 
significant influence upon cancer stage.  
For colorectal cancer the multi-level analysis did not produce  significant results, in fact 
it appears that a patient’s GP practice does not account for any of the variance in colorectal 
cancer stage at diagnosis.  Neither was the PCT in which a practice is located found to have 
a significant influence upon patient cancer stage.  However, in the regression analyses 
patient variables, specifically age and a patient income level, were found to have a 
significant affect upon cancer stage at diagnosis.  The QOF domains and total score were 
not found to have a significant affect; however, specific practice variables such as those 
related to elderly patients (those over 65) and a patient’s ability to see a doctor within two 
days were found to have a significant effect on cancer stage at diagnosis. 
As previously stated the original dataset of breast and colorectal cancer cases received 
from NYCRIS contained 28,964 individual cases.  After data cleaning the total number of 
cases within the NYCRIS dataset was n = 25,216 (n = 3,728 cases were excluded, see 
chapter 4 for further details).  These two cancers were separated into individual datasets, 
breast cancer had 13,610 cases (which was 54% of the original dataset) and colorectal 
11,606 cases (46% of the original dataset).  The breakdown of each individual dataset and 
analysis will now be reported in detail, starting with the colorectal cancer results first, 
followed by the breast cancer results. 
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5. 1.  Colorectal cancer 
 
5. 1. 1.  Descriptive and distribution analysis 
 
Initially a basic breakdown of each of the cancer types was conducted and the 
breakdown for colorectal cancer was as follows.   
Cancer stage ranged from 1-4 and unknown (further details can be found in Chapter 4; 
methods).  In the colorectal dataset 25.9% of the dataset had an unknown stage recorded 
and stage 3 and 4 cases, which are the more advanced stages, constituted 42.9% of the 
dataset (figure 5). 
Figure 5.  Distribution of colorectal cancer stage. 
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National data for patient recorded colorectal cancer stage in England is comparable 
with; stage 1 – 8.7%, stage 2 – 24.2%, stage 3 – 23.6%, stage 4 – 34.3%, and unknown stage 
34.3% (Abdel-Rahman et al., 2009). 
Within the patient information that was provided by NYCRIS, along with cancer stage, 
the key variables were age, sex and income domain (which was divided into quintiles, with 
1 being the least deprivied and 5 the most deprivied) .  Age had been categorised into 
working age (18-64) and retirement age (65+) and within the colorectal dataset there was a 
greater number of cases from patients of retirement age (73.3%) compared to working age 
(26.7%). 
Table 2.  Cross tabulation of colorectal cancer stage and patient age group. 
Stage Age Total 
18-64 65+ 
1 279 
(25.9%) 
798 
(74.1%) 
1077 
2 576 
(22.7%) 
1965 
(77.3%) 
2541 
3 643 
(28%) 
1657 
(72%) 
2300 
4 786 
(29.3%) 
1898 
(70.7%) 
2684 
Unknown 820 
(27.3%) 
2184 
(72.7%) 
3004 
Total 3104 
(26.7%) 
8502 
(73.3%) 
11606 
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Figure 6.  Distribution of colorectal cancer stage at diagnosis by age. 
 
Table 2 and Figure 6 show this distribution, that more cases were found in patients of 
retirement age, and a chi-square test showed that there was a significant relationship 
between a patient’s age and their cancer stage, X² (8) = 34.55, p < .0001. 
The sex distribution of cases was reasonably even, with 43% of cases being female and 
57% male patients.  For Table 3 it can be observed that for each individual stage the 
distribution between the two sexes follows a similar pattern, when a chi-square test was 
conducted it found the relationship between cancer stage and sex to be non-significant X² 
(4) = 3.86, p = .426.  National trends of colorectal cancer cases by patient sex showed that 
in 2010, 56% of new colorectal cancer cases were male and 44% female (Iyen-Omofoman 
et al., 2011). 
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Table 3.  Cross tabulation of colorectal cancer stage and patients’ sex. 
 
Stage Sex Total 
Female Male 
1 465 
(43.2%) 
612 
(56.8%) 
1077 
2 1125 
(44.3%) 
1416 
(55.7%) 
2541 
3 991 
(43.1%) 
1309 
(56.9%) 
2300 
4 1157 
(43.1%) 
1527 
(56.9%) 
2684 
Unknown 1252 
(41.7%) 
1752 
(58.3%) 
3004 
Total 4990 
(43%) 
6616 
(57%) 
11606 
 
 
Figure 7.  Distribution of colorectal cancer cases based on the sex of the patient. 
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Income domain is separated into quintiles (range is therefore 1-5) with five 
representing the most deprived and one the least deprived.  Distribution of stage across 
the five income domains ranges with the lowest percentage being the least deprived 
quintile (1 = 16.2%) and the most deprived quintile having the highest percentage of 
colorectal cancer cases (5 = 24.2%), the other quintiles range between these two. 
Table 4.  Cross tabulation of colorectal cancer stage and patient income domain. 
Stage Income domain Total 
1 2 3 4 5 
1 216 
(20%) 
217 
(20.2%) 
193 
(17.9%) 
206 
(19.1%) 
245 
(22.8%) 
1077 
2 424 
(16.7%) 
497 
(19.6%) 
517 
(20.4%) 
556 
(21.8%) 
547 
(21.5%) 
2541 
3 404 
(17.6%) 
473 
(20.6%) 
412 
(17.9%) 
484 
(21%) 
527 
(22.9%) 
2300 
4 398 
(14.8%) 
488 
(18.2%) 
512 
(19.1%) 
602 
(22.4%) 
684 
(25.5%) 
2684 
Unknown 440 
(14.7%) 
548 
(18.2%) 
584 
(19.4%) 
624 
(20.7%) 
808 
(27%) 
3004 
Total 1882 
(16.2%) 
2223 
(19.2%) 
2218 
(19.1%) 
2472 
(21.3%) 
2811 
(24.2%) 
11606 
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Figure 8.  Distribution of colorectal cancer cases across the different stages,  
                  grouped by patient income domain. 
 
The distributions in the above Table 4 and Figure 8 between cancer stage in colorectal 
cancer and patient income domain were found to be significant, X² (16) = 56.70, p<.0001. 
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5. 1. 2.  QOF data and distributions 
 
The QOF data used was from the 2009/2010 data, the most recent available at the time of 
the start of this project.  QOF is annually reviewed and changes made, such as the 
retirement or addition of indicators.  In 2009/2010 QOF was divided into four domains and 
these culminate into a total score.  The maximum scores for each domain and the 
maximum total score were: 
 
Clinical domain = 697 
Organisational domain = 167.5 (rounded up to 168) 
Patient experience domain = 91.5 (rounded up to 92) 
Additional services domain = 44 
Total score = 1,000 (Note: while the organisational and patient experience domains are rounded up 
the maximum total score attainable in QOF remains at 1000, instead of 1001) 
 
The distribution of the QOF data is important as it is well documented that there is a 
positive skew within QOF, with the majority of practices scoring either maximum points or 
near maximum.  Within this dataset there were 792 GP practices, Table 5 below shows a 
breakdown of the maximum and minimum scores for each of the domains and total score. 
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Table 5.  Summary statistics for each of the QOF domains and QOF total score. 
 Minimum Maximum Standard 
deviation 
Mean National average 
(Department of 
Health, 2002) 
Clinical domain 486 697 20.63 679.89 668.2 
Organisational 
domain 
102 168 6.56 164.14 161.4 
Patient experience 
domain 
30 92 17.50 62.94 65.4 
Additional services 
domain 
29 44 1.78 42.93 42.0 
Total score 722 1000 32.06 949.54 936.9 
 
 The box plots that follow show that there were a number of outlier practices which score 
much lower than the mean or even the standard deviation. 
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Figure 9.  Distribution of QOF total scores against colorectal cancer stage. 
 
Figure 10.  Distribution of QOF clinical domain scores against colorectal cancer  
       stage. 
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Figure 11.  Distribution of QOF organisational domain scores against colorectal  
                    cancer stage. 
 
Figure 12.  Distribution of QOF patient experience domain scores against  
                    colorectal cancer stage. 
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The patient experience domain was the only one of the domains which did not produce 
any outliers. 
Figure 13.  Distribution of QOF additional services domain scores against 
                    colorectal cancer stage. 
 
5. 1. 2. 1.  Deciles 
 
From looking at the distribution of scores across the domains and the total QOF score from 
the figures (9-13) and table (5), as expected there was a bias and the majority of practices 
were scoring the maximum or near maximum points available.  However, there were a 
number of practices which were outliers and were not scoring as high as the majority of 
practices, this observation prompted the decision to additionally separate the data into 
deciles so that the outcome of the top 10% and bottom 10% could be compared; effectively 
what could be termed as the best 10% of practices and the worst 10% of practices (for 
more details see chapter 4; methods). 
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5. 1. 3.  Correlation matrixes 
 
All colorectal cancer variables were put into a correlation matrix to investigate and 
establish whether there were already any existing correlations between the variables, see 
appendix 2; table 16.   
It was expected that certain variables would show a significant interaction as they are 
related or are components of each other.  For example, the QOF total score is the sum of 
the four individual QOF domains (clinical, organisation, patient experience and additional 
services).  Equally patient income domain is widely used in larger measures of deprivation, 
such as the practice deprivation score found in the practice profiles, therefore a correlation 
between these two variables would be expected. 
This was shown to be the case.  The QOF total score and patient experience domain 
correlated with all the individual specific variables which make up the QOF domains.  The 
clinical domain correlated significantly with all QOF variables except patient’s ability to see 
their preferred GP. In the organisational domain the exception rating variable was the only 
non-significant QOF variable and for the additional services domain the exception rate, 
IDAOPI, patient ability to book an appointment and patient ability to see their preferred GP 
were all non-significant.   
Patient income domain also correlated with the practice variables associated with 
deprivation (practice deprivation and IDAOPI [Income Domain Affecting Older People 
Index]).  Specifically these were all positive correlations, so as patient deprivation increases 
so does practice deprivation and all are to the significance level of p = 0.05.   
There was a well-recognised correlation between the QOF total score and the variables 
associated with deprivation, it was a negative correlation so as deprivation increased the 
QOF total score decreased (p < 0.05). 
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The only other significant correlation was between the cancer stage at diagnosis and 
patient income domain (p < 0.05), it was a positive correlation, so as income domain 
increases and therefore deprivation increases so does the cancer stage.   
5. 1. 4.  Regression analysis 
 
5. 1. 4. 1.  All colorectal data 
 
5. 1. 4. 1. 1.  Patient variables 
 
Of the patient variables only age and patient income domain were found to produce 
any significant results.     
Age produced a significant result between stage 4 versus 1, this was a negative 
coefficient which indicates that patients of working age, compared to those of retirement 
age, have a greater likelihood of being diagnosed at a more advanced stage.   
Patient income domain between stage 1 and stage 4 and unknown stage produced 
significant positive coefficients, so an increase in patient income domain and therefore 
their level of deprivation means patients are more likely to be diagnosed with a more 
advanced cancer stage or an unknown stage at diagnosis.  This relationship remained 
significant between stage 1 versus stage 4 when the analysis was run with just the top and 
bottom deciles.     
Patient sex was not found to have a significant affect upon patient cancer stage at 
diagnosis. 
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5. 1. 4. 1. 2.  QOF domains and total 
 
No significant relationships or findings were observed between the QOF domain or 
total scores and the breast cancer stage at diagnosis.  This did not change when the 
analysis was run with just the top and bottom deciles. 
5. 1. 4. 1. 3.  Practice variables and GP/PCT codes 
 
There was a significant association found between stage 1 and unknown stage 
colorectal cancer with whether a patient was able to see a doctor within two days, this is a 
specific indicator from the patient experience domain of QOF.   
All other specific practice variables were found to be not significant, these were; cancer 
reviewing within six months, cancer prevalence, exception rate for cancer indicators, 
percentage of patients aged 65+, deprivation score for the practice, IDAOPI, percentage 
satisfied with phone access, percentage able to book appointment >= 2 days ahead, 
percentage satisfied with opening hours, percentage able to see preferred GP, percentage 
aged 75+, and percentage aged 85+. 
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Table 6.  Base outcome output for colorectal data, with stage 1 as the base 
                 outcome. 
Full output is available in appendix (4). 
Multinomial logistic regression                   Number of obs   =      11491 
                                                  LR chi2(84)          =      145.84 
                                                               Prob > chi2          =      0.0000 
Log likelihood = -17880.668                        Pseudo R2            =      0.0041 
Stage Variable Relative 
Risk Ratio 
(rrr) 
Standard 
error 
z P>[z] [95% 
confidence 
interval] 
1 v 2 Income 
domain 
1.065 .0318 2.11 0.035 1.005 
1.129 
1 v 4 Age .8313 .0677 -2.27 0.023 .7087 
.9750 
 Income 
domain 
1.121 .0332 3.85 0.000 1.058 
1.188 
1 v 
Unknown 
Income 
domain 
1.137 .0332 4.40 0.000 1.074 
1.204 
 Ability to 
see Dr 
within 
two days 
.2197 .1361 -2.45 .014 .0652 
.7399 
 
5. 1. 4. 2.  Top and bottom deciles of the colorectal dataset 
 
When the regression analysis was repeated with just the top and bottom 10% of 
practices, based on the QOF total score, there was only one significant result.  This was 
between stage 1 and stage 4 and patient income domain, it was a positive coefficient which 
meant as patient income domain increased (patient income was lower) their likelihood of 
have a more advanced stage of colorectal cancer increased (table 7).  All previous 
significant results became non-significant. 
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Table 7.  Base outcome output, with just the top and bottom deciles of the QOF  
                 total score, base outcome is stage 1. 
Full output is available in appendix (5). 
Multinomial logistic regression                   Number of obs   =       2340 
                                                                 LR chi2(84)          =       75.41 
                                                          Prob > chi2         =       0.7374 
Log likelihood = -3643.9045                         Pseudo R2          =       0.0102 
Stage Variable Relative Risk 
Ratio (rrr) 
Standard 
error 
z P>[z] [95% 
confidence 
interval] 
1 v 4 Income 
domain 
1.139 .0758 1.96 0.050 .9997 
1.298 
 
The regression analysis was repeated with the colorectal dataset being separated into 
deciles based on each of the four QOF domains individually.  Therefore, the regression 
analysis was repeated with data from the top and bottom deciles of the QOF clinical 
domain, then repeated with the data from the top and bottom deciles based on the QOF 
organisational domain and so on.  The following variables were all found to be non-
significant across the four analyses; patient sex, the QOF domain and total scores, cancer 
reviewing within six months, cancer prevalence, exception rate for cancer indicators, 
deprivation score for the practice, IDAOPI, percentage able to book appointment >= 2 days 
ahead, percentage satisfied with opening hours, percentage able to see preferred GP, 
percentage aged 75+, and percentage aged 85+. 
The significant results are as follows: 
5. 1. 4. 2. 1.  Clinical domain 
 
Age was found to be significant between stage 1 versus stage 4 and unknown, but both 
with RRR of <1 which indicates that as patients get older (those of retirement age) they are 
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more likely to be diagnoised with a less advanced stage of coloretcal cancer (RRR of .695 
for stage 4 and .746 for unknown stage).  
The specific practice variable of patient satisfaction with phone access was also found 
to be significant between stage 1 and stage 4 and unknown, with RRR of 3.37 and 3.4 
respectively. 
Patient income domain quintile produced a significant result between stage 1 and 
stage unknown, with a RRR of 1.16. 
5. 1. 4. 2. 2.  Organisational domain 
 
Patient income domain was found to be a significant result between stage 1 and stage 
4 (RRR = 1.121) and unknown (RRR = 1.155), the RRR was >1 which suggests that as income 
domain increases (and therefore the patient’s deprivation), the likelihood of a more 
advanced or unknown stage being recorded increases. 
The QOF domain of additional services was found to be significant between stage 1 
versus stage 2 (RRR = 1.246) and stage unknown (RRR = 1.270), both with RRR >1 which 
suggests that as the score on the additional services domain increases so does the 
likelihood of a more advanced or unknown stage of colorectal cancer. 
Patient age was significant between stage 1 and stage 3, with a RRR of .758 implying 
that younger patients are more likley to be diagnoised with a more advanced stage of 
colorectal cancer.  The practice variable of the proportion of patients over the age of 85 
was significant but with a low RRR (>.0001). 
The specific practice variable of patient satisfaction with phone access was also found 
to be significant between stage 1 and stage 4 and stage unknown, with RRR of 3.109 and 
2.961 respectively . 
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5. 1. 4. 2. 3.  Patient experience domain 
 
Between stage 1 against stage 2 (RRR = 1.233), 4 (RRR = 1.169) and unknown (RRR = 
1.195) patient income domain was a significant result, all with RRR >1 implying that as 
patient income domain quintile and therefore level of deprivation, increases so does the 
likelihood of the cancer stage being more advanced or unknown. 
The specific practice variable of proportion of elderly patients (65+) within the practice 
was found to be significant between stage 1 versus 2 and 3, with RRR of 538 and 213 
respectively these are exceptionally greater than stage1 and implies that as the proportion 
of elderly patients increases so does the likelihood so the cancer stage being stage 2 or 3 
compared with stage 1. 
Other significant practice variables were between stage 1 and stage 4 whether a cancer 
review was conducted within six months, a RRR of 6.329, and between stage 1 and stage 
unknown a patient’s ability to see their preferred GP had a RRR of .107. 
5. 1. 4. 2. 4.  Additional services domain 
 
Patient income domain was found to be a significant result between stage 1 and stage 
4 (RRR = 1.108) and unknown (RRR = 1.117), the RRR was >1 which suggests that as income 
domain increases (and therefore the patient deprivation), the likelihood of a more 
advanced or unknown stage being recorded increases. 
The specific practice variable of patient satisfaction with phone access was also found 
to be significant between stage 1 and stage 3, with a RRR of 2.31 this suggests as 
satisfaction with phone access increases so does the likelihood of a patient being diagnosed 
with a more advanced stage of colorectal cancer. 
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Age was also found to be significant between stage 1 and stage 4, with a RRR of .808, 
and between stage 1 and unknown stage the specific practice variable of patient’s ability to 
see their doctor within two days was also significant (RRR = .154). 
There is the concern that, due to the large number of variables in this analysis a type 
one error may occur and significant results may be found by chance rather than because 
they are statistically significant.  For this data there are a few considerations as each 
variable differed in their distribution; some variables have normal and expected 
distributions, while others are much more varied.  For multinomial regression in Stata it is 
recommended (Institute for digital research and education, no date) to refer to the ‘prob > 
chi2’, a measure of ‘good-fit’, and ‘pseudo R2’, which is McFadden’s pseudo R-adjusted, 
and these were all <0.05 with the exception of the regression analysis for colorectal cancer 
with just the top and bottom decile included in the analysis.   
A marginal effects analysis was additionally conducted to further investigate, and this 
found that there were significant results for a patient’s income domain, percentage of 
elderly patients within a practice, and patient satisfaction with opening hours of the 
practice, this was in line with the signifcant results found prior to the adjustment. 
5. 1. 5.  Multi-level model 
 
From the regression analysis there were only a small number of significant findings and 
all but one of these were from patient level variables, therefore it was unsurprising when 
the multi-level analysis for colorectal cancer did not produce any significant results to 
suggest a relationship between GP practice or PCT and patient cancer stage at diagnosis.  
Specifically from the analysis between each of the cancer stages variance is less than 
0.01%.   
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The analysis was repeated with just the top and bottom deciles to see if this would 
draw out any effect but again the variance attributed to GP practice and PCT does not 
exceed 0.01%. 
5. 1. 6.  Dichotomised stage 
 
It was recommended to combine colorectal cancer stages together as an additional 
analysis.  For the previous analyses there had been five cancer stage categories for both 
breast and colorectal cancer, stage 1-4 and unknown stage.  By combining stage 1 and 2, 
the less advanced stages, together and combining stage 3, 4 and unknown, the more 
advanced stages, it provided the opportunity for a more direct comparison of the more 
advanced cancer cases against the less advanced cases (a more detailed explanation is 
provided in chapter 4; methods).  
5. 1. 6. 1.  Colorectal cancer stage 1 & 2 combined and against all other  
                   stages combined 
 
When cancer stage was dichotomised, the variables of patient age and income domain 
remained significant results.  All other variables were found to be non-significant. 
5. 1. 7.  Trend analysis 
 
The decision was made to also conduct a trend analysis using the top and bottom 
deciles of each of the QOF domains and total score.  
From the colorectal dataset only the patient experience domain deciles were significant 
against stage (p = 0.035).  The three remaining QOF domains and total score were not 
significant.  
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Putting the data into deciles and only taking the top and bottom deciles was considered, as 
there might be a skew in the distribution of the cancer stage, i.e. those in the top decile will 
be mainly less advanced stage cases while the bottom decile will be more advanced stages.  
However, when colorectal cancer stage was cross-tabulated against each of the deciles it 
became clear that for colorectal cancer the distribution of different stages is representative 
across the deciles for each of the QOF domain and total scores. 
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5. 2.  Breast cancer 
 
5. 2. 1.  Descriptive and distribution analysis 
 
Initially a basic breakdown of each of the cancer types was conducted and the 
breakdown for breast cancer was as follows.   
Cancer stage ranged from 1-4 and unknown, stage 0 cases had been removed as 
detailed in chapter 4; methods.  In the breast cancer dataset (n = 13,556) the majority of 
cases, 80.92% were recorded as stage 1 or 2.  The more advanced stages, 3 and 4, 
constituted 11.78% of the cases in the dataset.  National data for breast cancer stage in 
England shows that 41% were stage 1, 45% - stage 2, 9% - stage 3, 5% - stage 4, and 8% 
were unknown (Lyratzopoulos et al., 2012a). 
Figure 14.  Distribution of breast cancer stage. 
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Within the patient information that was provided by NYCRIS, along with the cancer 
stage the key variables were age and income domain quintile.  In the breast dataset, sex 
was disregarded as a variable due to the natural bias of breast cancer cases, where it is 
predominantly a female disease with nearly all cases being female.  In this particular 
dataset there were male cases, n = 99, which constituted 0.7% of the total number of 
breast cancer cases.   
Age had been categorised into working age (18-64) and retirement age (65+) and 
within the breast dataset the distribution was nearly equal with patients of working age 
making up 55.4% of the dataset while patients of retirement age made up 44.6%.  National 
data for the effect of patient age on breast cancer stage has found that older patients, 
specifically those 70+ are more likely to be diagnosed with a more advanced stage of breast 
cancer (Lyratzopoulos et al., 2012a). 
Table 8.  Cross tabulation of breast cancer stage and patient age. 
Stage Age Total 
18-64 65+ 
1 3264 
(61%) 
2086 
(39%) 
5350 
2 3251 
(57.9%) 
2368 
(42.1%) 
5619 
3 526 
(54.8%) 
434 
(45.2%) 
960 
4 249 
(39.1%) 
388 
(60.9%) 
637 
Unknown 222 
(22.4%) 
768 
(77.6%) 
990 
Total 7512 
(55.4%) 
6044 
(44.6%) 
13556 
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Figure 15.  Distribution of breast cancer stage by patient age. 
 
A chi-square test to further analyse the relationship between breast cancer stage and 
age was conducted and produced a significant result, X² (4) = 586.32, p < .0001. 
Income domain is separated into quintiles (range is therefore 1-5) with 5 representing 
the most deprived and one the least deprived.  From the Figure 16 below it is difficult to 
see whether there is any variance in the distribution or potential relationship between the 
income domain and patient cancer stage due to the higher number of cases which have 
been diagnosed at the less advanced stages.  National data in this area has shown that 
patients diagnosed with breast cancer are more likely to be living in more affluent areas, 
and are therefore more likely to have a higher income (income domain 1  = high level 
income; income domain 5 = low level income); however, it still remains that patients living 
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in deprived areas are more likely to be diagnosed with a more advanced cancer stage 
(Cuthbertson et al., 2009, Rutherford et al., 2013)(Downing et al., 2007a).  The Table 9 and 
Figure 16 below show the distribution of the data and a chi-square test found there to be a 
significant relationship between a patient’s cancer stage and income domain level, X² (16) = 
66.33, p < .0001. 
Figure 16.  Distribution of breast cancer stages by patient income domain. 
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Table 9.  A cross tabulation of patient income domain against cancer stage at  
                diagnosis for breast cancer. 
Stage Income domain Total 
1 2 3 4 5 
1 1066 
(19.9%) 
1153 
(21.6%) 
1072 
(20%) 
1029 
(19.2%) 
1030 
(19.3%) 
5350 
2 1008 
(17.9%) 
1217 
(21.7%) 
1049 
(18.7%) 
1161 
(20.7%) 
1184 
(21%) 
5619 
3 176 
(18.3%) 
183 
(19.1%) 
209 
(21.8%) 
191 
(19.9%) 
201 
(20.9%) 
960 
4 88 
(13.8%) 
110 
(17.3%) 
134 
(21%) 
140 
(22%) 
165 
(25.9%) 
637 
Unknown 141 
(14.2%) 
192 
(19.4%) 
194 
(19.6%) 
219 
(22.1%) 
244 
(24.7%) 
990 
Total 2479 
(18.3%) 
2855 
(21.1%) 
2658 
(19.6%) 
2740 
(20.2%) 
2824 
(20.8%) 
13556 
 
 
5. 2. 2.  Screening data 
 
In the case of breast cancer there is a national breast screening programme that was 
running during the time period that the data has come from.  For colorectal cancer, while 
there are screening programmes in place now, they had not yet been implemented during 
2006-2008. 
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For the time period of data requested NYCRIS also had information available regarding 
screening information and status recorded for patients; for example, whether they were 
diagnosed following screening or whether they had been screened but were over the 
guideline age range for the screening programme etc.  Within the NYCRIS dataset for breast 
cancer there was 14,387 cases of breast cancer.  Of these just over half (n = 8,636) have 
information related to screening, i.e. lapsed attender, overage etc., and of these half again 
were cases of screen detected cancer (n = 4,202).  In total 35.6% of the breast cancer cases 
within the data were detected via screening. 
Where no information was available regarding whether a case was screen detected or 
not the decision was made to treat it as an unscreened case, therefore cases with no 
information were categorised with  the cases which were not screen detected . 
When looking at the cancer stage against the screening information, within the breast 
cancer cases, trends are observable in the impact that screening has.  For those cases 
detected through screening over half (59.08%) were diagnosed at stage 1, compared with 
the cases which have no screening information where the majority (45.9%) of the cases 
were diagnosed at stage 2. 
National data from ‘the second all breast cancer report’ (Lawrence et al., 2011) found 
that in 2007, 32% of breast cancer cases were diagnosed via a screening pathway.  It has 
also been reported that patients who are diagnosed through a screening pathway are also 
more likely to have a less advanced stage recorded at diagnosis. 
A chi-square test did find the relationship between breast cancer stage and whether 
the cancer was screen detected or not to be significant, X² (4) = 1.40, p < .0001, and the 
distribution of the data is shown below in Figure 17. 
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Figure 17.  Distribution of breast cancer stage by screening pathway. 
 
5. 2. 3.  QOF data 
 
As detailed in the colorectal QOF results, the QOF data used was from the 2009/2010 and is 
divided into four domains and these culminate in total score, the maximum of which is 
1,000 points.  Within the breast cancer dataset there were 840 GP practices, Table 10 
below shows a breakdown of the maximum and minimum scores for each of the domains 
and total score. 
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Table 10.  Summary statistics of the QOF domain scores and QOF total score. 
 Minimum Maximum Standard 
deviation 
Mean National average 
Verdecchia et al., 
2007b 
Clinical domain 486 697 20.62 679.91 668.2 
Organisational 
domain 
98 168 6.94 164.05 161.4 
Patient experience 
domain 
30 92 17.75 63.48 65.4 
Additional services 
domain 
29 44 1.83 42.94 42.0 
Total score 722 1000 32.37 950.02 936.9 
 
The box plots show that there are a number of outlier practices which score much lower 
than the mean or even the standard deviation. 
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Figure 18.  Distribution of QOF total scores against breast cancer stage. 
 
Figure 19.  Distribution of QOF clinical domain scores against breast cancer stage. 
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Figure 20.  Distribution of QOF organisational domain scores against breast cancer  
                    stage. 
 
Figure 21.  Distribution of QOF patient experience domain scores against breast  
                    cancer stage. 
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Figure 22.  Distribution of QOF additional services domain scores against breast  
                    cancer stage. 
 
5. 2. 4.  Correlation matrixes 
 
All breast cancer variables were put into a correlation matrix to investigate and 
establish whether there were already any existing correlations between the variables; see 
Appendix 3 Table 17.  As with the colorectal dataset it was expected that certain variables 
would show a significant interaction as they are related or are components of each other.   
This was again found to be the case when the deprivation variables were positively 
correlated with each other, at the p < 0.05 level. 
Breast cancer stage was found to correlate with patient age, practice variables related 
to age (% of practice population over 65, % of patients over 75 and % of patients over 85), 
patient income domain and practice deprivation variables, and the specific practice 
variables of patient ability to see a doctor within two days.   
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The majority of individual QOF variables correlated with the total QOF score and the 
patient experience domain of QOF.  The exceptions were in the clinical domain where the 
only individual variable that was non-significant was the percentage of patients unable to 
see their preferred GP; in the organisational domain the variable for exception rating was 
non-significant; and for the additional services domain the variables of the percentage of 
patients over 85, percentage able to see their preferred GP and patient ability to book an 
appointment were not found to be significant. 
5. 2. 5.  Regression 
 
For the regression analysis, and following analyses, cases within the breast cancer 
dataset that had been identified and diagnosed through a screening pathway were 
removed.  This decision was made as it was thought that these cases may obscure the 
results.  The primary aim of this project is to investigate the potential association between 
GP practice quality and cancer stage at diagnosis.  The breast cancer screening programme 
is a national programme conducted externally to GP practices, therefore GPs have little or 
no direct influence on screening detected breast cancer cases. 
5. 2. 5. 1.  Breast cancer data, excluding screening detected cases 
 
5. 2. 5. 1. 1.  Patient variable 
 
Of the patient variables only age and a patient’s income domain were found to produce 
any significant results. 
Between stage 1 and stage 4 and unknown stage there was a significant finding for age 
and cancer stage at diagnosis.  The RRR were 2.147 for stage 1 and stage 4 and 5.262 for 
stage 1 and stage unknown, with a RRR >1 this implies that a patient of retirement age, 
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compared to working age, is signficantly more likely to be diagnoised with a more advanced 
and unknown stage breast cancer.   
The patient income domain produced a positive correlation at stage 4 against stage 1 
breast cancer, with a RRR = 1.094.  Thus as income domain increases, meaning that 
patients are earning a lower income, the likelihood of more advanced and unknown stage 
breast cancer increases.     
5. 2. 5. 1. 2.  QOF domains and total 
 
The only significant results were between stage 1 versus stage 4 breast cancer.  The 
QOF domains, clinical (RRR = .8209), organisational (RRR = .8198), patient experience (RRR 
= .8244) and additional services (RRR = .8028), produced rrr’s <1, so as the QOF domain 
score decreased the prevalence of more advanced stage at diagnosis increased.  The QOF 
total score (RRR = 1.218) also produced a significant result but it had a RRR <1 which 
suggests that as the QOF total score increases so does the prevalence of more advanced 
stage breast cancer.   
5. 2. 5. 1. 3.  Practice variables and GP/PCT codes 
 
There were a number of specific practice variables which produced significant results. 
Between stage 2 versus stage 1 the variable for patients being able to see their 
preferred GP was significant with a RRR = 1.6998.   
Between stage 1 and unknown stage breast cancer the variables of; cancer review 
within six months of diagnosis, cancer prevalence rate within practice, patients’ satisfaction 
with opening hours, and percentage of patients aged 85+, were all significant. 
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All other specific practice variables were found to be not significant, these were; exception 
rate for cancer indicators, percentage of patients aged 65+, deprivation score for the 
practice, IDAOPI, percentage satisfied with phone access, percentage able to see doctor 
within two days, percentage able to book appointment >= 2 days ahead, and percentage 
aged 75+. 
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Table 11.  Baseoutcome output for breast cancer, screen detected cases removed,  
                   base outcome is stage 1. 
Full output is available in appendix (6). 
Multinomial logistic regression                 Number of obs   =       8689 
                                                          LR chi2(105)       =       631.59 
                                             Prob > chi2         =       0.0000 
Log likelihood = -11532.981                       Pseudo R2          =       0.0267 
Stage Variable Relative Risk 
Ratio (rrr) 
Standard 
error 
z P>[z] [95% 
confidence 
interval] 
1 v 2 Ability to see 
preferred GP 
1.699 .4668 1.93 0.053 .9922 
2.912 
1 v 4 Age 2.147 .2071 7.92 0.000 1.777 
2.594 
 Income domain 1.094 .0436 2.25 0.025 1.011 
1.183 
 QOF clinical domain .8209 .0635 -2.55 0.011 .7055 
.9552 
 QOF organisational 
domain 
.8198 .0631 -2.58 0.010 .705 
.9534 
 QOF patient 
experience domain 
.8244 .0637 -2.50 0.012 .7085 
.9592 
 QOF additional 
services domain 
.8028 .0649 -2.72 0.007 .6852 
.9407 
 QOF total score 1.218 .0940 2.55 0.011 1.047 
1.417 
1 v 
Unknown 
Age 5.262 .4884 17.90 0.000 4.387 
6.312 
 Cancer prevalence 
within practice 
population 
4.44e+08 4.05e
+09 
2.19 0.029 7.778 
2.54e+16 
 Cancer review 
conducted within 6 
months 
.3242 .1580 -2.30 0.021 .1247 
.8428 
 Patients’ satisfaction 
with opening hours 
13.086 12.67 2.66 0.008 1.962 
87.29 
 Percentage of 
patients aged 85+ 
3.05e-11 3.15e
-10 
-2.34 0.019 4.87e-20 
.0191 
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5. 2. 5. 2.  Top and bottom deciles of the breast cancer dataset 
 
When the regression analysis was repeated with just the top and bottom 10% of 
practices, based on the QOF total score, many of the significant results remained or 
strengthened.   
On the patient level, age remained significant and the RRR increase to 2.325 between 
stage 1 and stage 4 and 6.022 for stage 1 and stage unknown. 
The four QOF domains and the QOF total score remained significant between stage 1 
and stage 4 breast cancer.  The QOF domains and QOF total score also became significant 
between stage 1 and stage 3.  The QOF domains, clinical (RRR = .7022), organisational (RRR 
= .7158), patient experience (RRR = .6978) and additional services (RRR = .6366), produced 
rrr’s <1, so as the QOF domain score decreased the prevalence of more advanced stage at 
diagnosis increased.  The QOF total score (RRR = 1.429) also produced a significant result 
but it had a RRR <1 which suggests that as the QOF total score increases so does the 
prevalence of more advanced stage breast cancer.   
Between stage 1 and stage 2 breast cancer the specific variable of a patient’s ability to 
see a doctor within two days became significant with a RRR of .1239. 
Between stage 1 and unknown stage breast cancer, the variable of a patient’s 
satisfaction with opening hours remained significant and between stage 1 and stage 4 the 
variable of percentage of patients’ satisfied with phone access became significant.   
All other specific practice variables were found to be not significant, these were; cancer 
review within six months of diagnosis, cancer prevalence rate within practice, exception 
rate for cancer indicators, deprivation score for the practice, IDAOPI, percentage satisfied 
with phone access, percentage able to see doctor within two days, percentage able to book 
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appointment >= 2 days ahead, percentage of patients aged 65+, percentage aged 75+, and 
percentage of patients aged 85+. 
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Table 12.  Baseoutcome output for breast cancer, screen detected cases removed,  
                   with just top and bottom deciles of QOF total score. 
Full output is available in appendix (7). 
Multinomial logistic regression                   Number of obs   =       1727 
                                                     LR chi2(105)        =       195.28 
                                                                   Prob > chi2          =       0.0000 
Log likelihood = -2194.4279                         Pseudo R2           =       0.0426 
Stage Variable Relative 
Risk Ratio 
(rrr) 
Standard 
error 
z P>[z] [95% 
confidence 
interval] 
1 v 2 Ability to see GP 
within two days 
.1239 .1239 -2.09 0.037 .0174 
.8795 
1 v 3 QOF clinical 
domain 
.7022 .1199 -2.07 .038 .5025 
.9813 
 QOF 
organisational 
domain 
.7158 .1225 -1.95 .051 .5118 
1.001 
 QOF patient 
experience 
domain 
.6978 .1202 -2.09 .0367 .4978 
.978 
 QOF additional 
services domain 
.6366 .1121 -2.57 .010 .4509 
.8989 
 QOF total score 1.429 .2349 2.09 .037 1.022 
1.996 
1 v 4 Age 2.325 .5205 3.77 <.0001 1.499 
3.606 
 QOF clinical 
domain 
.5883 .1219 -2.56 .010 .3920 
.883 
 QOF 
organisational 
domain 
.5850 .1210 -2.59 .010 .3900 
.8775 
 QOF patient 
experience 
domain 
.5954 .1238 -2.49 .013 .3962 
.895 
 QOF additional 
services domain 
.5638 .1221 -2.65 .008 .3688 
.862 
 QOF total score 1.706 .3533 2.58 .010 1.137 
2.56 
 Percentage 
satisfied with 
phone access 
8.618 9.631 1.93 .05 .9642 
77.03 
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1 v 
Unknown 
Age 6.023 1.25 8.66 <.0001 4.011 
9.043 
 Patient 
satisfaction with 
opening hours 
115.16 270.37 2.02 .043 1.156 
11473.3 
 
The regression analysis was repeated with the breast dataset being separated into 
deciles based on each of the four QOF domains individually.  Therefore, the regression 
analysis was repeated with data from the top and bottom deciles of the QOF clinical 
domain, then repeated with the data from the top and bottom deciles based on the QOF 
organisational domain and so on.  The following variables were all found to be non-
significant across the four analyses; exception rate for cancer indicators, deprivation score 
for the practice, percentage able to book appointment >= 2 days ahead, percentage aged 
75+, and percentage aged 85+. 
The significant results are as follows: 
5. 2. 5. 2. 1.  Clinical domain 
 
Age was found to be significant between stage 1 and stage 2, 4 and unknown, these all 
had rrr’s >1 which implies that as patient age increases so does the likelihood of their 
diagnosis being recorded as a more advanced stage of breast cancer or stage unknown. 
Between stage 1 and stage 4 patient income domain was significant with a RRR of 
1.1997, so as patient income domain increases (and therefore their deprivation) so does 
the likelihood that they will have a more advanced stage recorded at diagnosis.  The 
practice variable of IDAOPI was significant between stage 1 and stage 2, with a RRR of 
.0296.  
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Some specific practice variables were found to be significant between certain stages, 
specifically stage 1 versus 3  and unknown stage patient ability to see their preferred GP, 
the rrr’s were both >1, between stage 1 versus unknown stage GP practice opening hours 
was signifcant with a RRR >1, and stage 1 versus stage 4 the additional services domain of 
QOF and the practice variable of a cancer review being conducted within six months were 
both significant and with rrr’s <1. 
5. 2. 5. 2. 2.  Organisational domain 
 
Age was found to be significant between stage 1 and stage 4 and unknown, these had 
rrr’s of 1.717 and 4.712 respecticaly, suggesting that as a patient’s age increases so does 
the likelihood of their diagnosis being recorded as a more advanced stage of breast cancer 
or stage unknown. 
A patient’s income domain was signicant between stage 1 and stage 4 with a RRR = 
1.155, while the specific practice variable of a patient’s ability to see their preferred GP was 
significant across stage 1 versus stage 2 and 4, with rrr’s >1.  Between stage 1 and stage 
unknonw the prevelance rate of cancer within a practice was signicant with a RRR >1 and 
between stage 1 versus stage 4 all the QOF domains were significant with rrr’s <1 while the 
QOF total score was significant with a RRR >1. 
5. 2. 5. 2. 3.  Patient experience domain  
 
Age was found to be significant between stage 1 and stage 4 and unknown, these were 
rrr’s >1 suggesting that as a patient’s age increases so does the likelihood of their diagnosis 
being recorded as a more advanced stage of breast cancer or stage unknown. 
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Between stage 1 versus stage 3 and 4 all the QOF domains were significant, except the 
additional services domain between stage 1 and stage 4, with rrr’s <1, while the QOF total 
score was significant with rrr’s >1. 
The specific practice variable for a patient’s satisfaction with phone access was found 
to be significant with a RRR of .0742, which suggests that as a patient’s satisfaction 
increases they are more likely to be diagnoised with a less advanced breast cancer stage. 
5. 2. 5. 2. 4.  Additional services domain  
 
Age was found to be significant between stage 1 and stage 4 and unknown, these were 
with rrr’s >1 suggesting that as a patients’ age increases so does the likelihood of their 
diagnosis being recorded as a more advanced stage of breast cancer or stage unknown.   
Patient income domain between stage 1 against stage 4 and unknown was significant 
and had rrr’s >1, which suggests as a patient deprivation increases so does the likelihood of 
their being diagnoised with a more advanced or unknown breast cancer stage.   
Between stage 1 versus unknown the specific practice variables of the GP practice 
opening hours, and whether a cancer review had been conducted within six months were 
all significant. 
Between stage 1 versus stage 4 all the QOF domains were significant, with rrr’s <1, 
while the QOF total score was significant with rrr’s >1. 
As mentioned in the colorectal cancer results there is the concern that, due to the large 
number of variables in this analysis a type one error may occur and significant results may 
be found by chance rather than because they are statistically significant.  The ‘prob > chi2’, 
a measure of ‘good-fit’, and ‘pseudo R2’, which is McFadden’s pseudo R-adjusted, and 
these were all <0.05 for the breast cancer regression analyses.   
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A marginal effects analysis was additionally conducted to further investigate, and this 
found that there were significant results for a patient’s income domain, percentage of 
elderly patients within a practice, and patient satisfaction with opening hours of the 
practice. 
5. 2. 6.  Multi-level model 
 
The regression analysis produced a number of results whereby practice variables were 
found to have a significant affect upon cancer stage at diagnosis, most notably the QOF 
domains and total score.  This was reflected in the multi-level analysis which showed that 
GP practices and also the PCT contribute to the variance between breast cancer stage at 
diagnosis.   
5. 2. 6. 1.  All breast data, screening detected cases excluded 
 
Between the different cancer stages between 12% and 18% of the variance was 
attributed to the patients’ GP practice, it was only between stage 1 and 4 where GP 
practice did not show any significant affect (<0.0001%). 
At the PCT level it was only between stage 1 and 4 that any variance was found, 11%, 
while between other stages the variance was found to be less than 0.001%. 
Table 13.  Multi-level variance at GP and PCT level for breast cancer with  
                   screening cases excluded. 
Stage GP PCT 
1 v 2 12% 0.0001% 
1 v 3 18% 0.0001% 
1 v 4 0.0001% 11% 
1 v unknown 13% 0.0001% 
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5. 2. 6. 2.  Breast cancer data with screening detected cases excluded and  
                   just the top and bottom 10% of practices included 
 
When just the top and bottom deciles of the QOF total score was included, the GP 
practice was found to account for between 16-29% of the variance between the cancer 
stages at diagnosis. 
On the PCT level variance ranged between 5-21%, except when stage 1 was compared 
against stage 3 where the variance attributed to PCT became < 0.001%. 
Table 14.  Multi-level variance at GP and PCT level for breast cancer with  
                   screening cases excluded and just top and bottom deciles. 
Stage GP PCT 
1 v 2 21% 5% 
1 v 3 26% 0.0001% 
1 v 4 16% 21% 
1 v unknown 29% 7% 
 
5. 2. 7.  Dichotomised stage 
 
As with the colorectal dataset, additional analyses were conducted with the breast 
cancer stages dichotomised, combining stage 1 and 2 together, and combining stage 3, 4 
and unknown together.  
5. 2. 7. 1.  Breast cancer stage 1 & 2 combined and against all other stages 
                   combined 
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When cancer stage was dichotomised, age and whether the cancer was detected 
through a screening pathway, were the only significant findings; both were a positive 
coefficient.   
When the analysis was done with the top and bottom deciles for the QOF total score 
the finding with age remained and each of the individual QOF domains along with the total 
QOF score also became significant results, with all of the domains being negative 
coefficients and the total QOF score a positive coefficient. 
These findings remained when the top and bottom deciles for the patient experience 
domain were compared.  Patient  age and the QOF domains and total score remained as 
significant results and when the top and bottom deciles for the clinical domain were 
compared the finding for the patient variable of age remains but the QOF domain and total 
scores become non-significant. 
5. 2. 8.  Trend analysis 
 
A trend analysis was conducted using the top and bottom deciles of each of the four 
QOF domains and the QOF total score against breast cancer stage. 
There were no significant findings from any of these analyses. 
5. 2. 9.  Screening age patients removed 
 
As mentioned in chapter 4, there was concern about possible screening effects, similar 
to a Hawthorne effect, in the breast cancer data. 
Once patients aged between 50-70 years old were removed a total of n = 6,373 
patients remained.  Some descriptive analysis was conducted to observe disributions, in the 
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case of stage at diagnosis this remained consistent with the larger dataset, with the 
majority of cases being diagnosed at stage 1 (39.7%) and stage 2 (40.9%). 
The distribution of screening information was also conducted and it was found that 
34.77% (n = 2,216) were cases which had been detected and diagnosed through screening, 
the most likely explaination for this is patients entering the screening programme early due 
to family history, and 20.6% of the screen detected cases where patients were overage 
(70+) but had remained in the screening programme. 
These screen detected cases were additionally removed and the analyses repeated.   
5. 2. 9. 1.  Regression analysis 
 
5. 2. 9. 1. 1.  Patient variable 
 
Of the patient variables, age and a patient’s income domain were found to produce 
significant results. 
Between stage 1 and stage 4 and unknown stage there was a significant outcome 
between age and cancer stage at diagnosis, both with rrr’s >1 which suggests that a patient 
of retirement age, compared to a patient of working age, is significantly more likely to be 
diagnoised with a more advanced and unknown stage breast cancer.   
The patient income domain produced a positive correlation at stage 4 against stage 1 
breast cancer, this had a RRR of 1.148.  Thus as income domain increases, meaning that 
patients are earning a lower income, the likelihood of more advanced and unknown stage 
breast cancer increases.     
5. 2. 9. 1. 2.  QOF domains and total 
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The only significant results were between stage 1 versus stage 4 breast cancer.  The 
QOF domains, clinical, organisational, patient experience and additional services, produced 
rrr’s <1, so as the QOF domain score decreased the prevalence of more advanced stage at 
diagnosis increased.  The QOF total score also produced a significant result but it had a RRR 
>1 which suggests that as the QOF total score increases so does the prevalence of more 
advanced stage breast cancer.   
5. 2. 9. 1. 3.  Practice variables and GP/PCT codes 
 
There were a number of specific practice variables which produced significant results, 
these included: 
Between stage 2 versus stage 1 the variable for patients being able to see their 
preferred GP was found to be signifcant.   
Variables related to age and the propoportion of elderly patients within a practice were 
also significant when stage 3, 4 and unknown were compared against stage 1, specifically 
the variables were, the percentage of elderly (65+) patients within a practice, the 
percentage of patients aged over 75, and the percentage of patients aged over 85.   
Between stage 1 and unknown stage breast cancer, the practice variable of cancer 
prevalence rate were significant, as was satisfaction with practice opening hours. 
All other specific practice variables were found to be not significant, these were; cancer 
review within six months of diagnosis, deprivation score for the practice, IDAOPI, 
percentage satisfied with phone access, exception rate for cancer indicators, percentage 
able to see doctor within two days and percentage able to book appointment >= 2 days 
ahead. 
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Table 15.  Base outcome output for breast cancer, screen detected cases and patients of  
                   screening age removed. 
Full output is available in appendix (8). 
Multinomial logistic regression                   Number of obs   =       4101 
                                                     LR chi2(105)        =       441.42 
                                                                   Prob > chi2          =       0.0000 
Log likelihood = -5292.1196                         Pseudo R2           =       0.0400 
Stage Variable Relative 
Risk Ratio 
(rrr) 
Standard 
error 
z P>[z] [95% 
confidence 
interval] 
1 v 2 Patient’s ability 
to see preferred 
GP  
2.345 .9388 2.13 0.033 1.070 
5.139 
1 v 3 Percentage of 
elderly patients 
(65+) 
9.19e-06 <.0001 -2.36 0.018 6.01e-10 
.1406 
 Percentage of 
patients aged 
75+ 
1.74e+11 1.80e+12 2.49 0.013 257.11 
1.18e+20 
1 v 4 Age 2.424 .3522 6.10 0.000 1.823 
3.223 
 Income domain 1.148 .0684 2.32 0.020 1.022 
1.290 
 QOF clinical 
domain 
.7602 .088 -2.37 0.018 .6059 
.9547 
 QOF 
organisational 
domain 
.7644 .0880 -2.33 0.020 .6099 
.9579 
 QOF patient 
experience 
domain 
.7509 .0870 -2.47 0.014 .5982 
.9425 
 QOF additional 
services domain 
.6997 .8491 -2.94 0.003 .5516 
.8876 
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 QOF total score 1.317 .1523 2.38 0.017 1.05 
1.65 
 Percentage of 
elderly patients 
(65+) 
451355.4 2686717 2.19 0.029 3.869 
5.46e+10 
 Percentage of 
patients aged 
75+ 
2.02e-14 2.56e-13 -2.48 0.013 3.15e-25 
.0013 
1 v 
unknown 
Age 5.4609 .7724 12.00 0.000 4.139 
7.205 
 Cancer 
prevelance 
3.98e+18 5.46e+19 3.12 0.002 8307295 
1.90e+30 
 Patient 
satisfaction with 
opening hours 
24.42 35.20 2.22 0.027 1.447 
411.96 
 Proportion of 
patients aged 
over 85+ 
4.62e-14 7.05e-13 -2.01 0.044 4.65e-27 
.4593 
 
5. 2. 9. 1. 4.  Top and bottom deciles of the breast cancer dataset with screening age  
                        removed 
 
Based on the QOF total score, some of the results changed when the regression 
analysis was repeated without the screening age patients and with just the top and bottom 
10% of practices.   
On the patient level, age remained significant between stage 4 and unknown stage 
against stage 1, but income domain was no longer significant. 
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The four QOF domains and the QOF total score were no longer significant between 
stage 1 and stage 4 breast cancer, but the additional services domain became significant 
between stage 3 and stage 1. 
At stage 4 versus stage 1 breast cancer the specific practice variables of a cancer review 
within six months, percentage of elderly (65+) patients at the practice, percentage of 
patients satisfied with phone access, and percentage of patients over 75 all became 
significant. 
Between stage 1 and unknown stage breast cancer the variable of proportion of cancer 
prevelance within a practice became significant.   
All other specific practice variables were found to be not significant, these were; 
patient income domain quintile, exception rate for cancer indicators, deprivation score for 
the practice, IDAOPI, percentage able to see their prefered GP, percentage able to see 
doctor within two days, percentage able to book appointment >= 2 days ahead, and 
percentage of patients aged 85+. 
The analysis was repeated with each of the four QOF domains, taking the top and 
bottom deciles in each, the significant results are as follows: 
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Table 16. Base outcome output for breast cancer, screen detected cases and screening    
                  age patient removed, with just top and bottom deciles of QOF total score. 
Full output is available in appendix (9). 
Multinomial logistic regression                   Number of obs   =       828 
                                                     LR chi2(105)        =     171.36 
                                                                   Prob > chi2          =     0.0000 
Log likelihood = -1036.5142                         Pseudo R2           =     0.0764 
Stage Variable Relative 
Risk Ratio 
(rrr) 
Standard 
error 
z P>[z] [95% 
confidence 
interval] 
1 v 3 QOF additional 
services domain 
.5713 .1406 -2.28 0.023 .3527 
.9254 
1 v 4 Age 3.279 1.176 3.31 0.001 1.624 
6.622 
 Cancer review 
within six 
months 
.0667 .0868 -2.08 0.037 .0052 
.8534 
 Percentage of 
elderly patients 
(65+) 
1.78e+16 2.84e+17 2.35 0.019 490.5 
6.47e+29 
 Percentage 
satisfied with 
phone access 
370.1 741.5 2.95 0.003 7.292 
18783.1 
 Percentage of 
patients aged 
over 75 
6.09e-37 1.98e-35 -2.57 0.010 1.40e-64 
2.65e-09 
1 v 
unknown 
Age 6.293 1.869 6.19 0.000 3.516 
11.26 
 Cancer 
prevalence 
1.20e+28 3.98e+29 1.95 0.05 .7596 
1.90e+56 
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5. 2. 9. 1. 5.  Clinical domain 
 
Age was found to be significant between stage 1 and stage 4 and unknown, these both 
had rrr’s >1 suggesting that as a patient’s age increases so does the likelihood of their 
diagnosis being recorded as a more advanced stage of breast cancer or stage unknown. 
Additional practice variables related to age were found to be significant between stage 
1 and stage 3, these were the proportion of elderly (65+) patients within the practice and 
percentage of patients aged 75+ within the practice. 
Between stage 1 and stage unknown patient income domain was a significant result 
with a RRR of 1.207, so as patient income domain increases (and therefore their 
deprivation) so does the likelihood that they will have a more advanced or unknown stage 
recorded at diagnosis.  
Some specific practice variables were found to be significant between certain stages, 
specifically stage 1 versus 4 the variable of cancer review within six months was significant 
and between stage 1 versus unknown cancer prevelance within the practice was also 
significant. 
5. 2. 9. 1. 6.  Patient experience domain 
 
Age was found to be significant between stage 1 and stage 4 and unknown.  
The specific practice variables of a patient’s ability to see their preferred GP and 
patient satisfaction with practice opening hours was significant between stage 1 and 2.  
Also between stage 1 versus stage 4 all the QOF domains were significant with rrr’s <1, 
while the QOF total score was significant with a RRR of 2.324.   
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The rate of cancer prevelance within a practice was signficiant between stage 1 and 
unknown stage. 
5. 2. 9. 1. 7.  Organisational domain  
 
Age was found to be significant between stage 1 and stage unknown, with a RRR of 
3.887, suggesting that as a patient’s age increases so does the likelihood of their diagnosis 
being recorded as a more advanced stage of breast cancer or stage unknown. 
Patient income domain was signifcant with a RRR of 1.276 between stage 1 and stage 4 
breast cancer. 
Between stage 1 versus stage 4 all the QOF domains were significant with rrr’s <1, 
while the QOF total score was significant with a RRR of 1.840 . 
Specific variables which were significant were between stage 1 and stage 2 where the 
percentage of patients able to see their preferred GP was significant, and between stage 1 
and stage unknown where the rate of cancer prevelance was also significant. 
5. 2. 9. 1. 8.  Additional services domain  
 
Age was found to be significant between stage 1 and stage 4 and stage unknown.  
Between stage 1 versus stage 4 the practice variables of the proportion of elderly patients 
(65+) and the proportion of patients aged over 75 were found to be significant. 
Patient income domain was significant between stage 1 and stage 4 and unknown 
stage, both with rrr’s >1. 
Between stage 1 and stage 4 the additional services domain of QOF was significant with 
a RRR of .7510.  Remaining significant results were the specific practice variables of cancer 
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prevalence within the practice, the exception rate of the practice and patient satisfaction 
with practice opening hours, which were all signifcant between stage 1 and unknown stage.  
5. 2 .9 .1 .9.  Multi-level model 
 
5. 2. 9. 1. 9. 1.  All breast data, screening detected cases and patients of screening   
                            age excluded 
  
 A multi-level analysis was repeated on this dataset. 
 Between stage 1 versus stage 2 and unknown stage between 17.5% and 24.9% was 
attributed to the GP practice level, while between stage 1 versus stage 3 and stage 4 
variance was <0.0001%.  At the PCT level between stage 1 and stage 3 had the highest 
variance attributed to PCT level, 13.1%, while at all other stages it was 0.0002% or lower. 
Table 17.  Multi-level variance at GP and PCT level for breast cancer with screening  
                   detected case and patients of screening age excluded. 
Stage GP PCT 
1 v 2 24.9% 0.0002% 
1 v 3 <0.0001% 13.1% 
1 v 4 <0.0001% 0.0002% 
1 v unknown 17.5% 0.0001% 
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5. 2. 9. 1. 9. 2.  All breast data, screening detected cases and patients of screening 
                            age excluded and just the top and bottom deciles based on practices     
                            total QOF score. 
 
 With this repeated analysis the variance attributed to GP practice level ranged 
between 32.14% and 42.9%, while at the PCT level the highest variance was 0.0009% 
between stage 1 and stage 3 breast cancer. 
Table 18.  Multi-level variance at GP and PCT level for breast cancer with screening cases 
                   and patients of screening age excluded and just top and bottom deciles. 
Stage GP PCT 
1 v 2 32.14% <0.0001% 
1 v 3 36.66% 0.0009% 
1 v 4 41.79% <0.0001% 
1 v unknown 42.9% 0.0005% 
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6. Chapter 6 – Discussion 
 
This chapter brings together and discusses the information so far presented within 
this thesis.  This includes a summary of the findings and a detailed interpretation of the 
results from the different analyses which were conducted.  Possible explanations for the 
findings and overlaps with current research are also discussed, along with where the 
findings fit within the wider context of this research area.   
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6. 1.  Aims and objectives 
 
 The aim of this project was to investigate whether there was a relationship 
between GP practice quality and patient cancer stage at diagnosis. 
 The objective of this project was to use a secondary data analysis method by 
utilising and obtaining data from existing health databases is order to analyse if 
there was a potential link between GP practice quality and patient cancer stage at 
diagnosis in breast and colorectal cancer in the North East region of England. 
6. 2.  Key findings 
 
The objective of this research project was met, in that data was obtained from existing 
health databases, specifically NYCRIS, the GP practice profiles and the NHS IC, and analysis 
was successfully carried out to investigate the potential link between GP practice quality 
and cancer stage at diagnosis.  This research project also met the aim by finding a link 
between GP practice quality and cancer stage in breast cancer and links between aspects of 
GP practice quality and both breast and colorectal cancer stage.   
Specifically, between 12% and 18% of the variance in breast cancer stage at diagnosis 
could be attributed to the variance at the GP practice level.  When just the top and bottom 
10% of practices, based on their QOF total score were compared, this increased to between 
16% and 29%.  It was also observed that the PCT a practice was located in also contributed 
to some of the variance in cancer stage at diagnosis.  Specifically when stage 1 and stage 4 
were compared, 11% of the variance was attributable to the PCT and when just the top and 
bottom 10% of practices were analysed this increased to 21%. 
A range of analyses were conducted to try and identify and understand more specific 
variables that could influence a patient’s cancer stage at diagnosis.  From the regression 
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analysis of the breast cancer data some specific variables relating to quality were found to 
have a significant effect upon cancer stage at diagnosis.  The QOF total score and each of 
the individual domains were found to be significant, as well as: the prevalence of cancer 
within a practice, whether a patient is given a review by their GP within six months of 
diagnosis, a patient’s ability to see their preferred GP when making an appointment and  
the opening hours of the GP practice.    
For colorectal cancer evidence of a link between GP practice quality and cancer stage at 
diagnosis was not found.  In the regression analysis, where specific variables which make 
up the QOF scores were individually analysed, a significant link was found between one of 
the variables, patient ability to see a GP within two working days, and patient cancer stage 
at diagnosis. 
Patient income domain and practice deprivation had a significant effect on cancer stage 
at diagnosis in both breast and colorectal cancer.  That as deprivation and patient income 
domain increased so does the likelihood and relative risk of the patient being diagnosed 
with a more advanced or unknown cancer stage. 
Age was found to be a significant variable in both cancers, in colorectal cancer as age 
decreased the likelihood of being diagnosed with a more advanced or unknown cancer 
stage increased.  However, in the breast cancer analysis the reverse was found, as patient 
age increased so did the likelihood and relative risk of a more advanced or unknown cancer 
stage. 
Patient sex was not included as a variable in the breast dataset, due to it being a 
predominantly female disease.  For the colorectal analyses it was not found to contribute 
or have a significant influence on colorectal cancer stage. 
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6. 3.  Interpretation of findings 
 
To begin with, a number of descriptive and distributional analyses were conducted to 
further examine and understand the make-up of the data that had been brought together.  
When investigating the QOF data it was found that the overall QOF score and individual 
domains were positively skewed, with many of the practices scoring the maximum amount 
or close to maximum score.  This effect is well documented, as it serves a purpose for the 
practice to meet QOF standards and obtain as high a score as possible to receive the 
maximum amount of funding (Department of Health, 2002, Downing et al., 2007b, Steel 
and Willems, 2010).  However, what was identified in this project was while the majority of 
practices scored highly, there were a number of outlying practices which scored 
significantly lower, and even below national averages. 
Previous research has identified a number of practice characteristics which can affect 
and influence QOF scores and attainment, specifically the size of a practice (Wang et al., 
2006) and the deprivation level of the area the practice is located in (Wright et al., 2006).  A 
correlation was found between QOF domains (excluding the additional services domain) 
and total score and deprivation levels within a practice and patient income domain in both 
breast and colorectal cancer.  Therefore, it could be suggested that these outlying practices 
are potentially located in deprived areas and as such are attaining lower QOF scores 
because of this. 
The exception to this was the patient experience domain.  The distributions for this 
particular domain did not produce any outliers; one possible explanation for this could be 
that the patient experience domain is smaller (max. of 92 points) in comparison to the 
clinical (max. of 697 points) and organisational (max. of 168 points) domains.  However, the 
additional services domain is the smallest with a maximum points score of 44, and outliers 
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were found when the distribution was observed in both breast and colorectal cancer.  
Scores for the patient experience domain come from the GP patient survey so a possible 
explanation could be the survey itself, that there is little variation in this domain because 
the results of the survey are biased or have little variation. 
The GP patient survey is a national level survey that has been conducted annually since 
2007, and bi-annually since 2011.  Responses from the survey contribute to the patient 
experience domain of QOF and previous research has identified that variance in responses 
is low, with a significant number of respondents reporting high levels of satisfaction 
(Kontopantelis et al., 2010, Roland et al., 2009).  In addition, in their assessment of the GP 
patient survey Campbell et al. (2013) found a positive bias within their data, of patients 
having a favourable impression of primary care.  More recent research has now specifically 
linked the GP survey and QOF, to investigate the effect of patient experience on quality of 
primary care (Llanwarne et al., 2013) and confirms, as this project suggests, associations 
between QOF and quality of care with patient experience. 
Patient surveys are reguarly used within research as an outcome measure, equally they 
are used to create healthcare measures such as the patient experience domain of QOF with 
little evidence base regarding their validity.  While, as highlighted above, there is a range of 
previous research which has looked at bias and experience of respondents it is only 
recently that the validity of individual items within the GP patient survey has been 
researched.  Lyratzopoulos et al. (2011) investigated the reliability and correlations of the 
individual questions within the GP patient survey, finding that while a small sub-set of 
questions had lower relliability the majoirty of questions had excellent reliability. 
A correlation analysis was also conducted to investigate how the range of variables 
within the data interacted, particularly as some of the variables contribute to each other.  
As expected, the QOF domain scores and QOF total score were found to correlate with the 
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majority of specific QOF and practice profile indicators in both the breast and colorectal 
data. 
Variables related to deprivation (patient income domain, practice deprivation score 
and IDAOPI (Income Domain Affecting Older People Index)), were found to correlate 
together in both the breast and colorectal cancer data.  This was an unsurprising finding as 
patient income domain contributes to indicators of deprivation, such as the Index of 
Multiple Deprivation (IMD), which is then used to calculate scores such as practice 
deprivation and IDAOPI.   
The QOF total score and variables associated with deprivation were found to correlate 
together, again this is an established and well recognised association, that practices in 
deprived areas attain lower scores in QOF (Wright et al., 2006, Downing et al., 2007b). 
6. 3. 1.  Colorectal 
 
The distribution and descriptive analyses showed that there were a greater number of 
patients of retirement age (73.3%) compared to working age (26.7%) and this is a 
commonly observed and expected distribution within cancer populations, as aging is 
known to be a key cause of the development of cancer (Rutherford et al., 2013, Boreham et 
al., 2002).   
The sex distribution of cases was nearly even, with 43% of cases being female and 57% 
male, and this is in line with national statistics for colorectal cancer (Cancer Research UK, 
2013).   
In the correlation analysis it was found that  patient cancer stage at diagnosis and 
patient income domain were correlated; those who had a higher income domain quintile 
and therefore were receiving more financial support and benefits were more likely to have 
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a more advanced or unknown stage of cancer.  This is a well-established correlation, that 
patients of low socio-economic status, of which a low income is a part, tend to have more 
advanced stages of cancer at diagnosis.  It is also a common association that patients from 
low socio-economic backgrounds have higher incidence rates of cancer (Una et al., 2000, 
Kontopantelis et al., 2010, Lyratzopoulos et al., 2011, Roland et al., 2009).   
In the regression analysis when stage 1 and stage 4 were compared it was found that 
patient  age had a significant effect.  A RRR of .8313 shows that patients of working age 
were more likely to be diagnosed with the more advanced stage 4, compared to patients of 
working age.  Similar findings have been found in previous research, specifically, Bowel 
Cancer UK (2012) conducted research into the experiences of younger bowel cancer 
patients  and found that 69% of younger patients were diagnosed with a more advanced or 
unknown stage of cancer.  It is suggested that this may be due to preconceptions regarding 
the age profile of high risk patients.  Increasing age is established as a risk factor and cause 
of cancer (Rutherford et al., 2013, Adams et al., 2004a, Boreham et al., 2002, Collerton et 
al., 2009), and in colorectal cancer the focus has been on the high risk to older populations.  
This was certainly the finding of Bowel Cancer UK (2012) where younger patients reported 
being misdiagnosed with other conditions and had delays of up to six months to receive a 
diagnosis.  However, other research has found that only 13% of patients who go on to 
receive a diagnosis of bowel cancer wait more than two months for a referral for diagnosis 
(Lyratzopoulos et al., 2013).  
Patient income domain also produced significant results, as patients reported a lower 
income, the likelihood of a more advanced or unknown cancer stage increased, with rrr’s 
ranging from 1.065 when stage 1 and stage 2 were compared to 1.137 when stage 1 and 
stage unknown were compared in the analysis.  Patient income domain was the only 
available measure from NYCRIS and has been used in this project as an indicator of patient 
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deprivation.  Income domain quintile is a component of wider known measures of 
deprivation and socio-economic status, specifically the national measure of the IMD.  There 
is a well-recognised link between cancer stage and deprivation, or socio-economic status, 
and the findings of this research support previous research (Iyen-Omofoman et al., 2011, 
Parikh‐Patel et al., 2006, Forrest et al., 2014).   
It had been expected to find an association between patients’ sex and their cancer 
stage at diagnosis would be found, as previous research had found delays in female 
patients receiving a diagnosis and for being diagnosed with a more advanced or unknown 
stage of colorectal cancer compared with male patients (Lyratzopoulos et al., 2012a, Doran 
et al., 2014).  In the case of the study conducted by Bowel Cancer UK (2012) this was a 
small survey (n = 109) of young people who had been diagnosed with bowel cancer and 
therefore it is difficult to compare the results.  However, the study by Neal and Allgar 
(2005) used national data for six cancers, including bowel, with a total sample size of n = 
65,192, which could be considered more comparable with this study where the sample size 
for bowel data was n = 11,606.  The data for the Neal and Allgar study came from the 
National Survey of NHS Patients: Cancer (Boreham et al., 2002, Department of Health, 
2002) and the survey was conducted in 2000, compared with the data for this present 
study coming from 2006-2008.  It could be that finding that sex did not prove to have a 
significant effect upon cancer stage at diagnosis, in the regression analysis of this present 
study, suggests that the inequality found by Neal and Allgar may have been due to chance, 
at least within the North East region of England. 
No significant association was found between the QOF domain scores and total score 
with cancer stage.  This was unexpected as colorectal cancer during the time period of the 
data did not have a screening programme in the North East of England and cases would 
have been diagnosed primarily through a symptomatic route via a patient’s GP.  Therefore, 
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it had been hypothesised that GP quality, as measured by QOF, would influence colorectal 
cancer stage. 
Despite none of the QOF domains or total score showing an association, one of the 
specific practice variables from QOF did prove to be significant.  ‘A patient’s ability to see a 
doctor within two days’ is a variable from the patient experience domain of QOF, with an 
RRR of .2197. This shows that as a patient reports being unable to see a doctor within two 
days of asking for an appointment then the likelihood of them being diagnosed with an 
unknown colorectal cancer stage increases.  This specific QOF indicator has previously been 
linked to emergency admissions for cancer (Kontopantelis et al., 2010, Bottle et al., 2012). 
Following on from this, when the regression analysis was repeated with just the top 
and bottom 10% of practices, other specific variables became significant; the proportion of 
elderly patients within a practice and a patient’s ability to speak with a GP via telephone.  
The association with age is well recognised (Iyen-Omofoman et al., 2011, Rutherford et al., 
2013) and there is a range of previous research that has highlighted the variable of a  
patient’s access to GP services as an influence upon a patient’s cancer diagnosis and 
outcomes (Bain and Campbell, 2000, Campbell et al., 2001, Launoy et al., 1992, Parikh‐Patel 
et al., 2006, Stevenson et al., 2003).   
Following the multinomial regression analyses, a trend analysis was conducted on the 
individual QOF domains against patient colorectal cancer stage and it was found that the 
patient experience domain was significantly associated with colorectal cancer stage, 
further supporting the findings from the regression analysis.  Previous research has 
identified that performance in the GP patient survey and the patient experience domain of 
QOF is strongly linked, and that both are linked to a practice’s performance in achieving 
higher QOF scores, indicators, and aspects of patient experience, to be significantly 
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associated with patient outcomes for cancer (Kontopantelis et al., 2010, Llanwarne et al., 
2013, Lyratzopoulos et al., 2012b).  
The multi-level analysis did not find any significant variance between breast cancer 
stage at the GP practice level.  With few findings from the regression analysis this was 
unsurprising but as discussed previously it had been hypothesised and expected that GP 
quality would have an influence upon colorectal cancer stage at diagnosis, due to the 
nature of diagnostic pathways for colorectal cancer at this time. 
6. 3. 2.  Breast 
 
The descriptive and distribution analyses found that the majority of patients had been 
diagnosed with less advanced stages of breast cancer; 80.92% had a diagnosis of stage 1 or 
2 (Lyratzopoulos et al., 2012a).  This higher proportion of cancer cases being diagnosed at 
less advanced stages is an expected pattern in breast cancer.  There is a national screening 
programme for breast cancer in England and the screening information obtained revealed 
that 35.61% of the breast cancer cases in the data were identified through screening which 
compares to the national average of 32% (Lawrence et al., 2011).  Of the screened cases 
92.47% were diagnosed with stage 1 or 2 breast cancer. 
The distribution between the two age categories was almost even, with patients of 
retirement age constituting 44.6% of the breast cancer data and 55.4% of the patients 
being of working age.  The distribution of breast cancer stage and patient age was found to 
be significant, specifically that patients of retirement age had more advanced or unknown 
stage at diagnosis which supports previous research findings (Lyratzopoulos et al., 2012a, 
Bastiaannet et al., 2010, Cuthbertson et al., 2009, Adams et al., 2004a).     
The correlation analysis provided a range of findings which were similar to the 
colorectal cancer data correlation analysis.  Specifically breast cancer stage was found to 
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correlate with patient income domain; as a patient’s income increases, the likelihood of 
more advanced breast cancer stage at diagnosis reduces and this finding supports previous 
research (Adams et al., 2004b, Una et al., 2000, Rutherford et al., 2013).   
Patient age was found to significantly correlate with breast cancer stage, but this time a 
patient’s age was a positive correlation, whereby patients of retirement age were more 
likely to have a more advanced or unknown cancer stage at diagnosis compared to patients 
of working age (Boreham et al., 2002, Cuthbertson et al., 2009, Lyratzopoulos et al., 
2012a).  Lyratzopoulos et al. (2012a) found patients aged >70 years to have a higher 
frequency of more advanced breast cancer stage at diagnosis and suggested that this could 
be linked to patient level of deprivation; those of low socio-economic status were more 
frequently diagnosed with a more advanced breast cancer stage.  Cuthbertson et al. (2009) 
also suggested that this effect could be associated with the age restrictions on the national 
breast cancer screening programme.  In England during this time period, the advised age 
range for screening was females aged 50-70.  In females over the age of 70 only 7% of cases 
are screen detected, compared with the national average of 32% (Lawrence et al., 2011). 
Screening information for the breast cancer data was available and while this 
information was excluded from the later and more advanced analyses it was included in the 
initial and descriptive analyses.  In the correlation analysis it was found that patients who 
had no information or were not diagnosed through a screening pathway were more likely 
to have a more advanced or unknown cancer stage at diagnosis.  This finding fits with 
previous research that breast cancer screening identifies breast cancer at earlier and less 
advanced stages (Lawrence et al., 2011). 
In the regression analysis it was found that patient age had a significant association 
(RRR ranged from 2.424 to 5.461) with breast cancer stage, continuing the findings from 
the correlation analysis that patients of retirement age are more likely to be diagnosed 
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with a more advanced or unknown cancer stage.  Within the practice profile there are 
specific variables related to elderly patients, specifically the percentage of patients within a 
practice who are over 75, the proportion of patients who are classed as elderly (65+), and 
the percentage of patients within the practice who are over 85.  All three of these variables 
also produced a significant association between increased age and a greater likelihood of 
more advanced or unknown breast cancer stage.  This is a trend that has been observed in 
previous cancer research and also within breast cancer specific research (Adams et al., 
2004a, Cimprich et al., 2002, Cuthbertson et al., 2009, Richardson et al., 1992, Boreham et 
al., 2002, Rutherford et al., 2013, Lyratzopoulos et al., 2012a, Bastiaannet et al., 2010). 
The findings surrounding the QOF domains and total score was of interest, with the 
domains producing an RRR of <1 while the total score was >1.  This was an interesting 
finding as such results have not previously been reported. However, this specific and 
particular analysis had not been done previously.  An explanation or suggestion has yet to 
be formulated, despite contact and conversation with members of the NHS information 
centre, it therefore appears to be an idiosyncratic result and finding. 
A number of specific variables from the patient experience domain were found to be 
significant in the regression analysis, including opening hours of the practice and patients 
being able to see their preferred GP.  Both of these variables are from the patient 
experience domain and these findings suggest that this may be a key area that contributes 
to patient cancer stage at diagnosis.  This is a similar finding to data from the regression 
analysis of the colorectal data and previous research has found an association between 
patient experience and satisfaction and cancer outcomes (Llanwarne et al., 2013, 
Kontopantelis et al., 2010, Bottle et al., 2012).   
Specific variables from the QOF clinical domain were also found to be significant.  
Firstly, the cancer review variables, which is an indicator of whether  a GP performs a 
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review of the cases within three months of diagnosis once a diagnosis has been made.  This 
particular indicator has been highlighted as a problematic and questionable indicator 
within QOF.  Adams et al. (2011) in their study reported that GP and primary care teams 
did not feel that the current cancer review format was helpful and that there was scope for 
improvement within this area.  Equally the cancer charity, Macmillan developed an 
alternative cancer care review template which was trialled amongst a group of GPs and was 
found to be more useful and user friendly (Macmillan, 2012). 
Secondly, the variable of cancer prevalence, which is the prevalence of cancer cases 
diagnosed within the practice population; specifically it was found that as the prevalence of 
cancer cases increases in a practice so does the likelihood of breast cancer cases being 
diagnosed with an unknown stage.  This could suggest and direct towards previous 
research and findings such as the inverse care law, that practices which are dealing with a 
high volume of healthcare issues struggle to deal with demand and as a result the overall 
care and quality of that care is diminished (McLean et al., 2006, Mercer and Watt, 2007, 
Watt, 2002). 
When additional regression analyses were conducted with just the top and bottom 10% 
of practices, a number of other specific variables were found to have a significant 
association.  These were; the practice opening hours, a patient’s ability to see their 
preferred GP and a patient’s ability to see a doctor within two days.  All three of these 
variables are indicators from the patient experience domain of QOF, therefore further 
adding support to the findings of this and previous research (Bottle et al., 2012), of the 
association between patient experience and cancer stage. 
It should be noted that while a number of significant findings, between stage 1 and 
stage 4 and stage unknown and between stage 1 and stage 3 in the top and bottom decile 
analysis were found, there is a potential issue of power.  From the distribution of cancer 
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stage, within the breast cancer dataset, there is a higher proportion of cases diagnosed at 
stage 1 and 2, a trend which remains even after screen detected cases are removed.  This 
creates a potential argument for bias within the results as a smaller group of more 
advanced stage patients have been compared to a larger group of less advanced stage 
patients.  However, this bias in numbers, as mentioned, is representative of the distribution 
in cancer stage within breast caner nationally, even if proportionally they are biased.  
Dichotimising cancer stage was a method used to try and reduce this bias, while still 
retaining a represenative sample. 
The trend analysis, between cancer stage and the individual QOF domains and total 
score, did not identify any significant results.  This was a surprising result as the QOF 
domains and total score had previously provided a significant correlation in the regression 
analysis. 
In the multi-level analysis a relationship was found between GP practice quality and 
cancer stage at diagnosis.  This was an unsurprising finding as the QOF domains and total 
score had been found to be significant in the regression analysis, along with a range of 
specific practice level variables.  When this analysis was conducted with the top and 
bottom 10% of practices, the association between GP quality and breast cancer stage 
nearly doubled in the majority of the results.    
As yet there is no research that has looked specifically at breast cancer stage at 
diagnosis and GP practice quality, as measured by QOF.  Other measures of assessing 
quality have been used, such as referral rates for breast cancer and these have provided 
mixed results (Rubin et al., 2011, Potter et al., 2007, Cornford et al., 2004).  Time from 
presentation to receiving a diagnosis and survival outcomes for breast cancer are 
significantly better compared with other cancer types (Baughan et al., 2009, Allemani et al., 
2010, Coleman et al., 2003, Møller et al., 2009, Thomson and Forman, 2009).   However, 
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the findings from this project highlight that there is still room for improvement and indicate 
that GPs contribute significantly to this area.   
 
6. 4.  Interpretation of results in wider context 
 
The key finding of this research was the evidence of a significant link between GP 
practice quality and patient cancer stage.  While this was more clearly demonstrated and 
found in the breast cancer dataset, there were findings in the colorectal cancer dataset that 
demonstrated a significant relationship between aspects of GP practice quality and patient 
cancer stage.  The combination of different analyses meant that it was possible to uncover 
these more specific variables that related to GP practices and their provision of quality.  
Specifically in both breast and colorectal cancer many of these specific variables were from 
the patient experience domain of QOF; in breast cancer, additional variables from the 
clinical domain were also significant. 
It could be suggested that in the breast cancer findings, the significant specific variables 
from the regression analysis are the key contributors on the variance in quality observed in 
the multi-level model.  If so this suggests that patient experience at a primary care level is 
key to practice quality and increasing the likelihood of patients being diagnosed with a less 
advanced breast cancer stage. 
Patient experience and satisfaction is a well-recognised component of primary 
healthcare.  Since the late 1980s, Howie (Howie et al., 1997, Howie et al., 2004, Howie et 
al., 1989, Howie et al., 1991, Howie et al., 1999) has researched the impact of GP 
consultations and their length on patient satisfaction and outcomes and highlighted 
continually the importance of a patient leaving a consultation feeling understood, able to 
cope with their symptoms and satisfied.  Recent research by Llanwarne et al. (2013) 
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examined the relationship between QOF and GP patient survey data to see if there was a 
relationship between clinical quality and patient experience.  While associations were 
found and the strongest associations were found between quality of care and access which 
supports the findings of this research, it was also highlighted that aspects such as the 
quality of interpersonal care should be considered separately.  This again demostrates that 
while a greater understanding is being gained;  patient experience and the provision of 
primary care are still complex areas which can be influenced by a range of factors. 
Previous research has identified a range of factors which can affect GPs’ decisions 
regarding potential cancer cases, such as: a GP’s sex (Robertson et al., 2004), whether the 
GP works full or part time (Parkerton et al., 2003), the size of the practice (Hippisley-Cox et 
al., 1997, Wang et al., 2006), the number of previous consultations (Lyratzopoulos et al., 
2012a), co-morbidity (Jiwa et al., 2004), and a GP’s training (Pockney et al., 2009, Wade et 
al., 2010).   
GPs are often considered to be ‘gatekeepers’ between primary and secondary care, 
and it has been suggested that this role within a healthcare system can have a negative 
effect upon patient cancer outcomes (Vedsted and Olesen, 2011).  However, in other 
countries that have GPs as ‘gatekeepers’ cancer outcomes do not appear to be affected by 
this form of healthcare structure and it is instead suggested that there are other 
organisational and resource factors that are a greater influence upon cancer outcomes 
(Brown et al., 2014, Rubin et al., 2011).  It could, therefore, be suggested that the variance 
and significant factors observed in this study are not associated with the GPs and practice 
characteristics but instead some other unaccounted for factor and influence.  While the 
total score of the organisational domain of QOF was included in the analysis perhaps the 
inclusion of individual QOF items from this domain could be included in future research. 
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A patient’s psychological and individual factors can also contribute to their own 
experience and consultation with a GP.  It is well-recognised that many patients delay 
before presenting symptoms to their GP (de Nooijer et al., 2001, Macdonald et al., 2006, 
Neal et al., 2008b, Tromp et al., 2005, Pitiphat et al., 2002), and this can be for a range of 
reasons from simple time constraints (Shack et al., 2008) to personal beliefs such as feeling 
undeserving of healthcare action (Corner et al., 2006). 
Geographical influences have also been found to affect patient access to primary care 
services and ultimately in some cases, patient cancer outcomes.  Patients who live in rural 
areas tend to be diagnosed with a more advanced cancer stage at diagnosis and report 
more problems accessing services (Bain and Campbell, 2000, Campbell et al., 2001, Launoy 
et al., 1992, Liff et al., 1991, Parikh‐Patel et al., 2006, Lovett et al., 2002, Pitchforth et al., 
2002, Jones et al., 2008, Goddard et al., 2010, Baird and Wright, 2006).  However, research 
has also suggested the opposite effect, in that close proximity to a cancer centre is 
associated with delays in diagnosis and treatment (Robertson et al., 2004, Tørring et al., 
2013). 
The issue of access is an important component of patient experience and satisfaction, 
not just in terms of geography and being able to travel to a GP or primary care provider, 
but there is also a growing issue regarding access to these services.  Specifically many of 
the points from the GP patient survey, which are used as indicators by QOF, are related to 
being able to access a GP by means of an appointment or phone consultation.  Llanwarne 
et al (2013) recently supported this concept in their investigation into the association 
between QOF and patient experience, finding that aspects of the GP patient survey related 
to access had the strongest correlation with clinical score from QOF.    
Research that has utilised data from the GP patient survey has found that overall, 
patients report being satisfied and report positive experiences of primary care (Bottle et al., 
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2008, Lyratzopoulos et al., 2012b).  Participation in the GP patient survey, like QOF, is 
voluntary and Nagraj et al. (2013) conducted a study to look at the disenrollment rates of 
GP practices from the scheme.  They found that GPs who had dropped out were most likely 
to be from practices which had received low scores, however there was still substantial 
drop out from practices with higher scores.  
Patient income domain was used in this project as a measure of deprivation.  Income 
domain is used along with other indicators to create the IMD, a wider and national 
measure of deprivation and socio-economic status.  It was a significant finding in this 
project for both breast and colorectal cancer that patients with a low level income were 
more likely to be diagnosed with a more advanced breast or colorectal cancer stage.  
Patient deprivation has been previously linked with more advanced cancer stage, but it has 
also been significantly linked with reduced and problematic access to primary care services, 
with GP practices located in deprived areas showing worse health outcomes and higher 
rates on ill health (Forrest et al., 2014, Una et al., 2000, Macdonald et al., 2006, 
Kontopantelis et al., 2010, Baird and Wright, 2006, McLean et al., 2006, Rutherford et al., 
2013, Strong et al., 2006, Wright et al., 2006).  It could therefore be suggested that 
variables related to deprivation such as income domain are related and contribute to 
patient satisfaction and that was found in the correlation analysis of the variables in both 
breast and colorectal cancer (p > .05 between patient experience domain and patient 
income domain, practice deprivation level and IDAOPI).  This finding is supported by 
previous research which has examined the link between GP practice performance and 
socio-economic status (Richardson et al., 1992, Wang et al., 2006).   
Research in other disease areas has highlighted similar findings and issues.  Levene et 
al. (2010) conducted a cross-sectional national study of patient factors affecting coronary 
heart disease mortality and found variation in mortality across the country to be 
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significantly associated with patient factors, such as socioeconomic status and ethnicity, 
while measures of clinical performance and practice quality were not signifcant.  Bottle et 
al. (2008) reflected this in their earlier study which suggested improvements in primary 
care quality would not equate to improved outcomes and reduced secondary care burdens. 
Looking at the influence of GP quality on cancer stage at diagnosis and using cancer 
stage at diagnosis as the outcome measure against QOF and practice profile data as a 
measure of GP quality is a novel approach which has not been used previously.  As a 
contrast, GP referrals have previously been used as a measure for primary care cancer 
outcomes and quality and similar results have been found (Haikel et al., 2011, Neal et al., 
2008b, Potter et al., 2007, Neal et al., 2007, Kirwan et al., 2002).   
Foot et al. (2011) conducted an inquiry, for the King’s fund, into the quality of GP 
diagnosis and referrals.  This national review studied variables and factors that influence 
referral rates, finding that while there is a large body of research in this area, the findings 
are inconsistent.  There is evidence that GPs have a substantial influence on referral rates, 
but what specific GP factors and variables cause that relationship are unclear and any 
suggestions were found to be wide ranging, see table 19 below.  The findings of this study 
echo this, that GPs clearly have a significant influence upon patient cancer diagnosis, in 
particular patient experience is a key component of this, but an explanation as to how this 
influence works is not yet clear.   
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Table 19.  Factors associated with referral rate, taken from Foot et al. (2010). 
GP or practice factors Patient factors Structural factors 
GP beliefs or expectations about 
benefits of referral 
Severity of symptoms Distance to specialist 
service 
GP age or experience Desire for referral Area deprivation 
GP gender Age Availability or 
accessibility of specialist 
care 
Degree of training in relevant 
specialty 
Gender  Availability of community 
alternatives to specialist 
care 
GP–patient relationship, 
congruence between GP’s and 
patient’s attitudes 
Social class Time available for 
consultation 
GP relationship with specialist Diagnosis  
Practice size Co-morbidities  
Fund-holding history Help-seeking behaviour  
Services available in practice Perception of the problem  
GP psychological characteristics  
– for example, ability to tolerate 
uncertainty, concern that non-
referral might damage patient 
relationships 
Attitudes towards 
treatment 
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6. 5.  Strengths of the study 
 
Selecting just two cancer types and using data from the Northern and Yorkshire region 
of England was of benefit for a range of reasons.  Initially it provided focus for the project 
and these limits also aided in maintaining an achievable time scale for this study, as too 
broad a focus and a larger amount of data would have significantly increased the required 
time scale. 
Working with just one cancer registry was also of benefit as they were able to advise 
and recommend cancers to focus upon in addition to advising on questions regarding 
ethics.  As a result, breast and colorectal cancer were selected as they had the highest 
completeness rate within NYCRIS, but are also two of the most common cancers within the 
UK and as such are a high priority for research.  Using data from just the Northern and 
Yorkshire regions of England also became a strength, as geographical differences between 
regions have been observed in previous research especially between Northern and 
Southern regions (Walters et al., 2011, Goddard et al., 2010, Bambra and Popham, 2010).  
Therefore, narrowing the focus of the study by selecting breast and colorectal cancer with 
northern regions of England, not only made this study achievable within the time 
constraints but the impact of this research was also increased.   
Prior to any analyses taking place a number of ethics applications had to be made.  Due 
to the nature of the research and the possibility of potentially identifiable patient data 
being used, the NIGB were consulted.  At the point at which ethics applications were being 
made for this study, the NHS REC and NIGB had not dealt with this specific data 
combination approach and a number of discussions regarding methodology and treatment 
of data were held with the NIGB.  This meant that for ethical approval, this study and its 
methodology was reviewed by three distinct organisations, NIGB, NHS REC, and University 
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ethics, and granted approval.  This is a rigorous process and a strength of the study which 
benefited both from having been reviewed by and having had the input of a number of 
external organisations and institutions.   
While the national colorectal screening programme had not fully taken effect for the 
time period of data used in this study (2008-2008) the national breast screening 
programme was in effect.  NYCRIS collects information regarding cancer cases identified 
through screening and was able to provide this data so that cases within the breast cancer 
dataset that were screen detected, could be excluded.  This accounted for 35.6% of the 
breast cancer cases which were then excluded reducing any potential skewing of the 
analysis and results. 
While some preparation of the NYCRIS data was required, one of the benefits of using 
the data from the practice profiles and QOF was that it is made publically available and the 
data has already been prepared and searched for errors. 
The range of analyses used were also a strength of the study as it created the 
opportunity to look at the specific, as well as the overall effects of a wide range and 
number of variables.  Separating key variables, such as patient demographics and the QOF 
domains and total scores and analysing them against breast and colorectal cancer stage 
provided a more in-depth understanding of the data.  It also provided the opportunity to 
test well recognised associations, such as the effect of age upon cancer stage.  Conducting 
a multi-level analysis gave an overall view of whether GP practice quality was associated 
with patient cancer stage, while also conducting a regression analysis provided details 
about which specific variables were significantly associated.  For example, while colorectal 
cancer stage was found in the multi-level analysis to not be significantly affected by GP 
practice quality, it was found in the regression analysis that variables from the patient 
experience domain of QOF did have a significant affect upon patient cancer stage. 
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6. 6.  Limitations of the study 
 
QOF is a national and government backed quality scheme and while the use of such a 
large healthcare dataset can be seen as a strength of the study, QOF does have its 
limitations.  Previous research has criticised the validity of QOF and questioned whether it 
is an effective measure of quality (Steel and Willems, 2010, de Wet et al., 2012, Downing et 
al., 2007b, Short, 2007).  In terms of disease indicators and specifically those related to 
cancer, QOF is limited, in fact at the time of this project there were only three points within 
QOF which were cancer specific (Downing et al., 2007b, Office of National Statistics, 2012).  
In previous research it is also well documented that QOF has a positive bias, with the 
majority of practices scoring highly and this was reflected in the descriptive analysis of this 
project.  While dividing the practices into deciles and using just the top and bottom 
practices to try and account for this positive bias was a solution that has previously been 
used (Wilson et al., 2010, Møller et al., 2012), it is not possible to remove the bias 
completely.  Even the lower performing practices achieve over 80% of the total available 
QOF points, therefore there remains a small difference between the highest and lowest 
performing practices.  This small level of variation could potentially explain some of the 
negative and non-significant results, in that variation in GP practices was found to not have 
an affect upon the cancer stage of a patient simply because there was no variation in the 
GP practices.  However, this suggestion had been the motivation for exploring and using 
the methodology of comparing top and bottom deciles practices to provide a potentially 
more suitable sample for comparison.  A suggestion would be to use an alternative 
measure of primary care quality but, as previously discussed, at  the time of this research 
QOF was the most comprehensive and national measure of primary care quality available. 
While breast and colorectal cancer were identified as common cancers, the number of 
cancers that had a good completeness rate of cancer stage at diagnosis was limited.  The 
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consideration at the start of this project had been to include at least three of the most 
common and priority cancer types for analysis, of which breast and colorectal are two, but 
also other cancer types such as lung.  Lung cancer was of particular interest due to its poor 
survival rate, particularly in comparison to other common cancers like breast and colorectal 
(Holmberg et al., 2010, Neal et al., 2007, Thomson and Forman, 2009, Verdecchia et al., 
2007a).  Upon consultation with NYCRIS it was discovered that cancer types such as lung 
had very low recording rates for cancer stage, less than 10%.  However, despite being one 
of the better recorded cancer types, of the colorectal data received from NYCRIS, nearly 
50% of the cases were assigned an unknown stage of colorectal cancer, but this is in line 
with national statistics. 
An alternative to using data from NYCRIS may have been to use data from another 
cancer registry or an alternative data source, such as the General Practice Records 
Database (GPRD).  The GPRD has been widely used within research (Wood and Martinez, 
2004, Glaser et al., 2013, Rachet et al., 2010, Hwang et al., 2009), but for this particular 
project it would have raised issues of access, specifically a longer ethics process.  The GPRD 
is also not disease specific and the cancer registries obtain their data from a range of 
healthcare resources, including the GPRD, so hold better and more detailed data that was 
of benefit to this project.   
Working with the data, once it was received, was a process which took longer than 
anticipated.  Specifically, the data cleaning took longer than hoped as there were a range of 
small problems including errors in the data, missing and incomplete information, finding a 
method to merge the different databases, and formatting and software issues.  For 
example, Stata is widely used within healthcare research but is not used by the NHS, so 
data which was received from NYCRIS and ERPHO, had to be converted.  Efforts were made 
to keep the analysis straightforward so as not to over-manipulate the data; for the analysis 
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this meant separating the data on occasion and running a number of individual tests, which 
took more time.  In essence there were a number of small and wide ranging issues which 
arose while working with the data which caused delays and meant the process took longer 
than anticipated. 
In the case of the analysis of the colorectal dataset there was a lack of significant 
results for which a possible explanation may be found in the design of the study. 
While a large number of practices were included in this analysis, a number were 
excluded as part of the ethical process due to small numbers.  The excluded practices had 
seen less than five cases of colorectal cancer in a three year period and as such they were 
likely to be a small or single-handed practice.  Equally if a practice does not participate in 
QOF or has a small list size it is excluded from QOF and these practices were also removed 
from the analysis.  The practices that remained in the analysis could, therefore, be 
considered biased, as they do not capture the full range of practice types within the 
geographical areas studied.  Previous research has suggested that in some cases these 
small and single-handed practices are likely to be located in areas of high deprivation, areas 
with a transient population, and in areas where disease incidence and co-morbidity is high 
(Wang et al., 2006, Campbell et al., 2001, Saxena et al., 2007).  However, equally within 
these studies the quality of care provided by small and single-handed practices is not 
dissimilar to that of larger practices, for example, in Wang et al. (2006) they found smaller 
practices scored fewer QOF points but this was primarily within the prganisational domain 
of QOF, not clinical care. 
Attempting to address this problem was part of the rationale for repeating the analysis 
with just the top and bottom decile based on QOF scores, to try and gain a better 
perspective on the range of practice performance.  Again, however, in doing this the 
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number of patient cases and practices included in the analysis was further reduced, from 
11,491 colorectal cases to just 2,340.   
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7. Chapter 7 – Conclusions 
 
This concluding chapter presents the key findings of this thesis, followed by a 
reflection and critique of the strengths and limitations of the project as a whole.  From this, 
suggestions for directions and improvements for future work in this area of research are 
made.  In light of the findings and conclusion of this thesis, recommendations for future 
health and primary care policy are made, before a final summary of this project is 
presented. 
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7. 1.  Key findings 
 
The key findings of this project were as follows: 
 From the systematic review there was found to be a lack in research that had 
investigated primary care quality and its impact upon cancer diagnosis.  Previous 
research was also found to rely on self-reporting questionnaires from GPs 
regarding their adherence to guidelines, identifying a lack of research that had 
effectively utilised existing healthcare databases and sources. 
 An association between GP practice quality and breast cancer was found in the 
multi-level analysis, with GP quality accounting for between 12 – 18% of the 
variance between breast cancer stage.  No variance, less than .01%, was found 
between GP practice quality and colorectal cancer stage. 
 A number of significant associations were found between both breast and 
colorectal cancer stages and specific GP practice indicators, most notably indicators 
associated with patient experience and satisfaction such as; patients’ reported 
ability to see a doctor within two days and opening hours of the practice. 
 Well recognised associations between cancer stage and the patient variables of age 
and income domain, were also found to be significant in both breast and colorectal 
cancer.  Specifically in breast cancer, older patients and those with a lower income 
were more likely to be diagnosed with a more advanced stage of breast cancer. 
Colorectal patients who are younger and have a lower income are more likely to be 
diagnosed with a more advanced stage of colorectal cancer. 
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7. 2.  Strengths of the project 
 
Conducting a systematic narrative review prior to the analysis was beneficial as it 
provided a more rigorous rationale for the study but also aided in informing and directing 
the methodology.  For example, the findings that only a small number (n = 2) of papers had 
utilised QOF in their research highlighted the need for research in that area, but also lent 
support to the objective to utilise existing healthcare databases.  The methodology of the 
systematic review, such as the hand searching of reference sections for additional papers, 
the use of more than one database and the use of a second reviewer within the systematic 
review all helped to ensure papers were not missed and also reduced researcher bias and 
provided an outside/second opinion.   
Using data from just the Northern and Yorkshire region of England also became a 
strength, as geographical differences between regions has been observed in previous 
research especially between Northern and Southern regions (Walters et al., 2011, Goddard 
et al., 2010, Bambra and Popham, 2010).   
Selecting just two cancer types was a strength of this project for a number of reasons.  
Firstly it provided focus for the project.  Breast and colorectal cancer are two of the most 
common cancers within the UK and as such are a high priority for research, therefore, by 
selecting breast and colorectal cancer it also increases the impact of this research. It would 
have made it difficult to complete the project in the timescale if other or all cancer types 
had been included. 
Breast and colorectal cancer differ in a number of ways, from the profile of patients 
they affect, symptomology, diagnostic pathways etc. (Jiwa et al., 2008, Cornford et al., 
2004, Bekkink et al., 2010, Cancer Research UK, 2013).  Focusing on just two differing 
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cancer types provided the opportunity to explore and analyse whether GP practice quality 
affected breast and colorectal cancer in different way. 
From the perspective of data quality and analysis, focusing on two of the most 
common cancers ensured a good sample size for this project.  Out of the most common 
cancers, NYCRIS had the best reporting rates for breast and colorectal cancer, which was 
essential as cancer stage at diagnosis was being used as the outcome measure for this 
project.  In the case of breast cancer, NYCRIS held information regarding screen detected 
cases, which meant screen detected cases which have no or little GP involvement in 
presentation and diagnosis, could be excluded and reduce skewing the analysis and results. 
With the data that was received from NYCRIS, the process of data cleaning identified 
common areas where errors occurred.  A procedure was developed to find and identify 
missing information and using this procedure 1,437 cases with fields of missing or incorrect 
data were found and the correct information was given to NYCRIS.  The procedure used 
was also disseminated back to NYCRIS.  Conversely, data from the practice profiles and QOF 
is publically available and has therefore already been prepared and checked for errors. 
The use of secondary data analysis and existing databases in health research is 
becoming more common (Adams et al., 2004b, Downing et al., 2007b, de Wet et al., 2012, 
Ivbijaro et al., 2008, All Party Parliamentary Group on Cancer, 2009, Holmberg et al., 2010, 
Lyratzopoulos et al., 2013, Llanwarne et al., 2013).  The practice profiles were only created 
and made publicly available in late 2010, during the second year of this project and since 
then cancer specific practice profiles have also been created and made available in 
December 2012.  At the point at which the ethics application was being made for this 
research the NHS REC and NIGB had not dealt with this specific data combination approach.  
That this research required working with the NIGB on ethical issues I believe is a strength as 
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it meant and demonstrated that the research had a new and novel approach and also 
underwent close and considered scrutiny. 
The range of analyses used were also a strength of the study as it created the 
opportunity to look at the specific, as well as the overall effects of a wide range and 
number of variables.  For example, while colorectal cancer stage was found in the multi-
level analysis to not be significantly affected by GP practice quality, it was found in the 
regression analysis that variables from the patient experience domain of QOF did have a 
significant affect upon patient cancer stage.  In the breast cancer dataset the incorporation 
of additional analysis with all patients of screening age (50-70 years) excluded was another 
strength of the research as it ensured that potential for confounding by variation of 
screening uptake and any screening/Hawthorne effect that may occur within a practice was 
accounted for. 
I believe an overall strength of this project has been the continued input of individuals, 
organisations and institutions external to this project, which has meant that this project has 
been continually reviewed throughout each stage.  This has included a second reviewer for 
the systematic review, contact regarding ethics and ethical approval from the NIGB, NHS 
REC, and Durham University ethics, guidance from statisticians within Durham University, 
opportunities to discuss issues with other health researchers within FUSE (The Centre for 
Translational Research in Public Health), and annual reviews of the project by Durham 
University School of Medicine and Health. 
 
 
 
216 
 
7. 3.  Limitations of the project 
 
The systematic narrative review which was conducted prior to analysis had some 
limitations.  While two databases were used and searched there was overlap between the 
search results, due to both databases specialising in medical and biomedical studies, 
therefore, the inclusion of an additional database(s), such as PubMed, may have been of 
benefit and produced additional papers which may have been missed.  While a more 
rigorous review, such as a meta-analysis, would have been the aim it was not possible to 
conduct because of the varied methodologies and outcome measures of the papers 
included.  This in itself became a strength and finding of the review regarding the 
inconsistent approach to quality of primary cancer care research. 
While the use of a national scheme and database such as QOF can be viewed as a 
strength, particularly in light of the systematic review highlighting the lack of research that 
had utilised QOF as a research resource, QOF does have its weaknesses.  These have been 
previously discussed, such as criticisms of validity (Steel and Willems, 2010, de Wet et al., 
2012, Downing et al., 2007b, Short, 2007), and limitations of cancer specific items  
(Downing et al., 2007b, Office of National Statistics, 2012).  Since this research was 
undertaken, in line with the move from research councils like the ESRC to utilise large 
datasets and secondary analysis, there has been an increase in research projects of this 
type.  As such a greater understanding of the limitations and considerations that must be 
undertaken when using large datasets such as QOF have been indentified.  Specifically 
Saunders and Abel (2014) reviewed this issue in a publication earlier this year that provides 
an outline on the considerations around the design of large ecological studies which use 
varied outcome measures, and certainly any future research in this area should follow this 
guidance. 
217 
 
There are a number of considerations around study design which while they can be 
considered and discussed it was simply not practical or feasible to carry these out.  For 
example, in their article Saunders & Abel (2014)  highlighted the issue of comparing 
individual data against aggregated group data.  Ideally instead of using totals and averages 
from the GP survey for a practice, linking individual patient’s cancer data and outcomes 
with a patient’s individual response to a GP patient survey would be the best option.  
However, GP patient surveys are not completed by all patients, only a selective number of 
surveys are sent out to patients, and equally it would be difficult to gain permissions for 
that particular level of indivudal patient data from NHS and ethics organisations. 
Within this study there were also a large number of variables which were included in 
the analysis, because of this there was the potential that a type one error may occur and 
signifcant results may be the result of chance rather than an observable effect.  This was a 
concern for the study design and findings regarding this multiple testing and while steps 
were taken to reduce the risk of this issue of multiple testing it was not possible, and 
therefore remains a limitation, to eliminate the problem altogether. 
In the multi-nomial regression analyses there were 7 patient and 18 GP variables, and 
this analysis was being conducted multiple times, therefore, at least one of the signifcant 
findings could be assumed to be signifcant by chance.  Measures of fit were investigated, 
for multinomial regression in Stata it is recommended (Institute for digital research and 
education, no date) to refer to the ‘prob > chi2’ and ‘pseudo R2’, these were all <0.05 with 
the exception of the regression analysis for colorectal cancer with just the top and bottom 
decile included in the analysis.  The repetition of analyses with just the top and bottom 
deciles of GP practices also provided a sense check of sorts.  While some variables did 
change in significance the majoirty of findings from the larger analyses remained in the 
refined analyses, which suggests the findings are not simply by chance.  Equally once intial 
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analyses were conducted reduced variable models, where variables with no correlation 
were removed and analyses were conducted again, showed that signifcant results 
remained.  There is still a risk that the same signifcant results are coming up time and again 
by chance, but it is not possible to eliminate all type one error, however the repition of 
analyses using specific sample groups and reduced variable models does provide an 
opportunity to observe changes in signifcant findings.  
Breast and colorectal cancer were good cancer types to focus on for this project, but 
the availability of cancers with a good completeness rate of cancer stage at diagnosis was a 
problem.  The consideration at the start of this project had been to include at least three of 
the most common and priority cancer types for analysis, of which breast and colorectal are 
two, but also other cancer types such as lung.  However, upon consultation with NYCRIS it 
was discovered that cancer types such as lung had very low recording rates for cancer 
stage, less than 10%, while breast and colorectal had some of the highest rates.   
Despite being one of the better recorded cancer types, the colorectal data received 
from NYCRIS had nearly 50% of the cases assigned to an unknown stage of colorectal 
cancer.  However, this is in line with national statistics. 
An alternative may have been to use data from another cancer registry, but NYCRIS is 
one of the leading cancer registries for colorectal cancer and has the highest rate of 
completeness for colorectal cancer data.  Another alternative to using cancer registry data 
would have been to use the General Practice Records Database (GPRD), and this database 
has been widely used within research (Wood and Martinez, 2004, Glaser et al., 2013, 
Rachet et al., 2010, Hwang et al., 2009).  For this particular project using the GPRD would 
have raised issues of access, specifically a longer ethics process.  The GPRD is not disease 
specific, while the cancer registries are, and the cancer registries obtain their data from a 
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range of healthcare resources, including the GPRD, so hold better and more detailed data 
that was of benefit to this project.   
My own experience and knowledge was a limitation for this project, particularly in the 
beginning.  While I had experience of research and conducting a large scale study, I had not 
previously studied or worked within the area of NHS and healthcare research.  Specifically, I 
had no previous experience of NHS or NIGB ethic procedures and this was a large part of 
the early stages of the project, taking a total of nine months. 
For the data management and analysis it was recommended to use the statistical 
software package Stata.  This was not a statistical software package I had prior experience 
of using and therefore it required me to spend time learning, attend workshops, and simple 
trial and error on how the software worked, which took time.  I had also not used multi-
level modelling as an analysis method before, which again required attending workshops, 
seeking help from statisticians and trial and error.   
Working with the data once I had received it was also a process which took longer than 
anticipated.  Specifically data cleaning, for which there was a range of small problems from; 
errors in the data, missing and incomplete information, finding a method to merge the 
different databases and formatting and software issues.  For example, Stata is widely used 
within healthcare research but is not used by the NHS, so data that was received from 
NYCRIS and ERPHO had to be converted.  Efforts were made to keep the analysis 
straightforward and not over-manipulate the data; for the analysis this meant separating 
the data on occasion and running a number of individual tests, which took more time.  In 
essence there were a number of small and wide ranging issues which arose while working 
with the data which caused delays and meant the process took longer than anticipated. 
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7. 4.  Suggestions for future research and policy 
 
There are two key primary directions that future research in this area should take.  The 
first would be to include more cancer types.  What this project has demonstrated is that 
the level of influence that GP quality has upon a patient’s cancer stage, varied.  It has been 
established in previous research that the diagnosis, treatment and outcomes of different 
cancer types can vary widely (Allgar and Neal, 2005a, Baughan et al., 2009, de Nooijer et 
al., 2001, Rubin et al., 2011, Jones et al., 2009, Jones et al., 2007, Cancer Research UK, 
2013), which is why with over 200 different cancer types, understanding which cancer 
types are currently most, or least, influenced by GP quality is of importance for guiding and 
informing future policy and research.   
With this in mind the addition and/or inclusion of more cancer types, such as the other 
most common cancers of prostate, lung and skin, would be of benefit.  In this project while 
there were some similar results between breast and colorectal cancer there were also 
some distinct findings for both cancers.  Therefore, exploring what other cancer types are, 
or are not, associated with GP practice quality would be of benefit to identify cancer types 
which perhaps need to be prioritised at that level. 
Breast and colorectal cancer should also be included in any future research as they 
continue to be two of the most common cancers but also there is now more up-to-date 
data available for these two cancers, compared to time range of data used for this project.  
In particular a screening programme has since been introduced for colorectal cancer and 
new guidelines for the diagnosis and treatment of colorectal cancer have been introduced 
(Macmillan, 2012, Chew-Graham et al., 2013). 
The second key direction is the extension of the geographical area to include data from 
other cancer registries and/or national data.  This project was only conducted with data 
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from the North East region of England and its findings may differ in other regions of the 
country.   
Each region of England presents different geographical issues and these mean that 
different regions often face different challenges (Department of Health, 2013, National 
Cancer Intelligence Network, 2014, Walters et al., 2011, Rabe-Hesketh and Skrondal, 2012, 
Institute for digital research and education, nd, Goddard et al., 2010) and in particular it 
has been previously identified that there is a continued and clear North/South divide 
(Walters et al., 2011, Goddard et al., 2010, Whitehead and Doran, 2011, Rachet et al., 
2010).  Therefore, conducting this research in different geographies would not only provide 
the opportunity to investigate geography as a factor in the association between GP practice 
quality and cancer stage, but also enable more accurate and tailored findings for each 
region of the country. 
This project has demonstrated that multiple healthcare data sources can successfully 
be brought together, combined and analysed in a variety of ways. As outlined by the ESRC, 
it was one of the key aims and compulsory aspects of this project to utilise and combine 
existing sources of healthcare data.  While this was a novel approach at the start of this 
project, there is a growing interest and momentum within health research towards using 
and creating combined healthcare databases and secondary data analysis. 
Since the start of this project in 2009, other healthcare data has become available.  
Most notably the NCIN has produced GP practice cancer profiles, which first became 
available in 2012, and databases such as QOF and NYCRIS have been updated.  In the case 
of NYCRIS, cancer registries in England still operate on a regional level but the data from 
each registry is now collated in a central register, ENCORE, which enables registration staff 
to collate further information with reference to staging, such as pathology reports, imaging 
data etc.  There have also been recent developments within the overall management of 
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NHS data, with the introduction in 2013 of the General Practice Extraction Service (GPES).  
The GPES is now responsible for centrally managing and collating primary care data in 
England, including QOF.   
The key benefit of both of these initiatives is that regional data is now centrally held 
and national data is therefore available from one source.  For example, prior to ENCORE, 
acquiring national data would have required seeking approval and requesting the 
information from each of the regional cancer registries.  As a result future research should 
look to utilise these collated databases, and in the case of furthering this research, look to 
replicate this project with national level data. 
While there are national surveys of patient satisfaction and experience of primary care, 
GP practices do also conduct their own local and practice surveys of patient satisfaction.  As 
the area of patient experience and satisfaction was a key finding from this project, the 
inclusion of more and wider ranging patient survey data would be of benefit in future 
research. 
With the range of results in both breast and colorectal cases that demonstrated 
significant associations between the patient experience domain and specific QOF indicators 
from the patient experience domain, with cancer stage at diagnosis, it is suggested that the 
area of patient experience should be a focus of future research and policy.  GPs and 
primary care providers have been identified as key in not just providing access to secondary 
healthcare and specialist services  but actively contributing to improving early cancer 
diagnosis, outcomes and prevention (Richards, 2009, Daly and Collins, 2007, Thomson and 
Forman, 2009, Allgar and Neal, 2005b, Barrett et al., 2010).  Indicators from the patient 
experience domain of QOF are centred on access to GP services and this is an area that has 
been highlighted as a barrier to early diagnosis and future health outcomes (Daly and 
223 
 
Collins, 2007, Una et al., 2000, Hippisley-Cox et al., 2001, Robertson et al., 2004, Stevenson 
et al., 2003).   
The inclusion of further details regarding GP practices’ characteristics may also be a 
consideration for future research, as previous research has found an association between 
GP characteristics, such as; GPs’ qualifications (United Nations, 2007) and practice size 
(Walters et al., 2011), with the quality outcomes of the practice and patient experience and 
satisfaction. 
A growing focus on patient experience and satisfaction has already begun, both within 
research and healthcare organisations, and this project supports that direction of focus.  
The findings of this project found that indicators of patient experience and satisfaction had 
a significant effect upon cancer stage in both breast and colorectal cancer.  Many of these 
indicators related to a patient’s access to their GP, such as their reported ability to see a 
doctor within two days and the opening hours of the practice, and previous research has 
produced similar findings.  Therefore, in terms of policy it would seem that working 
towards improving a patient’s access to GP services and GPs’ relationships with patients to 
improve satisfaction should be a priority for healthcare policy. 
There are also a number of theoretical and methodological concepts that are 
acknowledged and discussed in this thesis, that future research should look to address and 
incorporate.  In particular the issues highlighted by Saunders and Abel (2014) regarding the 
generalisation of group/practice level data means that consideration about the use of 
alternative data to QOF is an implication for future research. 
The data that has been used in this research has moved forward signifcantly, not just 
improvements within QOF but equally a wider range of data resources are also now 
available.  In particular the development by the National Cancer Intelligence Network 
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(2014) of GP practice cancer profiles provides a more cancer specific alterntive to use as a 
measure of practice quality compared to QOF.  These profiles annually collect cancer 
specific data from GP practices and contain and provide details related to waiting times and 
screening which could be incorporated with the cancer registry data as outcome measure 
alongside cancer stage at diagnosis.  However, while these profiles are publically available 
they are again practice level measures of primary care quality where individual patient level 
data would be the best option. 
There is now a cancer specific national patient survey (Quality Health NHS England, 
2013), which while mainly focusing on treatment and longer term care provides data 
collected with regards to diagnosis and GP/patient interaction.  The national cancer patient 
survey also collects a range of demographic patient information which is not included in 
QOF, such as patients’ ethnicty, sexual orientation, employment status and the presence of 
other long term conditions.  Again broadening this research to incorpate this data provides 
cancer specific data, but again this is at an aggregated group level where individual patient 
level data would be preferable. 
7. 5.  Summary of the project 
 
The aim of this project was to investigate the potential link between GP practice quality 
and cancer stage at diagnosis, in breast and colorectal cancer in the North East of England.  
The objective was to achieve this by obtaining data from existing healthcare sources and 
databases and explore the potential link by using regression and multi-level analysis 
methods.  This project was funded by the ESRC as part of an e-health infrastructure 
initiative, in collaboration with the NIHR, to use and combine existing healthcare datasets 
for secondary data analysis. 
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Once ethical approval was gained from the NIGB, NHS research and ethics committee 
and Durham University School of medicine and health ethics committee, patient data was 
obtained from NYCRIS regarding breast and colorectal cancer cases between 2006-2008, 
and GP practice data was obtained from ERPHO and the NHS information centre.  All data 
was checked for errors before being converted and merged into Stata, with one dataset for 
colorectal cancer and the other for breast cancer. 
The two datasets were analysed separately using Stata and a range of statistical 
analyses; descriptive and distributional analyses, chi-squared test, correlation matrixes, 
regression analysis and multi-level analysis.  From the analysis the results were that while 
GP practice quality was found to contribute almost no variance for cancer stage at 
diagnosis in colorectal cancer, an association was found between breast cancer stage and 
GP practice quality.  From the regression analysis, specific practice indicators from the 
patient experience domain of QOF were found to have a significant impact on cancer stage 
in both breast and colorectal cancer.  Associations between cancer stage and patient age 
and income domain were also found in both breast and colorectal cancer. 
This project was successful in meeting its aims and objectives.  Different datasets were 
combined and analysed to find an association between GP practice quality and breast 
cancer and while a similar association was not found with colorectal cancer specific GP 
practice variables such as patient experience were found to have a significant affect upon 
cancer stage. 
It is hoped these findings can be used to direct and prompt future research and policy.  
It is suggested that this research could be expanded to include other cancer types and 
geographical regions of England and that further investigation into the effect and influence 
of patient experience and satisfaction on cancer stage would be particularly recommended 
for future policy research.  Since this project was started the datasets used have also been 
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improved and updated, and new sources of data, i.e. cancer practice profiles, ENCORE and 
GPES, have been created and made available.  This project has demonstrated that such 
datasets can successfully be combined and analysed and it is hoped that future research 
will utilise these new and existing datasets. 
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9. Appendix 
Appendix 1.  Ethical approval letter from NHS REC 
Sunderland Research Ethics Committee 
Room 002 
TEDCO Business Centre 
Viking Business Park 
Jarrow 
Tyne & Wear 
NE32 3DT 
 
Telephone: 0191 428 3566  
Facsimile: 0191 428 3432 
07 January 2011 
 
Ms. Helen Wareham 
Wolfson Research Institute 
Durham University, Queen's Campus 
Stockton on Tees 
TS17 6BH 
 
 
Dear Ms. Wareham 
 
Full title of study: Does good practice quality equate to earlier cancer stage at 
diagnosis? 
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REC reference number: 11/H0904/4 
 
The Proportionate Review Sub Committee of the Sunderland Research Ethics 
Committee reviewed the above application on 14 January 2011 via email correspondence. 
 
Ethical Opinion 
 
The Committee's main concern was that insufficient detail was given on the way data is 
to be processed before regression analysis and therefore it is not clear how the research 
question will be answered.  
The name of a statistician is given but not details of the way data will be processed. 
More information was requested on the way data is to be processed before regression 
analysis.  
The cancer stages of patients when they are referred for breast colorectal and lung 
cancer are to be extracted from the Northern and Yorkshire Cancer Registry and 
Information Service. More information was requested on how this data will be prepared for 
regression analysis. 
 Information on GP practice quality is given by sex, age band, deprivation index, patient 
satisfaction, practice demographics. How will this information be quantified for regression 
analysis? 
More information on the regression analysis needs to be given. 4. Will all 2500 patient 
cancer records be used in the analysis? 
 
You kindly responded to the queries as follows: 
The data that will be used for this research is coming from existing databases, which 
have been widely used for analysis and research.  Initial preparation will involve moving the 
data from excel files, as they will be supplied by NYCRIS and from the public health 
observatory websites in this format, and combining them into stata.  The cancer staging 
data will be linked with the relevant practice data from the practice profiles through the GP 
practice code, which NYCRIS will supply along with the cancer data. 
   
In the case of the cancer data, staging data for all three cancers will be in the TNM 
staging system.  It is the aim that all cancer records that are provide by NYCRIS should be 
used.   
The GP practice information is already in an interval format as many of the variables, 
particularly the ones being used in this research, have come from the QOF and GP patient 
survey data. The majority of this data, with the exception of deprivation index, is provided 
as a percentage and provides upper and lower confidence intervals for each variable as well 
as comparable data for PCT and national level. 
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It was decided that a regression analysis, specifically using general linear or stepwise 
models, would be best as these allow for the combination of interval and nominal 
datasets.  There is also the potential to use multi-level modeling as an additional method of 
analysis to further investigate the relationship between practice quality and cancer stage at 
diagnosis should any link be found via the regression analysis. 
On behalf of the Committee, the sub committee gave a favourable ethical opinion of 
the above research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
Ethical review of research sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see ‘Conditions of the favourable opinion’ below). 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the 
start of the study. 
Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned. 
The favourable opinion is subject to the following conditions being met 
prior to the start of the study. 
  
Management permission or approval must be obtained from each host 
organisation prior to the start of the study at the site concerned. 
  
Management permission (“R&D approval”) should be sought from all NHS 
organisation(s) involved in the study in accordance with NHS research 
governance arrangements.  Guidance on applying for NHS permission for 
research is available in the Integrated Research Application System (IRAS) or at 
http://www.rdforum.nhs.uk. 
  
Where a NHS organisation’s role in the study is limited to identifying and 
referring potential participants to research sites (“participant identification 
centre”), guidance should be sought from the R&D office on the information it 
requires to give permission for this activity. 
  
For non-NHS sites, site management permission should be obtained in 
accordance with the procedures of the relevant host organisation.  
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Sponsors are not required to notify the Committee of approvals from host 
organisations. 
 
Approved Documents 
 
The documents reviewed and approved were: 
 
  
Document    Version    Date      
REC application  IRAS 3.1  30 December 
2010  
  
Peer Review Letter  1  07 December 
2010  
  
Protocol  1  30 December 
2010  
  
Evidence of insurance or indemnity  1 - 
Professional 
Indemnity  
05 July 2010    
Evidence of insurance or indemnity  1 - 
Employer''s 
Liability  
02 July 2010    
Investigator CV  1  30 December 
2010  
  
Investigator CV  1  20 December 
2010  
  
Email correspondence from NIGB  1       
 
Membership of the Proportionate Review Sub Committee 
 
The members of the sub-committee who took part in the review are listed on the 
attached sheet. 
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Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
After Ethical Review 
 
Now that you have completed the application process please visit the National 
Research Ethics Service website  >After Review 
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure.  If you wish to make your 
views known please use the feedback form available on the website. 
 
The attached document ‘After ethical review – guidance for researchers’ gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light 
of changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to 
improve our service.  If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk 
 
 
11/H0904/4   Please quote this number on all correspondence 
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With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
 
 
Cheryl Anderson 
Vice Chair 
 
Email: leigh.pollard@nhs.net 
 
Enclosures:   List of names and professions of members who took part in the review 
 
                      ‘After ethical review – guidance for researchers’ 
 
Copy to: Professor D Petley Dept of Geography, Durham University, South Road, 
Durham, DH1 3LE 
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Sunderland Research Ethics Committee 
 
Attendance at PRS Sub-Committee of the REC meeting on 14 January 2011 via email 
correspondence 
 
 
Mrs Cheryl Anderson Vice Chair  Lay Member 
Mrs Gaynor Mitchell     Lay Member 
Mrs J Ryan      Expert Member (Co-Opted) 
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Table 20.  Appendix 2, correlation table of colorectal cancer variables.  *p = <.05 
 
 
Table 21.  Appendix 3, correlation table of breast cancer variables.  * p = <.05 
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Table 22.  Appendix 4.  Regression output for colorectal cancer 
 
Multinomial logistic regression                   Number of obs   =      11491 
                                                  LR chi2(84)     =     145.84 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -17880.668                       Pseudo R2       =     0.0041 
 
------------------------------------------------------------------------------ 
       Stage |        RRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
1            |  (base outcome) 
-------------+---------------------------------------------------------------- 
2            | 
         Sex |   1.032102    .076307     0.43   0.669     .8928742     1.19304 
        Age2 |   1.160068   .0975249     1.77   0.077     .9838401    1.367863 
incomedomain |   1.065076   .0317825     2.11   0.035      1.00457    1.129226 
        qofC |   1.030055   .0610158     0.50   0.617     .9171473    1.156863 
        qofO |   1.030545   .0609877     0.51   0.611     .9176832    1.157287 
        qofP |   1.022179   .0605732     0.37   0.711     .9100932     1.14807 
        qofA |   1.047298    .065228     0.74   0.458     .9269489    1.183273 
    qofTotal |   .9723868   .0575794    -0.47   0.636     .8658359     1.09205 
cancerrevi~V |   1.197309    .578635     0.37   0.709     .4643419     3.08727 
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 cancerprevV |   .1904272     1.5864    -0.20   0.842     1.54e-08     2348928 
exceptionr~V |   .7155785   .4900084    -0.49   0.625     .1869726     2.73865 
    elderlyV |   17.38697   53.40134     0.93   0.352     .0422565    7154.096 
deprivationV |   .9934199   .0093556    -0.70   0.483     .9752515    1.011927 
     IDAOPIV |   .5018519   .6859069    -0.50   0.614     .0344504    7.310662 
phoneaccessV |    1.15257   .4161332     0.39   0.694     .5679922    2.338794 
  drtwodaysV |   .6972154   .4446193    -0.57   0.572     .1997789    2.433237 
    bookingV |   1.323565   .6834361     0.54   0.587     .4810814    3.641428 
  openhoursV |   .9459607   .7995883    -0.07   0.948     .1804602    4.958664 
perferredGPV |   1.178247   .4607914     0.42   0.675     .5474527    2.535865 
seventyfiveV |   .0047524    .030498    -0.83   0.405     1.64e-08    1378.366 
 eightyfiveV |   .0537416    .506442    -0.31   0.756     5.12e-10     5645837 
-------------+---------------------------------------------------------------- 
3            | 
         Sex |   .9861577   .0740705    -0.19   0.853     .8511626    1.142563 
        Age2 |   .8795283   .0733831    -1.54   0.124     .7468445    1.035785 
incomedomain |   1.057005   .0319976     1.83   0.067     .9961153    1.121617 
        qofC |   1.039984   .0624736     0.65   0.514     .9244721     1.16993 
        qofO |   1.042611   .0625695     0.70   0.487     .9269141    1.172748 
        qofP |   1.041033     .06256     0.67   0.503     .9253633    1.171161 
        qofA |   1.069427   .0675764     1.06   0.288     .9448526    1.210425 
    qofTotal |   .9619481   .0577644    -0.65   0.518     .8551406    1.082096 
254 
 
cancerrevi~V |   .6533923   .3105134    -0.90   0.371     .2574276    1.658413 
 cancerprevV |   .0161077   .1360587    -0.49   0.625     1.04e-09    249443.6 
exceptionr~V |   .6059449   .4101525    -0.74   0.459     .1607944    2.283469 
    elderlyV |   18.29217    56.9276     0.93   0.350     .0410408    8152.941 
deprivationV |   1.000379   .0095396     0.04   0.968     .9818558    1.019252 
     IDAOPIV |   .3577681   .4950897    -0.74   0.458     .0237511    5.389129 
phoneaccessV |   1.326689   .4872059     0.77   0.441     .6459199    2.724957 
  drtwodaysV |   .3773445   .2441515    -1.51   0.132     .1061669     1.34118 
    bookingV |    .943334   .4923406    -0.11   0.911     .3391645    2.623739 
  openhoursV |   .4855748   .4158205    -0.84   0.399     .0906426    2.601237 
perferredGPV |   1.201872   .4773238     0.46   0.643     .5518272     2.61766 
seventyfiveV |   .0027774   .0180786    -0.90   0.366     8.00e-09      964.56 
 eightyfiveV |   42.34847   404.2759     0.39   0.695     3.17e-07    5.66e+09 
-------------+---------------------------------------------------------------- 
4            | 
         Sex |   1.006825   .0739335     0.09   0.926     .8718627    1.162678 
        Age2 |   .8312587   .0676645    -2.27   0.023     .7086771    .9750436 
incomedomain |   1.120863   .0331937     3.85   0.000     1.057656    1.187846 
        qofC |   1.030061   .0605388     0.50   0.614     .9179856    1.155819 
        qofO |   1.033014   .0606538     0.55   0.580     .9207198    1.159003 
        qofP |   1.013799   .0596247     0.23   0.816     .9034208    1.137663 
        qofA |   1.057608   .0653515     0.91   0.365     .9369737    1.193773 
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    qofTotal |   .9713624   .0570721    -0.49   0.621     .8657035    1.089917 
cancerrevi~V |   .9386144   .4399113    -0.14   0.892     .3745801    2.351959 
 cancerprevV |   .0001264   .0010437    -1.09   0.277     1.18e-11    1350.129 
exceptionr~V |   .6655139   .4425227    -0.61   0.540     .1807858    2.449908 
    elderlyV |   59.44135   181.5047     1.34   0.181     .1496017    23617.88 
deprivationV |   .9931029   .0092393    -0.74   0.457     .9751582    1.011378 
     IDAOPIV |   1.145689   1.543013     0.10   0.920     .0817843    16.04959 
phoneaccessV |   1.246182   .4460212     0.61   0.539     .6179141    2.513247 
  drtwodaysV |   1.431969   .9080253     0.57   0.571     .4132174    4.962365 
    bookingV |    2.20665   1.145002     1.53   0.127     .7980975    6.101138 
  openhoursV |   .9697271   .8142144    -0.04   0.971      .187048     5.02743 
perferredGPV |   1.383412   .5354498     0.84   0.402     .6478789    2.953991 
seventyfiveV |   .0001058   .0006758    -1.43   0.152     3.88e-10    28.83436 
 eightyfiveV |   296.6377   2782.607     0.61   0.544     3.07e-06    2.86e+10 
-------------+---------------------------------------------------------------- 
Unknown      | 
         Sex |   .9373915   .0678862    -0.89   0.372     .8133485    1.080352 
        Age2 |   .9087217   .0733184    -1.19   0.235     .7758065    1.064409 
incomedomain |   1.137169    .033238     4.40   0.000     1.073854    1.204216 
        qofC |   1.022993   .0592971     0.39   0.695     .9131317    1.146072 
        qofO |   1.023982    .059299     0.41   0.682      .914111    1.147058 
        qofP |   1.023363   .0593456     0.40   0.690     .9134148    1.146546 
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        qofA |   1.043463   .0636073     0.70   0.485     .9259549    1.175884 
    qofTotal |   .9786313   .0567062    -0.37   0.709     .8735681     1.09633 
cancerrevi~V |   1.291854   .6082395     0.54   0.587     .5133871    3.250738 
 cancerprevV |   .0008542   .0069457    -0.87   0.385     1.02e-10    7127.439 
exceptionr~V |   .5477527   .3676425    -0.90   0.370     .1469848    2.041253 
    elderlyV |   128.6995   386.5041     1.62   0.106     .3575115    46330.17 
deprivationV |   .9915663   .0090829    -0.92   0.355      .973923    1.009529 
     IDAOPIV |   .8115994   1.076209    -0.16   0.875     .0603418    10.91603 
phoneaccessV |   1.198323   .4223868     0.51   0.608      .600539     2.39115 
  drtwodaysV |   .2197106    .136122    -2.45   0.014     .0652361    .7399702 
    bookingV |   .7807198   .3890265    -0.50   0.619     .2940006    2.073204 
  openhoursV |   2.550401   2.109622     1.13   0.258     .5041012    12.90325 
perferredGPV |   .8899758   .3393884    -0.31   0.760     .4214793    1.879231 
seventyfiveV |   .0032136   .0201792    -0.91   0.361     1.45e-08    711.1029 
 eightyfiveV |   .0050196   .0462717    -0.57   0.566     7.15e-11    352548.1 
 
Table 23.  Appendix 5.  Regression output for colorectal cancer of top and bottom deciles of QOF total score 
Multinomial logistic regression                   Number of obs   =       2340 
                                                  LR chi2(84)     =      75.41 
                                                  Prob > chi2     =     0.7374 
Log likelihood = -3643.9045                       Pseudo R2       =     0.0102 
 
------------------------------------------------------------------------------ 
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       Stage |        RRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
1            |  (base outcome) 
-------------+---------------------------------------------------------------- 
2            | 
         Sex |   .9864838   .1553375    -0.09   0.931     .7245273    1.343152 
        Age2 |   1.121778     .20584     0.63   0.531     .7829182    1.607303 
incomedomain |   1.112701   .0739612     1.61   0.108     .9767858    1.267529 
        qofC |   1.239765   .1667042     1.60   0.110     .9525397    1.613599 
        qofO |   1.245419   .1684634     1.62   0.105     .9553811    1.623509 
        qofP |   1.199817   .1619154     1.35   0.177     .9209692    1.563092 
        qofA |   1.234899   .1737997     1.50   0.134     .9372025    1.627157 
    qofTotal |    .811796   .1091731    -1.55   0.121     .6236981    1.056621 
cancerrevi~V |   1.726359   1.244037     0.76   0.449     .4204784    7.087912 
 cancerprevV |   3.94e-07   7.73e-06    -0.75   0.452     7.97e-24    1.95e+10 
exceptionr~V |   5.014416   5.685237     1.42   0.155     .5434333    46.26946 
    elderlyV |   511.2832   3507.496     0.91   0.363     .0007401    3.53e+08 
deprivationV |   .9942759   .0200788    -0.28   0.776     .9556908    1.034419 
     IDAOPIV |   .2163749   .5941278    -0.56   0.577     .0009953    47.03896 
phoneaccessV |   1.623881     1.2827     0.61   0.539     .3452963    7.636887 
  drtwodaysV |   8.701534   12.56803     1.50   0.134     .5130571    147.5795 
    bookingV |   3.361388   4.870427     0.84   0.403     .1964194    57.52452 
  openhoursV |   .4849207   .9384503    -0.37   0.708     .0109237    21.52641 
perferredGPV |   .1617983   .1584511    -1.86   0.063     .0237346    1.102977 
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seventyfiveV |   .0336886   .4651799    -0.25   0.806     5.94e-14    1.91e+10 
 eightyfiveV |   .0023947    .044335    -0.33   0.744     4.17e-19    1.38e+13 
-------------+---------------------------------------------------------------- 
3            | 
         Sex |   .9653234   .1539466    -0.22   0.825     .7061973    1.319531 
        Age2 |   .7878737   .1417161    -1.33   0.185     .5537958    1.120892 
incomedomain |    1.06973   .0716139     1.01   0.314     .9381874    1.219715 
        qofC |   1.091389   .1490888     0.64   0.522     .8350292    1.426454 
        qofO |     1.0912   .1498064     0.64   0.525     .8337705    1.428113 
        qofP |   1.051057   .1440357     0.36   0.716     .8034864    1.374909 
        qofA |   1.104938   .1585918     0.70   0.487     .8339974    1.463898 
    qofTotal |   .9228917   .1260974    -0.59   0.557     .7060713    1.206293 
cancerrevi~V |   .5947928   .4006974    -0.77   0.441     .1588298    2.227406 
 cancerprevV |   2.36e-07   4.68e-06    -0.77   0.442     3.08e-24    1.81e+10 
exceptionr~V |   2.076705   2.238822     0.68   0.498     .2510293    17.18007 
    elderlyV |   399.9446    2778.55     0.86   0.388      .000488    3.28e+08 
deprivationV |   1.005586   .0203959     0.27   0.784     .9663946    1.046366 
     IDAOPIV |   .1595574    .439153    -0.67   0.505     .0007247     35.1314 
phoneaccessV |   1.928976   1.548565     0.82   0.413     .3999353    9.303879 
  drtwodaysV |   2.177459    3.19502     0.53   0.596      .122735     38.6306 
    bookingV |   4.737193   6.909132     1.07   0.286     .2716784    82.60133 
  openhoursV |   .6672062   1.317245    -0.20   0.838     .0139238     31.9714 
perferredGPV |   1.011468   1.003276     0.01   0.991     .1447586    7.067403 
seventyfiveV |   .0217169   .3029134    -0.27   0.784     2.91e-14    1.62e+10 
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 eightyfiveV |   .4625606   8.672615    -0.04   0.967     5.08e-17    4.21e+15 
-------------+---------------------------------------------------------------- 
4            | 
         Sex |   1.017256   .1607362     0.11   0.914     .7463327    1.386527 
        Age2 |   .7303373   .1298515    -1.77   0.077     .5154455    1.034818 
incomedomain |   1.139022   .0758125     1.96   0.050     .9997165     1.29774 
        qofC |   1.182106   .1607277     1.23   0.219     .9055672    1.543092 
        qofO |   1.184178   .1617138     1.24   0.216     .9060975      1.5476 
        qofP |   1.127548    .153744     0.88   0.379      .863121    1.472986 
        qofA |     1.2044   .1714425     1.31   0.191     .9111812    1.591976 
    qofTotal |   .8493387    .115453    -1.20   0.230     .6506908    1.108631 
cancerrevi~V |    1.59098   1.086005     0.68   0.496     .4174778    6.063115 
 cancerprevV |   1.86e-13   3.66e-12    -1.49   0.136     3.49e-30    9944.041 
exceptionr~V |   5.120608   5.448875     1.53   0.125     .6361391    41.21839 
    elderlyV |   4047.497   27924.52     1.20   0.229     .0054271    3.02e+09 
deprivationV |   .9797776   .0197509    -1.01   0.311     .9418213    1.019264 
     IDAOPIV |   1.821004   4.949306     0.22   0.825     .0088477    374.7927 
phoneaccessV |   2.133905     1.6889     0.96   0.338     .4523588    10.06623 
  drtwodaysV |   9.185653   13.35165     1.53   0.127     .5319377    158.6205 
    bookingV |   13.36697   19.25134     1.80   0.072     .7945435    224.8786 
  openhoursV |    1.59959   3.143182     0.24   0.811     .0339941    75.26855 
perferredGPV |   .3963011   .3876373    -0.95   0.344     .0582683    2.695369 
seventyfiveV |   .0000413   .0005726    -0.73   0.467     6.38e-17    2.67e+07 
 eightyfiveV |   .0001908   .0035892    -0.46   0.649     1.87e-20    1.95e+12 
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-------------+---------------------------------------------------------------- 
Unknown      | 
         Sex |   .9446125   .1444725    -0.37   0.709     .6999513    1.274793 
        Age2 |   .8135653   .1410252    -1.19   0.234     .5792197    1.142724 
incomedomain |   1.117073   .0718065     1.72   0.085     .9848395    1.267061 
        qofC |   1.142916   .1486379     1.03   0.304     .8857564    1.474736 
        qofO |   1.141261   .1491922     1.01   0.312     .8833061    1.474549 
        qofP |   1.107889   .1444388     0.79   0.432     .8580696    1.430441 
        qofA |   1.126441   .1534115     0.87   0.382     .8625456    1.471074 
    qofTotal |   .8790489   .1143043    -0.99   0.321     .6812865    1.134217 
cancerrevi~V |   1.384858   .9148405     0.49   0.622     .3794017    5.054882 
 cancerprevV |   1.51e-06   .0000288    -0.70   0.482     9.13e-23    2.49e+10 
exceptionr~V |   1.592944   1.756097     0.42   0.673     .1835764    13.82242 
    elderlyV |   10.73257   71.56708     0.36   0.722     .0000226     5089796 
deprivationV |   .9862183   .0193606    -0.71   0.480     .9489929    1.024904 
     IDAOPIV |   .8695913   2.309707    -0.05   0.958     .0047693     158.554 
phoneaccessV |   1.531626   1.175529     0.56   0.579     .3402923    6.893715 
  drtwodaysV |   3.071715   4.288165     0.80   0.421     .1991083    47.38844 
    bookingV |   5.561176   7.783932     1.23   0.220     .3578879    86.41444 
  openhoursV |   .7616285   1.438792    -0.14   0.885     .0187819    30.88498 
perferredGPV |   .5570431   .5268776    -0.62   0.536     .0872534    3.556275 
seventyfiveV |   3.481399    46.5542     0.09   0.926     1.44e-11    8.40e+11 
 eightyfiveV |   .0011639   .0209669    -0.38   0.708     5.39e-19    2.51e+12 
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Table 24.  Appendix 6.  Regression output for breast cancer 
 
Multinomial logistic regression                   Number of obs   =       8646 
                                                  LR chi2(80)     =     614.05 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -11270.588                       Pseudo R2       =     0.0265 
 
------------------------------------------------------------------------------ 
       stage |        RRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
1            |  (base outcome) 
-------------+---------------------------------------------------------------- 
2            | 
         Age |   1.042447   .0544917     0.80   0.426     .9409341    1.154911 
income_dom~n |   1.013582   .0217131     0.63   0.529     .9719058    1.057045 
        qofC |    1.01864   .0427464     0.44   0.660     .9382111    1.105963 
        qofO |   1.018075   .0425475     0.43   0.668     .9380073    1.104977 
        qofP |   1.018787   .0427238     0.44   0.657     .9383992    1.106062 
        qofA |   .9950925   .0439985    -0.11   0.911     .9124879    1.085175 
    qofTotal |   .9834413   .0412352    -0.40   0.690     .9058537    1.067675 
  cancerrevV |   1.178704   .3931829     0.49   0.622       .61301    2.266428 
 cancerprevV |   49.30148   285.7124     0.67   0.501     .0005754     4224267 
exceptionr~V |   1.136761   .5863657     0.25   0.804     .4136194    3.124188 
    elderlyV |   .0385173   .0827565    -1.52   0.130     .0005712    2.597221 
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deprivationV |    1.01108   .0066198     1.68   0.092     .9981883    1.024138 
     IDAOPIV |   .5010236   .4683795    -0.74   0.460     .0801893      3.1304 
phoneaccessV |   1.185202   .3012523     0.67   0.504     .7201714    1.950515 
  drtwodaysV |   .7822216   .3498785    -0.55   0.583     .3255348    1.879586 
    bookingV |   .5607552     .20848    -1.56   0.120     .2705888    1.162082 
openinghou~V |   .4791623   .2877029    -1.23   0.220     .1477054    1.554421 
   preferGPV |   1.699778   .4668472     1.93   0.053     .9922204    2.911899 
seventyfiveV |   458.1953    2070.27     1.36   0.175     .0653213     3214006 
 eightyfiveV |   .0376273   .2476771    -0.50   0.618     9.39e-08    15081.07 
-------------+---------------------------------------------------------------- 
3            | 
         Age |   1.090611   .0913863     1.04   0.301      .925432    1.285272 
income_dom~n |   1.008439   .0346597     0.24   0.807     .9427449    1.078711 
        qofC |   1.032593   .0695653     0.48   0.634     .9048658     1.17835 
        qofO |    1.05533   .0708137     0.80   0.422     .9252767    1.203662 
        qofP |   1.039295    .070006     0.57   0.567     .9107571    1.185974 
        qofA |   1.012544   .0717393     0.18   0.860     .8812633    1.163381 
    qofTotal |   .9661939   .0650319    -0.51   0.609     .8467832    1.102444 
  cancerrevV |   1.130923   .5946247     0.23   0.815      .403536    3.169449 
 cancerprevV |   .0267991   .2513739    -0.39   0.700     2.78e-10     2584193 
exceptionr~V |    .966559   .7780918    -0.04   0.966     .1995266    4.682265 
    elderlyV |   .0142491   .0494922    -1.22   0.221     .0000157    12.89185 
deprivationV |   1.008611   .0103592     0.83   0.404     .9885101     1.02912 
     IDAOPIV |   1.022509   1.480932     0.02   0.988     .0598198    17.47791 
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phoneaccessV |    1.02986   .4236097     0.07   0.943     .4598914     2.30622 
  drtwodaysV |   .6356859   .4615495    -0.62   0.533     .1531844    2.637974 
    bookingV |   1.070482    .671734     0.11   0.914     .3129288    3.661959 
openinghou~V |   .2032289   .1963322    -1.65   0.099     .0305964    1.349898 
   preferGPV |   1.891914   .8418636     1.43   0.152     .7909225    4.525525 
seventyfiveV |    1012.47   7373.727     0.95   0.342       .00064    1.60e+09 
 eightyfiveV |   .0000402   .0004262    -0.95   0.340     3.77e-14    42822.12 
-------------+---------------------------------------------------------------- 
4            | 
         Age |   2.146935   .2071182     7.92   0.000      1.77706    2.593795 
income_dom~n |   1.093708   .0436122     2.25   0.025     1.011485    1.182615 
        qofC |     .82093   .0634539    -2.55   0.011     .7055249    .9552123 
        qofO |   .8198378    .063129    -2.58   0.010     .7049915    .9533931 
        qofP |   .8243793   .0636973    -2.50   0.012     .7085284    .9591728 
        qofA |   .8028211   .0649018    -2.72   0.007     .6851816    .9406581 
    qofTotal |   1.218007   .0940725     2.55   0.011     1.046905    1.417073 
  cancerrevV |   1.097795   .6402831     0.16   0.873     .3499956    3.443341 
 cancerprevV |   .3869602   4.137073    -0.09   0.929     3.07e-10    4.88e+08 
exceptionr~V |   1.426103   1.262478     0.40   0.688     .2515431    8.085169 
    elderlyV |   1421.028   5690.165     1.81   0.070     .5548429     3639444 
deprivationV |   1.002258   .0117485     0.19   0.847     .9794937    1.025551 
     IDAOPIV |   6.539637   10.78184     1.14   0.255     .2583362    165.5473 
phoneaccessV |   .8833132   .4071103    -0.27   0.788     .3579352    2.179842 
  drtwodaysV |   1.577513   1.277081     0.56   0.573     .3227603    7.710203 
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    bookingV |   .5671669   .3820578    -0.84   0.400     .1514678    2.123741 
openinghou~V |   .2706802    .299092    -1.18   0.237     .0310391    2.360499 
   preferGPV |    1.47645   .7344652     0.78   0.433     .5569109     3.91428 
seventyfiveV |   2.99e-07   2.53e-06    -1.78   0.075     1.96e-14    4.580244 
 eightyfiveV |   6.668179   81.86139     0.15   0.877     2.37e-10    1.88e+11 
-------------+---------------------------------------------------------------- 
unknown      | 
         Age |   5.261777   .4883817    17.89   0.000     4.386586    6.311583 
income_dom~n |    1.06711   .0363513     1.91   0.057     .9981896     1.14079 
        qofC |   1.025193   .0682651     0.37   0.709     .8997591    1.168114 
        qofO |   1.022637   .0677688     0.34   0.736     .8980769    1.164473 
        qofP |   1.024137   .0680862     0.36   0.720     .8990189    1.166668 
        qofA |   1.052621   .0739961     0.73   0.466     .9171389    1.208117 
    qofTotal |   .9756474   .0648885    -0.37   0.711     .8564086    1.111488 
  cancerrevV |   .3242332   .1580274    -2.31   0.021      .124736    .8427971 
 cancerprevV |   4.44e+08   4.05e+09     2.19   0.029      7.77811    2.54e+16 
exceptionr~V |   .2733443   .2312044    -1.53   0.125     .0520875    1.434455 
    elderlyV |   10.53973   35.63656     0.70   0.486     .0139565    7959.442 
deprivationV |   .9962867    .010156    -0.36   0.715     .9765788    1.016392 
     IDAOPIV |   3.771301   5.477904     0.91   0.361     .2188269    64.99525 
phoneaccessV |   1.294933    .518162     0.65   0.518      .591075    2.836952 
  drtwodaysV |   .3667392   .2527654    -1.46   0.146     .0949924    1.415878 
    bookingV |   .6036123   .3339736    -0.91   0.362     .2040776    1.785339 
openinghou~V |   13.08558   12.66998     2.66   0.008     1.961667    87.28919 
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   preferGPV |   2.060301   .8971706     1.66   0.097     .8775454    4.837172 
seventyfiveV |   1.193635   8.556229     0.02   0.980     9.45e-07     1508227 
 eightyfiveV |   3.05e-11   3.15e-10    -2.34   0.019     4.87e-20    .0191493 
------------------------------------------------------------------------------ 
 
Table 25.  Appendix 7.  Regression output for breast cancer with top and bottom deciles of QOF total score 
 
Multinomial logistic regression                   Number of obs   =       1727 
                                                  LR chi2(80)     =     195.28 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -2194.4279                       Pseudo R2       =     0.0426 
 
------------------------------------------------------------------------------ 
       stage |        RRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
1            |  (base outcome) 
-------------+---------------------------------------------------------------- 
2            | 
         Age |   1.108509   .1310879     0.87   0.384     .8791834    1.397652 
income_dom~n |   1.056981   .0521006     1.12   0.261     .9596429    1.164191 
        qofC |   .9775084   .0987685    -0.23   0.822     .8018888     1.19159 
        qofO |    .966692   .0977286    -0.34   0.738     .7929305    1.178531 
        qofP |   .9877455    .100678    -0.12   0.904     .8088809    1.206162 
        qofA |   .9387794    .099714    -0.59   0.552     .7623454    1.156047 
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    qofTotal |    1.02502   .1036244     0.24   0.807     .8407757    1.249639 
  cancerrevV |   1.412999    .760858     0.64   0.521     .4918074     4.05965 
 cancerprevV |   2738.223   39360.23     0.55   0.582     1.59e-09    4.71e+15 
exceptionr~V |   1.326661   1.121657     0.33   0.738      .252983    6.957104 
    elderlyV |   .0047423    .024161    -1.05   0.294     2.18e-07    102.9585 
deprivationV |   1.007284   .0143239     0.51   0.610     .9795969    1.035753 
     IDAOPIV |   .0969202   .1871721    -1.21   0.227     .0022008    4.268277 
phoneaccessV |   .5852591   .3384546    -0.93   0.354      .188408    1.818013 
  drtwodaysV |   .1238527   .1238695    -2.09   0.037     .0174417    .8794723 
    bookingV |   .2703389   .2807855    -1.26   0.208     .0353032    2.070154 
openinghou~V |   15.74729   22.58827     1.92   0.055     .9467226    261.9321 
   preferGPV |   3.613834   2.595667     1.79   0.074     .8842711    14.76899 
seventyfiveV |   .0974664   1.004512    -0.23   0.821     1.65e-10    5.77e+07 
 eightyfiveV |   21886.14   290449.7     0.75   0.451     1.11e-07    4.33e+15 
-------------+---------------------------------------------------------------- 
3            | 
         Age |   1.410984   .2718856     1.79   0.074     .9671686    2.058458 
income_dom~n |   .9741418   .0787535    -0.32   0.746     .8313955    1.141397 
        qofC |   .7021741   .1199009    -2.07   0.038     .5024541    .9812804 
        qofO |   .7158411   .1225239    -1.95   0.051     .5118283    1.001172 
        qofP |   .6977628    .120189    -2.09   0.037     .4978393     .977972 
        qofA |   .6366102    .112064    -2.57   0.010     .4508526    .8989025 
    qofTotal |   1.428738   .2438966     2.09   0.037     1.022459    1.996454 
  cancerrevV |   .7307671   .6349939    -0.36   0.718     .1330867    4.012577 
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 cancerprevV |   2.68e+14   6.56e+15     1.36   0.174     4.04e-07    1.78e+35 
exceptionr~V |   2.477506   2.814689     0.80   0.425       .26728    22.96481 
    elderlyV |   .0693259   .5887766    -0.31   0.753     4.09e-09     1175028 
deprivationV |    1.00546   .0237678     0.23   0.818     .9599387     1.05314 
     IDAOPIV |   3.637991   11.35137     0.41   0.679     .0080337     1647.43 
phoneaccessV |   .3718741   .3521435    -1.04   0.296     .0581242    2.379222 
  drtwodaysV |   .9712897    1.57668    -0.02   0.986     .0403279     23.3933 
    bookingV |    1.45388   2.528004     0.22   0.830      .048135     43.9133 
openinghou~V |   1.312692    3.13251     0.11   0.909     .0122157     141.061 
   preferGPV |   6.425006   7.530232     1.59   0.112     .6460243    63.89962 
seventyfiveV |   1.228242    21.1983     0.01   0.990     2.50e-15    6.03e+14 
 eightyfiveV |   6.35e-06    .000143    -0.53   0.595     4.13e-25    9.75e+13 
-------------+---------------------------------------------------------------- 
4            | 
         Age |   2.324933   .5204974     3.77   0.000     1.499155    3.605573 
income_dom~n |   1.160946   .1108063     1.56   0.118     .9628732    1.399764 
        qofC |   .5883319   .1218686    -2.56   0.010     .3920147    .8829628 
        qofO |   .5850423   .1210186    -2.59   0.010      .390043    .8775302 
        qofP |   .5954316   .1237935    -2.49   0.013     .3961525    .8949552 
        qofA |   .5638045   .1221204    -2.65   0.008     .3687718    .8619843 
    qofTotal |   1.705661   .3532591     2.58   0.010     1.136581    2.559675 
  cancerrevV |   .3517401   .3068456    -1.20   0.231     .0636303    1.944375 
 cancerprevV |    3.95254   108.1393     0.05   0.960     2.03e-23    7.68e+23 
exceptionr~V |   .7703513   1.004297    -0.20   0.841     .0598396    9.917204 
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    elderlyV |     444634    4444335     1.30   0.193     .0013798    1.43e+14 
deprivationV |   .9962126   .0265176    -0.14   0.887     .9455715    1.049566 
     IDAOPIV |   3.077347   10.80179     0.32   0.749      .003165    2992.113 
phoneaccessV |   8.618001   9.631007     1.93   0.054     .9641623    77.03054 
  drtwodaysV |   .0437812    .079883    -1.71   0.086     .0012252    1.564536 
    bookingV |   .1100789   .2001554    -1.21   0.225     .0031187    3.885398 
openinghou~V |   2.540654   7.006125     0.34   0.735       .01142    565.2294 
   preferGPV |   1.722533   2.334217     0.40   0.688     .1209758    24.52657 
seventyfiveV |   2.55e-13   5.14e-12    -1.44   0.151     1.63e-30    39817.74 
 eightyfiveV |   .0461552   1.259473    -0.11   0.910     2.73e-25    7.79e+21 
-------------+---------------------------------------------------------------- 
unknown      | 
         Age |   6.022633   1.249051     8.66   0.000     4.011006    9.043144 
income_dom~n |   1.154044   .0897704     1.84   0.065     .9908532    1.344111 
        qofC |   .8018779   .1281299    -1.38   0.167     .5862691     1.09678 
        qofO |   .8024827    .128207    -1.38   0.168     .5867394    1.097555 
        qofP |   .8005051   .1288684    -1.38   0.167     .5838945    1.097473 
        qofA |    .821007   .1372051    -1.18   0.238      .591692    1.139195 
    qofTotal |   1.243433   .1987872     1.36   0.173     .9089527    1.700998 
  cancerrevV |   .4044733   .3008158    -1.22   0.224     .0941526    1.737591 
 cancerprevV |   1.64e+14   3.84e+15     1.40   0.163     1.83e-06    1.47e+34 
exceptionr~V |   .0788736   .1220874    -1.64   0.101     .0037964    1.638686 
    elderlyV |   .0002512   .0020145    -1.03   0.301     3.75e-11    1682.059 
deprivationV |   .9977677   .0230432    -0.10   0.923     .9536108    1.043969 
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     IDAOPIV |   .0491173   .1538676    -0.96   0.336     .0001059     22.7906 
phoneaccessV |   .3367463   .3118927    -1.18   0.240     .0548182    2.068622 
  drtwodaysV |    .406651   .6594782    -0.55   0.579     .0169357      9.7643 
    bookingV |   1.830055   3.056663     0.36   0.717     .0693008    48.32703 
openinghou~V |   115.1611   270.3661     2.02   0.043     1.155906    11473.32 
   preferGPV |   3.915241   4.424611     1.21   0.227     .4273818    35.86748 
seventyfiveV |   .0238994   .3876479    -0.23   0.818     3.73e-16    1.53e+12 
 eightyfiveV |   3.95e+08   8.09e+09     0.97   0.334     1.40e-09    1.11e+26 
 
Table 26.  Appendix 8.  Base outcome output for breast cancer, screen detected cases and patient's of screening age 
removed. 
Multinomial logistic regression                   Number of obs   =       4101 
                                                  LR chi2(88)     =     441.42 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -5292.1196                       Pseudo R2       =     0.0400 
 
------------------------------------------------------------------------------ 
       stage |        RRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
1            |  (base outcome) 
-------------+---------------------------------------------------------------- 
2            | 
         Sex |   .9300976    .322639    -0.21   0.835     .4712567     1.83569 
         Age |    1.04247   .0810197     0.54   0.593     .8951776    1.213998 
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Screen_det~d |   1.025288   .0396209     0.65   0.518     .9505008     1.10596 
income_dom~n |   1.026903   .0318274     0.86   0.392     .9663795    1.091217 
        qofC |   1.014426   .0619626     0.23   0.815     .8999695    1.143439 
        qofO |   1.015571   .0617875     0.25   0.800     .9014113    1.144188 
        qofP |   1.007073   .0615897     0.12   0.908     .8933136    1.135319 
        qofA |   .9598048   .0624145    -0.63   0.528     .8449495    1.090273 
    qofTotal |   .9875454   .0602935    -0.21   0.837     .8761691     1.11308 
  cancerrevV |   1.167417    .547328     0.33   0.741     .4657482    2.926177 
 cancerprevV |   9431.217   78586.39     1.10   0.272     .0007618    1.17e+11 
exceptionr~V |   .9256643   .6742326    -0.11   0.916     .2220536    3.858773 
    elderlyV |   .1351089   .4167171    -0.65   0.516     .0003201    57.02281 
deprivationV |   .9998654   .0095532    -0.01   0.989     .9813158    1.018766 
     IDAOPIV |   2.631525   3.613905     0.70   0.481     .1783373    38.83048 
phoneaccessV |   1.616137   .5950589     1.30   0.192     .7853571    3.325747 
  drtwodaysV |   1.476548   .9632081     0.60   0.550     .4111273    5.302963 
    bookingV |   .6474844   .3452189    -0.82   0.415     .2277166    1.841043 
openinghou~V |   .2018222   .1741166    -1.86   0.064     .0372064    1.094762 
   preferGPV |   2.345115   .9387549     2.13   0.033     1.070104    5.139277 
seventyfiveV |     714.04   4677.224     1.00   0.316     .0018969    2.69e+08 
 eightyfiveV |    .002104   .0198323    -0.65   0.513     1.99e-11    222005.4 
-------------+---------------------------------------------------------------- 
3            | 
         Sex |   .8604146   .4552973    -0.28   0.776     .3049901    2.427336 
         Age |   1.088891    .133432     0.69   0.487      .856404    1.384491 
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Screen_det~d |   1.009427   .0618142     0.15   0.878     .8952614    1.138151 
income_dom~n |   .9878648   .0482093    -0.25   0.802     .8977544     1.08702 
        qofC |   1.057293   .1018307     0.58   0.563     .8754151    1.276959 
        qofO |   1.088221   .1045503     0.88   0.379     .9014427    1.313699 
        qofP |   1.068574   .1031727     0.69   0.492     .8843407    1.291188 
        qofA |   .9885068   .1006846    -0.11   0.910     .8096183    1.206922 
    qofTotal |    .941257   .0906283    -0.63   0.530     .7793828    1.136752 
  cancerrevV |   1.318246    .950425     0.38   0.702     .3208482    5.416181 
 cancerprevV |   668.5829   8881.647     0.49   0.624     3.29e-09    1.36e+14 
exceptionr~V |   1.273954   1.293835     0.24   0.812     .1740478    9.324783 
    elderlyV |   9.19e-06   .0000452    -2.36   0.018     6.01e-10    .1406329 
deprivationV |   1.000466   .0148193     0.03   0.975     .9718379    1.029937 
     IDAOPIV |   1.913411   4.030804     0.31   0.758     .0308079    118.8379 
phoneaccessV |   1.567038   .9147739     0.77   0.442     .4990939    4.920133 
  drtwodaysV |   .2645488   .2764404    -1.27   0.203     .0341226    2.051016 
    bookingV |   .7454711   .6605848    -0.33   0.740     .1312669    4.233568 
openinghou~V |   .3505684   .4787469    -0.77   0.443     .0241183     5.09565 
   preferGPV |   1.126826   .7217112     0.19   0.852     .3211281    3.953991 
seventyfiveV |   1.74e+11   1.80e+12     2.49   0.013     257.1066    1.18e+20 
 eightyfiveV |   3.50e-09   5.17e-08    -1.32   0.188     9.29e-22    13165.59 
-------------+---------------------------------------------------------------- 
4            | 
         Sex |    .629131   .3376437    -0.86   0.388     .2197435    1.801217 
         Age |   2.424239   .3521828     6.10   0.000     1.823546    3.222807 
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Screen_det~d |   .9272999   .0679527    -1.03   0.303     .8032376    1.070524 
income_dom~n |   1.148034   .0683679     2.32   0.020      1.02156    1.290166 
        qofC |   .7601744   .0879765    -2.37   0.018     .6059014     .953728 
        qofO |    .764397   .0880102    -2.33   0.020     .6099784    .9579074 
        qofP |   .7508751   .0870949    -2.47   0.014     .5981854    .9425396 
        qofA |   .6997287   .0849136    -2.94   0.003     .5516131    .8876153 
    qofTotal |   1.316682   .1522546     2.38   0.017     1.049669    1.651619 
  cancerrevV |   .7361196   .5865182    -0.38   0.701     .1544317    3.508815 
 cancerprevV |   .2365547   3.754614    -0.09   0.928     7.30e-15    7.66e+12 
exceptionr~V |   2.139989   2.451883     0.66   0.507     .2265432    20.21492 
    elderlyV |   451355.4    2686717     2.19   0.029     3.869865    5.26e+10 
deprivationV |   .9865596   .0173588    -0.77   0.442      .953117    1.021176 
     IDAOPIV |   9.946338   24.82999     0.92   0.357     .0745981    1326.169 
phoneaccessV |   3.289196   2.311951     1.69   0.090     .8294429    13.04346 
  drtwodaysV |   1.417941   1.708132     0.29   0.772     .1337372    15.03363 
    bookingV |   1.118656   1.149023     0.11   0.913     .1494132    8.375383 
openinghou~V |   .5095412   .8385852    -0.41   0.682     .0202442      12.825 
   preferGPV |   .9463649    .707849    -0.07   0.941     .2184684    4.099478 
seventyfiveV |   2.02e-14   2.56e-13    -2.48   0.013     3.15e-25    .0012889 
 eightyfiveV |    2060594   3.72e+07     0.81   0.420     8.95e-10    4.74e+21 
-------------+---------------------------------------------------------------- 
unknown      | 
         Sex |   1.591492   .8530726     0.87   0.386     .5565993    4.550573 
         Age |   5.460878   .7723778    12.00   0.000     4.138757     7.20535 
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Screen_det~d |   1.576219   .1183678     6.06   0.000     1.360488    1.826158 
income_dom~n |   1.095176   .0560101     1.78   0.075      .990721    1.210644 
        qofC |    1.13606    .113722     1.27   0.203     .9336722     1.38232 
        qofO |   1.139721   .1133732     1.31   0.189     .9378332    1.385069 
        qofP |    1.13025   .1130715     1.22   0.221     .9290081    1.375086 
        qofA |   1.150312   .1222946     1.32   0.188     .9339436    1.416806 
    qofTotal |   .8765135   .0876121    -1.32   0.187     .7205706    1.066205 
  cancerrevV |   .6059616   .4525077    -0.67   0.502     .1402175    2.618714 
 cancerprevV |   3.98e+18   5.46e+19     3.12   0.002      8307295    1.90e+30 
exceptionr~V |   .0754171   .1047813    -1.86   0.063     .0049528      1.1484 
    elderlyV |   30.62963   156.4201     0.67   0.503     .0013779    680890.5 
deprivationV |   .9948419   .0151293    -0.34   0.734     .9656265    1.024941 
     IDAOPIV |   3.638988   7.892454     0.60   0.551     .0518614    255.3391 
phoneaccessV |   1.441162   .8661314     0.61   0.543     .4437566    4.680377 
  drtwodaysV |   .4829545    .502072    -0.70   0.484     .0629521    3.705119 
    bookingV |   1.423067   1.176957     0.43   0.670     .2813413     7.19809 
openinghou~V |    24.4178   35.20225     2.22   0.027     1.447307    411.9577 
   preferGPV |   1.110619   .7280478     0.16   0.873      .307308    4.013804 
seventyfiveV |   .0320112   .3486659    -0.32   0.752     1.71e-11    5.98e+07 
 eightyfiveV |   4.62e-14   7.05e-13    -2.01   0.044     4.65e-27    .4593061 
 
Table 27.  Appendix 9.  Base outcome output for breast cancer, screen detected cases and screening age patient's 
removed, with just top and bottom deciles of QOF total score. 
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Multinomial logistic regression                   Number of obs   =        828 
                                                  LR chi2(87)     =     171.36 
                                                  Prob > chi2     =     0.0000 
Log likelihood = -1036.5142                       Pseudo R2       =     0.0764 
 
------------------------------------------------------------------------------ 
       stage |        RRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
1            |  (base outcome) 
-------------+---------------------------------------------------------------- 
2            | 
         Sex |   4.538425   5.322395     1.29   0.197      .455687    45.20055 
         Age |    1.32003   .2369412     1.55   0.122     .9285297      1.8766 
Screen_det~d |   .9715892   .0849161    -0.33   0.742     .8186313    1.153127 
income_dom~n |   1.007753    .073179     0.11   0.915     .8740643     1.16189 
        qofC |   .8353657   .1246819    -1.21   0.228     .6234924    1.119237 
        qofO |    .825985   .1234105    -1.28   0.201     .6163026    1.107007 
        qofP |   .8540583   .1285216    -1.05   0.294     .6359103    1.147042 
        qofA |   .7691898   .1219709    -1.65   0.098     .5637129    1.049564 
    qofTotal |   1.197152   .1787148     1.21   0.228     .8934682    1.604056 
  cancerrevV |   1.185779   .8921479     0.23   0.821     .2713831    5.181132 
 cancerprevV |   5.86e+11   1.20e+13     1.32   0.185     2.25e-06    1.53e+29 
exceptionr~V |   .5741981   .7052448    -0.45   0.651     .0517123    6.375722 
    elderlyV |   1.593843   11.60692     0.06   0.949     1.01e-06     2518801 
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deprivationV |   1.025676   .0214606     1.21   0.226     .9844648    1.068612 
     IDAOPIV |   .1441697   .4224087    -0.66   0.509     .0004623    44.96187 
phoneaccessV |   1.054014   .9002707     0.06   0.951     .1976081    5.621961 
  drtwodaysV |   .1431628   .2166627    -1.28   0.199     .0073726    2.779965 
    bookingV |   .1166017   .1805105    -1.39   0.165       .00561    2.423513 
openinghou~V |     5.6657   11.96433     0.82   0.411     .0903151    355.4242 
   preferGPV |    4.32586   4.514897     1.40   0.161     .5593376    33.45576 
seventyfiveV |   .0000194   .0002897    -0.73   0.468     3.70e-18    1.02e+08 
 eightyfiveV |   306.8741    5798.46     0.30   0.762     2.53e-14    3.72e+18 
-------------+---------------------------------------------------------------- 
3            | 
         Sex |   .9931966   1.194914    -0.01   0.995     .0939627    10.49821 
         Age |   1.651063   .4593362     1.80   0.071     .9570927    2.848219 
Screen_det~d |   .9589624   .1327747    -0.30   0.762     .7310499    1.257929 
income_dom~n |   .9064702   .1007864    -0.88   0.377     .7289743    1.127184 
        qofC |    .649911   .1536774    -1.82   0.068     .4088646    1.033066 
        qofO |   .6614383   .1571873    -1.74   0.082     .4151508    1.053835 
        qofP |   .6462588   .1541708    -1.83   0.067     .4048972    1.031498 
        qofA |   .5712666   .1405807    -2.28   0.023     .3526713    .9253534 
    qofTotal |   1.536919   .3634829     1.82   0.069     .9668092    2.443211 
  cancerrevV |     1.3752   1.537542     0.28   0.776     .1537025    12.30414 
 cancerprevV |   2.25e+26   7.74e+27     1.77   0.077     .0012531    4.05e+55 
exceptionr~V |   3.199545   4.743671     0.78   0.433     .1750208    58.49067 
    elderlyV |   .0003013   .0036895    -0.66   0.508     1.14e-14     7953106 
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deprivationV |   1.032894   .0337337     0.99   0.322     .9688485    1.101172 
     IDAOPIV |   .1488903   .6765975    -0.42   0.675     .0000202    1098.894 
phoneaccessV |   .3028384   .3900617    -0.93   0.354     .0242575    3.780724 
  drtwodaysV |   1.313511   3.012151     0.12   0.905     .0146708    117.6017 
    bookingV |   1.993882   4.856327     0.28   0.777     .0168462    235.9923 
openinghou~V |   .4000803   1.349328    -0.27   0.786     .0005387      297.13 
   preferGPV |   4.473955   7.423277     0.90   0.367     .1731254    115.6172 
seventyfiveV |   79.38125   1967.766     0.18   0.860     6.30e-20    1.00e+23 
 eightyfiveV |   .0000457   .0014251    -0.32   0.748     1.39e-31    1.51e+22 
-------------+---------------------------------------------------------------- 
4            | 
         Sex |   .1872778   .1711265    -1.83   0.067     .0312388    1.122738 
         Age |   3.279158   1.175869     3.31   0.001     1.623795    6.622066 
Screen_det~d |   .8262845   .1509909    -1.04   0.296     .5775446    1.182153 
income_dom~n |   1.235724   .1855905     1.41   0.159     .9206229    1.658676 
        qofC |   .7120157   .2367359    -1.02   0.307     .3710873    1.366164 
        qofO |   .7156713   .2371931    -1.01   0.313     .3737679     1.37033 
        qofP |   .7011549   .2327711    -1.07   0.285     .3657886    1.343996 
        qofA |   .6054272   .2097591    -1.45   0.148     .3070087    1.193914 
    qofTotal |   1.421552   .4718357     1.06   0.289     .7417122    2.724521 
  cancerrevV |   .0667087   .0867535    -2.08   0.037     .0052145    .8534049 
 cancerprevV |   9086.923   391630.1     0.21   0.833     1.88e-33    4.40e+40 
exceptionr~V |   1.675207   2.951767     0.29   0.770     .0529937    52.95565 
    elderlyV |   1.78e+16   2.84e+17     2.35   0.019     490.4599    6.47e+29 
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deprivationV |   .9872644   .0421488    -0.30   0.764     .9080161    1.073429 
     IDAOPIV |   21.24511   120.3052     0.54   0.589     .0003215     1404034 
phoneaccessV |   370.0995   741.5229     2.95   0.003     7.292403    18783.06 
  drtwodaysV |   .0348653   .1025248    -1.14   0.254     .0001095    11.10284 
    bookingV |   .0124664   .0343478    -1.59   0.112     .0000563    2.760572 
openinghou~V |   6.168556   26.53554     0.42   0.672     .0013444    28303.01 
   preferGPV |   5.577499   11.51288     0.83   0.405     .0975931     318.757 
seventyfiveV |   6.09e-37   1.98e-35    -2.57   0.010     1.40e-64    2.65e-09 
 eightyfiveV |    5507690   2.39e+08     0.36   0.721     5.67e-31    5.35e+43 
-------------+---------------------------------------------------------------- 
unknown      | 
         Sex |   5.49e+07   2.78e+08     3.52   0.000     2668.657    1.13e+12 
         Age |   6.292905   1.869182     6.19   0.000     3.515755    11.26377 
Screen_det~d |   1.509153   .2433171     2.55   0.011     1.100262    2.070001 
income_dom~n |    1.18405   .1329697     1.50   0.132     .9501222    1.475573 
        qofC |   .9666175   .2185809    -0.15   0.881     .6205442    1.505694 
        qofO |   .9801672    .222181    -0.09   0.930     .6285686    1.528437 
        qofP |   .9740085    .221844    -0.12   0.908     .6232895    1.522074 
        qofA |   .9708884    .233988    -0.12   0.902     .6053776    1.557085 
    qofTotal |   1.025867   .2322264     0.11   0.910     .6582693    1.598741 
  cancerrevV |   .6628693   .7179905    -0.38   0.704     .0793312    5.538748 
 cancerprevV |   1.20e+28   3.98e+29     1.95   0.051     .7595678    1.90e+56 
exceptionr~V |   .0220089   .0589841    -1.42   0.154     .0001152    4.205629 
    elderlyV |   34.95883   400.1086     0.31   0.756     6.33e-09    1.93e+11 
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deprivationV |    1.03265   .0328202     1.01   0.312     .9702862    1.099022 
     IDAOPIV |    .005278   .0232689    -1.19   0.234     9.33e-07    29.86107 
phoneaccessV |   .2359499   .3254563    -1.05   0.295     .0158023    3.523061 
  drtwodaysV |   .7553746   1.781011    -0.12   0.905     .0074338    76.75612 
    bookingV |   .9794039   2.441156    -0.01   0.993      .007402    129.5909 
openinghou~V |   2.337383   7.831273     0.25   0.800     .0032872    1662.012 
   preferGPV |   19.11772   31.77197     1.78   0.076     .7358921    496.6587 
seventyfiveV |   6.63e-16   1.54e-14    -1.50   0.133     1.06e-35    41580.97 
 eightyfiveV |   2.06e+08   6.22e+09     0.63   0.526     4.34e-18    9.79e+33 
------------------------------------------------------------------------------ 
 
 
 
